<div>

[Version 3.23.20]{.c8}

</div>

[]{.c75 .c81 .c22 .c66 .c80}

[]{.c59 .c42 .c33 .c66 .c77}

[![](media/image6.jpg)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 468.50px; height: 93.85px;"}

[Brigham and Women's Hospital]{.c59 .c33 .c62}

[COVID-19 Critical Care Clinical Guidelines ]{.c33 .c77}

[]{.c59 .c42 .c33 .c66 .c77}

[Updated: 3/23/2020]{.c23 .c77}

[]{.c59 .c62 .c33}

[This document is a work in progress. We have much to learn. ]{.c59 .c45
.c31}

[This is updated daily with evolving information; do not print.]{.c45
.c31 .c59}

[]{.c59 .c45 .c31}

[[SCCM
Guidelines](https://www.google.com/url?q=https://sccm.org/getattachment/Disaster/SSC-COVID19-Critical-Care-Guidelines.pdf?lang%3Den-US%26_zs%3DWSjjd1%26_zl%3Dj1cc6&sa=D&ust=1585016770800000){.c15}]{.c16
.c31}[ are being reviewed and incorporated but are not yet reflected in
this document]{.c59 .c45 .c31}

[]{.c59 .c31 .c66 .c80}

[Please send suggestions:]{.c31
.c57}[ ]{.c31}[<BWHCOVIDGuidelines@gmail.com>]{.c16 .c98}[ ]{.c59 .c31
.c66 .c80}

[]{.c59 .c42 .c33 .c66 .c77}

[Disclaimer: ]{.c10 .c33}[This document is intended as a resource for
clinicians caring for critically-ill COVID-19 patients, based on
available evidence and recommendations of governing bodies. The
recommendations do not replace clinical judgment or the need for
individualized patient care plans. While we attempt to keep this
document up-to-date, the literature on COVID-19 is rapidly evolving, and
we suggest that practitioners search for the most up-to-date literature
on any specific topic. These guidelines will also rapidly evolve as they
are implemented into clinical practice and we receive feedback from
practitioners. Finally, these guidelines were developed based on
practice patterns and infrastructure at Brigham and Women's Hospital in
Boston, MA; local factors should be taken into account if utilized at
other hospitals.]{.c10}

[COVID-19 one page Quick Guides:]{.c23 .c49} {#h.7amkd6138bxo .c44}
============================================

[[COVID-19 Initial work-up QUICK
GUIDE](https://www.google.com/url?q=https://www.dropbox.com/s/th0vxif5x3hoejs/INITIAL%2520WORKUP-%2520covid%2520quick%2520guide.pdf?dl%3D0&sa=D&ust=1585016770801000){.c15}]{.c16}

[[COVID-19 Respiratory Failure management QUICK
GUIDE](https://www.google.com/url?q=https://www.dropbox.com/s/1na1vj0kq7dt0ys/RESP%2520FAILURE-%2520covid%2520quick%2520guide.pdf?dl%3D0&sa=D&ust=1585016770801000){.c15}]{.c16}

[[COVID-19 ICU care QUICK
GUIDE](https://www.google.com/url?q=https://www.dropbox.com/s/9ff4h4a8wea35oq/ICU%2520CARE-%2520covid%2520quick%2520guide.pdf?dl%3D0&sa=D&ust=1585016770801000){.c15}]{.c16}

[ ]{.c85 .c42 .c33 .c66 .c96}

------------------------------------------------------------------------

[]{.c59 .c42 .c33 .c66 .c77}

[Table of Contents]{.c59 .c42 .c33 .c66 .c77}

[]{.c59 .c42 .c31 .c66}

[[COVID-19 one page Quick Guides:](#h.7amkd6138bxo){.c15}]{.c29
.c16}[        ]{.c29 .c16}[[1](#h.7amkd6138bxo){.c15}]{.c29 .c16}

[[Chapter 1: Non-ICU Management, Triage,
Transfers](#h.vpxc3qksjzgk){.c15}]{.c29 .c16}[        ]{.c29
.c16}[[3](#h.vpxc3qksjzgk){.c15}]{.c29 .c16}

[[Clinical Course of
COVID-19](#h.a8294aye0lbq){.c15}]{.c6}[        ]{.c6}[[3](#h.a8294aye0lbq){.c15}]{.c6}

[[Non-ICU Management
Principles](#h.ymvixg917k3e){.c15}]{.c6}[        ]{.c6}[[4](#h.ymvixg917k3e){.c15}]{.c6}

[[Chest Imaging and Point of Care Lung
Ultrasound](#h.tsr53lmedjah){.c15}]{.c6}[        ]{.c6}[[6](#h.tsr53lmedjah){.c15}]{.c6}

[[Triage to
ICU](#h.apqxkxatnuu){.c15}]{.c16}[        ]{.c16}[[6](#h.apqxkxatnuu){.c15}]{.c16}

[[Transfer
Process](#h.32yrxx2cn5j){.c15}]{.c6}[        ]{.c6}[[6](#h.32yrxx2cn5j){.c15}]{.c6}

[[Chapter 2: Respiratory Support for COVID-19
Patients](#h.hu2czim2nti8){.c15}]{.c16 .c29}[        ]{.c29
.c16}[[7](#h.hu2czim2nti8){.c15}]{.c29 .c16}

[[Respiratory Failure and
ARDS](#h.5z5wj4l0ghah){.c15}]{.c6}[        ]{.c6}[[7](#h.5z5wj4l0ghah){.c15}]{.c6}

[[Management of
Hypoxemia](#h.z178d8l3t5u1){.c15}]{.c6}[        ]{.c6}[[7](#h.z178d8l3t5u1){.c15}]{.c6}

[[Initial Mechanical
Ventilation](#h.welz4k559gib){.c15}]{.c6}[        ]{.c6}[[9](#h.welz4k559gib){.c15}]{.c6}

[[PEEP and
Mechanics](#h.mcb6j64zp5u6){.c15}]{.c6}[        ]{.c6}[[10](#h.mcb6j64zp5u6){.c15}]{.c6}

[[Targeting Sedation for Ventilator
Synchrony](#h.nhqe52dtgmrn){.c15}]{.c6}[        ]{.c6}[[11](#h.nhqe52dtgmrn){.c15}]{.c6}

[[General Management of Ventilated ARDS
Patients](#h.f3ug6fi0aj01){.c15}]{.c6}[        ]{.c6}[[12](#h.f3ug6fi0aj01){.c15}]{.c6}

[[Managing
Ventilation](#h.qrh9t96165ug){.c15}]{.c6}[        ]{.c6}[[13](#h.qrh9t96165ug){.c15}]{.c6}

[[Managing
Oxygenation](#h.4wvmhdtgo9di){.c15}]{.c6}[        ]{.c6}[[13](#h.4wvmhdtgo9di){.c15}]{.c6}

[[Proning and Pulmonary
Vasodilators](#h.wgrateeto9z4){.c15}]{.c6}[        ]{.c6}[[15](#h.wgrateeto9z4){.c15}]{.c6}

[[ECMO
consultation](#h.24j39tc7pjup){.c15}]{.c6}[        ]{.c6}[[16](#h.24j39tc7pjup){.c15}]{.c6}

[[Chapter 3: COVID-19 Therapies and Clinical
Trials](#h.kx686gedgtzg){.c15}]{.c29 .c16}[        ]{.c29
.c16}[[17](#h.kx686gedgtzg){.c15}]{.c29 .c16}

[[Note:](#h.cjp7h4q36i0a){.c15}]{.c16}[        ]{.c16}[[17](#h.cjp7h4q36i0a){.c15}]{.c16}

[[Clinical
trials](#h.hf0jef6dlsvm){.c15}]{.c16}[        ]{.c16}[[17](#h.hf0jef6dlsvm){.c15}]{.c16}

[[Antibiotic
stewardship](#h.8vhrbtln428m){.c15}]{.c6}[        ]{.c6}[[17](#h.8vhrbtln428m){.c15}]{.c6}

[[Metered-dose inhalers (MDIs) vs.
nebulizers](#h.eudti5z0ojjo){.c15}]{.c6}[        ]{.c6}[[18](#h.eudti5z0ojjo){.c15}]{.c6}

[[Airway
Clearance](#h.8pktimpr5u6o){.c15}]{.c6}[        ]{.c6}[[19](#h.8pktimpr5u6o){.c15}]{.c6}

[[Inhaled Pulmonary
Vasodilators](#h.ym3ao1e1uli3){.c15}]{.c6}[        ]{.c6}[[19](#h.ym3ao1e1uli3){.c15}]{.c6}

[[Systemic
Corticosteroids](#h.x05c129ivxrw){.c15}]{.c6}[        ]{.c6}[[20](#h.x05c129ivxrw){.c15}]{.c6}

[[Anti-IL6 Agents (Tocilizumab,
Siltuximab)](#h.m6l0vgre9d0s){.c15}]{.c6}[        ]{.c6}[[21](#h.m6l0vgre9d0s){.c15}]{.c6}

[[Hydroxychloroquine and
Chloroquine](#h.wr1agkjgho7b){.c15}]{.c6}[        ]{.c6}[[22](#h.wr1agkjgho7b){.c15}]{.c6}

[[Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II
Receptor Blockers
(ARB)](#h.uebugzw0ifj){.c15}]{.c6}[        ]{.c6}[[23](#h.uebugzw0ifj){.c15}]{.c6}

[[Non-steroidal anti-inflammatory drugs
(NSAIDs)](#h.msot2gdaj2bg){.c15}]{.c6}[        ]{.c6}[[24](#h.msot2gdaj2bg){.c15}]{.c6}

[[Blood
Products](#h.p7atxkt2b3sh){.c15}]{.c6}[        ]{.c6}[[24](#h.p7atxkt2b3sh){.c15}]{.c6}

[[Chapter 4: Cardiac Complications of
COVID-19](#h.6zfga8b63w2s){.c15}]{.c29 .c16}[        ]{.c29
.c16}[[25](#h.6zfga8b63w2s){.c15}]{.c29 .c16}

[[Acute Cardiac
Injury](#h.sxzvrsrmkd1g){.c15}]{.c6}[        ]{.c6}[[25](#h.sxzvrsrmkd1g){.c15}]{.c6}

[[Cardiovascular
Testing](#h.es6b8f4xqski){.c15}]{.c6}[        ]{.c6}[[26](#h.es6b8f4xqski){.c15}]{.c6}

[[Arrhythmias](#h.rm4wr985h2i8){.c15}]{.c6}[        ]{.c6}[[26](#h.rm4wr985h2i8){.c15}]{.c6}

[[Acute Coronary
Syndromes](#h.13b1uhteftcc){.c15}]{.c6}[        ]{.c6}[[27](#h.13b1uhteftcc){.c15}]{.c6}

[[Pericarditis and
Myocarditis](#h.txp16938ptwl){.c15}]{.c6}[        ]{.c6}[[28](#h.txp16938ptwl){.c15}]{.c6}

[[Chapter 5: Shock: Septic, Cardiogenic, and Cytokine
Storm](#h.dpe5gr1hwjp){.c15}]{.c29 .c16}[        ]{.c29
.c16}[[29](#h.dpe5gr1hwjp){.c15}]{.c29 .c16}

[[Undifferentiated Shock in
COVID](#h.bdbn9kepy2bs){.c15}]{.c6}[        ]{.c6}[[29](#h.bdbn9kepy2bs){.c15}]{.c6}

[[Differentiating
Shock](#h.ebuidko2u3iz){.c15}]{.c6}[        ]{.c6}[[30](#h.ebuidko2u3iz){.c15}]{.c6}

[[Septic Shock and Secondary
Infections](#h.lydcfzsuv4hc){.c15}]{.c6}[        ]{.c6}[[31](#h.lydcfzsuv4hc){.c15}]{.c6}

[[Cardiogenic
Shock](#h.ftupyxepmedz){.c15}]{.c6}[        ]{.c6}[[33](#h.ftupyxepmedz){.c15}]{.c6}

[[Cytokine Activation
Syndrome](#h.7i62kagnynf0){.c15}]{.c6}[        ]{.c6}[[35](#h.7i62kagnynf0){.c15}]{.c6}

[[Chapter 6: Thrombotic and Coagulation
Manifestations](#h.5s70bzlr4ojz){.c15}]{.c29 .c16}[        ]{.c29
.c16}[[36](#h.5s70bzlr4ojz){.c15}]{.c29 .c16}

[[Thrombotic
Disease](#h.9wzf9ick65rt){.c15}]{.c6}[        ]{.c6}[[36](#h.9wzf9ick65rt){.c15}]{.c6}

[[Disseminated Intravascular Coagulation
(DIC)](#h.vpg0k312hzmd){.c15}]{.c6}[        ]{.c6}[[37](#h.vpg0k312hzmd){.c15}]{.c6}

[[Chapter 7: Renal Manifestations](#h.9jn4ulxubc3h){.c15}]{.c29
.c16}[        ]{.c29 .c16}[[38](#h.9jn4ulxubc3h){.c15}]{.c29 .c16}

[[Acute Kidney
Injury](#h.fj20lj7bpd6o){.c15}]{.c6}[        ]{.c6}[[38](#h.fj20lj7bpd6o){.c15}]{.c6}

[[Chapter 8: Other Guidance](#h.l3i6lcz3jr27){.c15}]{.c29
.c16}[        ]{.c29 .c16}[[39](#h.l3i6lcz3jr27){.c15}]{.c29 .c16}

[[Liver
Disease](#h.fg1hqkm6u1r8){.c15}]{.c6}[        ]{.c6}[[39](#h.fg1hqkm6u1r8){.c15}]{.c6}

[[Considerations for Oncology
Patients](#h.aayfijcxre19){.c15}]{.c6}[        ]{.c6}[[40](#h.aayfijcxre19){.c15}]{.c6}

[[Goals of
Care](#h.t1khoickfgoo){.c15}]{.c6}[        ]{.c6}[[43](#h.t1khoickfgoo){.c15}]{.c6}

[[Management of Cardiac
Arrest](#h.ipfys4gecnv0){.c15}]{.c6}[        ]{.c6}[[43](#h.ipfys4gecnv0){.c15}]{.c6}

[[The Role of Palliative
Care](#h.6ogwg6sl9a40){.c15}]{.c6}[        ]{.c6}[[44](#h.6ogwg6sl9a40){.c15}]{.c6}

[[Ethical Considerations and Resource
Allocation](#h.foc01qidskrl){.c15}]{.c16}[        ]{.c16}[[44](#h.foc01qidskrl){.c15}]{.c16}

[[REFERENCES](#h.24n5wzicja05){.c15}]{.c33 .c72}[        ]{.c72
.c33}[[46](#h.24n5wzicja05){.c15}]{.c72 .c33}

[[ADDENDUM: COVID ICU Bundle Checklist](#h.9um4ryva0zlb){.c15}]{.c72
.c33}[        ]{.c72 .c33}[[50](#h.9um4ryva0zlb){.c15}]{.c72 .c33}

------------------------------------------------------------------------

[]{.c23 .c49} {#h.vpxc3qksjzgk .c44 .c79}
=============

[Chapter 1: Non-ICU Management, Triage, Transfers]{.c23 .c49} {#h.d36vdx67mxka .c44}
=============================================================

1.  Clinical Course of COVID-19[ ]{.c11} {#h.a8294aye0lbq style="display:inline"}
    ------------------------------------

```{=html}
<!-- -->
```
1.  [Clinical presentation: ]{.c33}non-specific, flu-like illness

```{=html}
<!-- -->
```
1.  [Fever (44-98%) ]{.c8}
2.  [Cough (46-82%)]{.c8}
3.  [Shortness of breath (20-64%)]{.c8}
4.  [Upper respiratory symptoms, nasal / sinus congestion  (5-25%)]{.c8}
5.  [GI symptoms (10%; usually before respiratory symptoms)]{.c8 .c0}

```{=html}
<!-- -->
```
2.  [Transmission:]{.c17 .c0}

```{=html}
<!-- -->
```
1.  [Large droplets and fomites]{.c8 .c0}

```{=html}
<!-- -->
```
1.  [Viral particles survive \< 24h on cardboard, \< 72h on plastic or
    steel (]{.c0}[[van Dorelmalen et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32182409&sa=D&ust=1585016770824000){.c15}
    ]{.c16 .c0}[[New Engl J
    Med,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32182409&sa=D&ust=1585016770824000){.c15}
    ]{.c14
    .c0}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32182409&sa=D&ust=1585016770824000){.c15}]{.c16
    .c0}[)]{.c8 .c0}

```{=html}
<!-- -->
```
2.  [Aerosols (droplet nuclei, \< 5 µm), estimated \< 4h ]{.c8 .c0}
3.  [Incubation period: median 4 days, common range 2-7 days, up to 24
    days]{.c8 .c0}
4.  [Symptomatic and asymptomatic patients can transmit the virus]{.c0}

```{=html}
<!-- -->
```
3.  [Disease Course]{.c33}[: ]{.c8}

```{=html}
<!-- -->
```
1.  [\~ 80% do not require critical care]{.c8}
2.  \~ 10-20% develop bacterial superinfection[ ]{.c8}
3.  \~ 2-25% have respiratory viral co-infection (Qingdao, China: [[Xing
    et
    al,](https://www.google.com/url?q=https://www.medrxiv.org/content/10.1101/2020.02.29.20027698v2&sa=D&ust=1585016770826000){.c15}
    ]{.c16}[[medRxiv,](https://www.google.com/url?q=https://www.medrxiv.org/content/10.1101/2020.02.29.20027698v2&sa=D&ust=1585016770826000){.c15}
    ]{.c14}[[2020
    preprint](https://www.google.com/url?q=https://www.medrxiv.org/content/10.1101/2020.02.29.20027698v2&sa=D&ust=1585016770827000){.c15}]{.c16};
    Stanford, CA, USA: [[Shah
    N,](https://www.google.com/url?q=https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333&sa=D&ust=1585016770827000){.c15}
    ]{.c16}[[Medium](https://www.google.com/url?q=https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333&sa=D&ust=1585016770827000){.c15}]{.c14}[[,
    2020 unpublished
    data](https://www.google.com/url?q=https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333&sa=D&ust=1585016770827000){.c15}]{.c16})
4.  \~ 20% develop ARDS
5.  [\~ 5% develop renal injury requiring renal replacement therapy
    ]{.c8}
6.  [Elevated AST / ALT (\~200s) is common; fulminant hepatitis not
    reported]{.c8}
7.  Cardiomyopathy in critically ill patients; some progress to
    cardiogenic shock late in course (anecdotal reports)

```{=html}
<!-- -->
```
4.  [Reasons for ICU admission:]{.c17}

```{=html}
<!-- -->
```
1.  [Hypoxemic respiratory failure is the most common indication for
    ICU.]{.c8}

```{=html}
<!-- -->
```
1.  [Reports of rapid progression to intubation within 12-24h]{.c8}

```{=html}
<!-- -->
```
2.  [Few patients with shock, can develop late in course]{.c8}
3.  [Median time from symptom onset to ICU transfer is \~10 days]{.c8}

```{=html}
<!-- -->
```
5.  [Poor prognostic indicators:]{.c17}

```{=html}
<!-- -->
```
1.  [Demographics: Age \> 65, male]{.c8}
2.  [Comorbidities: cardiovascular disease (includes hypertension),
    pulmonary disease, diabetes, malignancy, immunosuppression]{.c8}
3.  Lab findings: severe lymphopenia, elevated troponin, elevated
    creatinine, elevated LDH, elevated CRP, elevated D-dimer

```{=html}
<!-- -->
```
6.  [Cause of death:]{.c17}

```{=html}
<!-- -->
```
1.  [\~53% respiratory failure]{.c8}
2.  [\~33% concomitant respiratory and heart failure]{.c8}
3.  \~7% cardiac or heart failure alone
4.  Mortality rate appears to correlate with age and availability of
    medical resources ([[Ruan et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770831000){.c15}
    ]{.c16}[[Intensive Care
    Med,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770831000){.c15}]{.c14}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770831000){.c15}]{.c16})

[]{.c8}

2.  Non-ICU Management Principles {#h.ymvixg917k3e style="display:inline"}
    -----------------------------

```{=html}
<!-- -->
```
1.  [Diagnostic studies: ]{.c17}

```{=html}
<!-- -->
```
1.  [Labs & EKG: ]{.c8}

```{=html}
<!-- -->
```
1.  [On admission: CBC with differential, BMP, LFTs, LDH, CRP, D-dimer,
    Troponin / CPK, PTT / INR, Procalcitonin, baseline EKG]{.c8}
2.  [Daily: CBC with differential, BMP]{.c8}

```{=html}
<!-- -->
```
1.  [For stable floor patients, consider every other day]{.c8}

```{=html}
<!-- -->
```
3.  [Every other day: LFTs, LDH, CRP, D-dimer, Troponin / CPK (if in
    ICU), Triglycerides (if on propofol) ]{.c8}
4.  [If clinical worsening: LFTs, LDH, CRP, D-dimer, Troponin, CPK, PTT
    / INR, Procalcitonin, Ferritin, Fibrinogen, EKG ]{.c8}
5.  [Expert opinion does not recommend routine pro-BNP. ]{.c8}

```{=html}
<!-- -->
```
2.  [Chest imaging: Portable CXR is sufficient in most cases. Avoid
    routine daily CXR (unlikely to change management, evaluate
    case-by-case).]{.c8}

```{=html}
<!-- -->
```
1.  [Chest imaging variable; bilateral patchy opacities most
    common]{.c8}
2.  [Chest CT often will not change treatment; obtain only if necessary
    (risk of transmission, time associated with transport /
    decontamination of equipment)]{.c8}
3.  Point of Care Ultrasound of the lungs can be used but [by
    experienced providers only]{.c8}

```{=html}
<!-- -->
```
3.  [Obtain additional studies only if necessary]{.c8}

```{=html}
<!-- -->
```
1.  Avoid routine TTEs (for cardiac studies, see: [["Cardiac
    Complications of COVID"
    chapter](#h.6zfga8b63w2s){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
2.  [Medical management:]{.c17}

```{=html}
<!-- -->
```
1.  Further details in [["COVID Therapies and Clinical Trials"
    chapter](#h.kx686gedgtzg){.c15}]{.c16}
2.  [Management is largely supportive]{.c8}
3.  [Fluid management should be conservative due to risk of
    hypoxia/CHF]{.c8}
4.  [Antiviral and immune-modulating therapies are investigational
    ]{.c8}

```{=html}
<!-- -->
```
3.  [Early Advance Care Planning:]{.c17}

```{=html}
<!-- -->
```
1.  [In conscious patients, review or sign Health Care Proxy form ]{.c8}
2.  [Discuss and document goals of care on admission]{.c8}

```{=html}
<!-- -->
```
1.  [Educate patient and family on disease course ]{.c8}
2.  [Focus on desired quality of life and tolerance for ICU
    measures]{.c8}

```{=html}
<!-- -->
```
1.  Avoid implying availability of ICU measures if unknown (refer to
    local ethics guidance)

```{=html}
<!-- -->
```
4.  [Avoid increasing risk of transmission: ]{.c33}[Generally avoid
    transport if possible.]{.c8}

```{=html}
<!-- -->
```
1.  Further details in [["COVID Therapies and Clinical Trials"
    chapter](#h.kx686gedgtzg){.c15}]{.c16}
2.  [Non-Invasive Positive Pressure Ventilation (NIPPV: BiPAP, CPAP),
    High Flow Nasal Cannula (HFNC), Humidified Venturi Face Masks,
    Nebulizers increase aerosolization. ]{.c8}

```{=html}
<!-- -->
```
1.  [Any aerosol-generating intervention must be performed under Strict
    (Airborne) Isolation Precautions, in a negative pressure room.
    ]{.c41}
2.  In current policy, patients with [severe OSA]{.c42} may continue
    nocturnal CPAP / BiPAP but [must use a BWH]{.c42} NIPPV
    [mask]{.c42} and [machine]{.c42}[, not their home mask or nasal
    pillows which have elevated aerosol risk. BWH machines have dual
    limb (with HEPA filter); in contrast, home machines have a single
    limb so they have an anti-asphyxiation (pop-off) valve that
    increases aerosol risk. ]{.c8}

```{=html}
<!-- -->
```
1.  [Transition back to home machine if COVID-19 ruled out]{.c8}

```{=html}
<!-- -->
```
3.  Use m[etered dose inhalers instead of nebulizers. ]{.c8}

```{=html}
<!-- -->
```
1.  [Transition back to nebs if COVID-19 ruled out]{.c8}

```{=html}
<!-- -->
```
4.  [If patient already on BiPAP / CPAP / HFNC becomes COVID-suspected,
    transition to non-rebreather followed by intubation.]{.c8}
5.  [NIPPV\* is not used for ARDS; early intubation is preferred. ]{.c8}

\*Can be considered on a case-by-case basis for highly reversible
indications ([e.g.]{.c22}, [flash pulmonary edema with rapid
resolution). ]{.c8}

6.  [Similar to many U.S. medical centers, our current default is to
    avoid HFNC in DNI patients and to use NRB, although exceptions can
    be considered on a case-by-case basis. ]{.c8}

[]{.c8}

3.  [Chest Imaging and Point of Care Lung Ultrasound]{.c11} {#h.tsr53lmedjah style="display:inline"}
    -------------------------------------------------------

```{=html}
<!-- -->
```
1.  [This section is in progress]{.c75 .c81 .c22 .c66 .c80}

[]{.c8}

4.  [Triage to ICU]{.c11} {#h.apqxkxatnuu style="display:inline"}
    ---------------------

```{=html}
<!-- -->
```
1.  [Consult the ICU triage team EARLY for:]{.c33}[ ]{.c8}

```{=html}
<!-- -->
```
1.  [Provider concern]{.c8}
2.  Respiratory distress

```{=html}
<!-- -->
```
1.  [Need O2 \> 6 LPM to maintain SpO2 \> 92 or PaO2 \> 65.]{.c8}
2.  [Rapid escalation of oxygen requirement.]{.c8}
3.  [Significant work of breathing.]{.c8}

```{=html}
<!-- -->
```
3.  Hemodynamic instability after initial conservative[ fluid
    resuscitation ]{.c8}

```{=html}
<!-- -->
```
1.  [SBP \< 90, Mean arterial pressure \< 65, or Heart
    rate \> 120.]{.c8}

```{=html}
<!-- -->
```
4.  [Acidosis]{.c8}

```{=html}
<!-- -->
```
1.  [ABG with pH \< 7.3 or PCO2 \> 50 or above patient's baseline.]{.c8}
2.  [Lactate \> 2.]{.c8}

```{=html}
<!-- -->
```
5.  [Need for intensive nursing care or frequent laboratory draws
    requiring arterial line.]{.c8}
6.  [Severe comorbid illness / high risk for deterioration.]{.c8}

[]{.c8}

5.  [Transfer Process ]{.c11} {#h.32yrxx2cn5j style="display:inline"}
    -------------------------

```{=html}
<!-- -->
```
1.  [Additional details in Strict Isolation Procedures Manual.]{.c17}
2.  [Floor / ED to ICU:]{.c33}

```{=html}
<!-- -->
```
1.  [ICU RN brings ICU bed to the floor for transfer (to avoid bed
    transfer in COVID precautions room and subsequent bed
    cleaning).]{.c8}
2.  [Patient wears surgical mask, with an extra clean gown and sheet on
    top.   ]{.c8}
3.  [Providers wear standard PPE during transport.]{.c8}
4.  [Security facilitates the shortest and fastest transfer route, walks
    6 ft away from patient and providers, not required to wear PPE]{.c8}
5.  Necessary tests ([e.g.]{.c22}[ CT), should be obtained during
    transfer if possible.]{.c8}

```{=html}
<!-- -->
```
3.  [ICU to floor: ]{.c17}

```{=html}
<!-- -->
```
1.  [RN wears standard PPE]{.c8}
2.  [Patient travels in wheelchair or stretcher]{.c8}
3.  [Security facilitates the shortest and fastest transfer route, walks
    6 ft away from patient and providers, not required to wear PPE]{.c8}

```{=html}
<!-- -->
```
4.  [Floor to discharge: s]{.c33}[ee separate documentation of discharge
    criteria/planning]{.c33}[ ]{.c8}

```{=html}
<!-- -->
```
1.  [RN wears standard PPE]{.c8}
2.  [Patient travels in wheelchair ]{.c8}
3.  [Security facilitates the shortest and fastest transfer route, walks
    6 ft away from patient and providers, not required to wear PPE]{.c8}
4.  [Patient is escorted directly into vehicle; contact care management
    if patient does not have access to a personal vehicle]{.c8}

[Chapter 2: Respiratory Support for COVID-19 Patients]{.c23 .c49} {#h.hu2czim2nti8 .c44}
=================================================================

1.  [Respiratory Failure and ARDS ]{.c11} {#h.5z5wj4l0ghah style="display:inline"}
    -------------------------------------

```{=html}
<!-- -->
```
1.  [Pathophysiology: ]{.c17}

```{=html}
<!-- -->
```
1.  Histology shows [bilateral diffuse alveolar damage with cellular
    fibromyxoid exudates, desquamation of pneumocytes, pulmonary edema,
    and hyaline membrane formation (]{.c0}[[Xu et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&sa=D&ust=1585016770844000){.c15}
    ]{.c16 .c0}[[Lancet Respir
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&sa=D&ust=1585016770844000){.c15}]{.c14
    .c0}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&sa=D&ust=1585016770845000){.c15}
    ]{.c16
    .c0}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&sa=D&ust=1585016770845000){.c15}]{.c16
    .c0}[)]{.c0}
2.  Some evidence of direct viral injury to lung tissue, rather than
    purely hyperinflammatory process[ (]{.c0}[[Xu et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&sa=D&ust=1585016770845000){.c15}
    ]{.c16 .c0}[[Lancet Respir
    Med,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&sa=D&ust=1585016770846000){.c15}]{.c14
    .c0}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&sa=D&ust=1585016770846000){.c15}]{.c16
    .c0}[)]{.c0}

```{=html}
<!-- -->
```
2.  [Time course:]{.c17}

```{=html}
<!-- -->
```
1.  [Anecdotal reports that progression of hypoxemic respiratory failure
    occurs rapidly (within \~12-24 hours)]{.c8}
2.  [From onset of symptoms, median time to: ]{.c8}

```{=html}
<!-- -->
```
1.  Development of ARDS: [8-12 days (]{.c0}[[Wang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770847000){.c15}
    ]{.c16
    .c0}[[JAMA](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770847000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770848000){.c15}]{.c16
    .c0}[; ]{.c0}[[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770848000){.c15}
    ]{.c16
    .c0}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770848000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770848000){.c15}]{.c16
    .c0}[; ]{.c0}[[Huang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&sa=D&ust=1585016770849000){.c15}
    ]{.c16
    .c0}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&sa=D&ust=1585016770849000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&sa=D&ust=1585016770849000){.c15}]{.c16
    .c0}[)]{.c8 .c0}
2.  Mechanical ventilation: 10.5-14.5 days ([[Huang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&sa=D&ust=1585016770850000){.c15}
    ]{.c16
    .c0}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&sa=D&ust=1585016770850000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&sa=D&ust=1585016770850000){.c15}]{.c16
    .c0}[; ]{.c0}[[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770851000){.c15}
    ]{.c16
    .c0}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770851000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770851000){.c15}]{.c16
    .c0}[)]{.c8 .c0}

[]{.c8 .c0}

2.  [Management of Hypoxemia]{.c11} {#h.z178d8l3t5u1 style="display:inline"}
    -------------------------------

```{=html}
<!-- -->
```
1.  [Supplemental Oxygen:]{.c17}

```{=html}
<!-- -->
```
1.  Humidified nasal cannula (NC) 1 to 8 LPM for target SpO2 92-96%
2.  If a patient requires \> 8 LPM NC, initiate dry[ Venturi mask
    (non-humidified to reduce aerosolization risk) ]{.c8}

```{=html}
<!-- -->
```
1.  [Start Venturi mask at 9 LPM and FiO2 28%]{.c8}
2.  [Up-titrate FiO2 to goal SpO2 of 92-96% (not exceeding FiO2
    35%)]{.c8}
3.  [If FiO2 \> 35% then increase flow to 12 LPM]{.c8}

```{=html}
<!-- -->
```
3.  [Notify ICU triage pager]{.c8}

```{=html}
<!-- -->
```
2.  [Avoid ]{.c33}[high-flow nasal cannula (HFNC) ]{.c33}[and
    non-invasive positive pressure ventilation (NIPPV;
    ]{.c33}[i.e.]{.c33}[ CPAP/BiPAP) for ARDS.]{.c17}

```{=html}
<!-- -->
```
1.  Patients on nocturnal NIPPV at home should continue their nocturnal
    NIPPV. However, patient must use BWH NIPPV [mask]{.c42} and
    [machine]{.c42}[ (not home mask/nasal pillow or machine due to
    increased aerosol risk with home pillows/mask/machine) under strict
    airborne precautions.   ]{.c8}
2.  [If a patient already on HFNC or NIPPV becomes a COVID-19 PUI,
    transition to non-rebreather if safe]{.c8}

```{=html}
<!-- -->
```
1.  [Recommend that the patient be off an aerosol generating device like
     HFNC or NIPPV for 45 minutes prior to intubation if clinically
    feasible]{.c8}

```{=html}
<!-- -->
```
3.  If a patient is DNR/DNI or otherwise[ is not eligible for
    intubation: ]{.c8}

```{=html}
<!-- -->
```
1.  [Current policy advises avoiding HFNC or NIPPV in DNI/DNR patients.
    However, neither HFNC nor NIPPV is prohibited and case-by-case
    exceptions could apply. ]{.c17}
2.  T[his is an evolving area without definitive evidence or uniform
    policy that underwent multi-disciplinary discussion. ]{.c8}
3.  [Considerations include: ]{.c8}

-   [Safety of staff (particularly respiratory therapy and
    nursing);]{.c8}
-   Paucity of data on the increased aerosol risk; 
-   [[WHO interim guidance (published March
    13, 2020)](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770855000){.c15}]{.c16} on
    COVID-19 are more liberal about the usage of HFNC and NIPPV, stating
    that systems with "good interface fitting \[i.e., good seal, no air
    leak\][ do not create widespread dispersion of exhaled air and
    therefore should be associated with low risk of airborne
    transmission."]{.c0}^[\[a\]](#cmnt1){#cmnt_ref1}^[ ]{.c8 .c0}
-   [Difficulty in assessing how many patients failing NRB would survive
    on HFNC. ]{.c8}
-   [Pro-active treatment of air hunger through other means.]{.c8}
-   [HFNC has been utilized in lieu of ventilation of both full code and
    DNI/DNR patients in the setting of limited resources. ]{.c8}

[If HFNC or NIPPV used]{.c75 .c81 .c0 .c22 .c66 .c80}

1.  For HFNC, recommend patient wear surgical mask and [limit flow rate
    to \< 30 L/min]{.c8}
2.  [For BiPAP, use an in-line viral filter.]{.c8}
3.  [Ensure masks/devices fit well and there is minimal air leak (as
    leaks propel potentially infected air significant distances - see
    "Rationale" below)]{.c8}

```{=html}
<!-- -->
```
4.  [Rationale]{.c22}[: General consensus suggests that HFNC and NIPPV
    increase the risk of viral transmission. Given the rapid progression
    of disease, we do not expect many patients can be salvaged/avoid
    intubation using HFNC/NIPPV, but this is unknown]{.c8}

```{=html}
<!-- -->
```
1.  A systematic review on SARS found that NIPPV was associated with
    increased risk of viral transmission to healthcare workers (n=2
    studies), but HFNC was not (n=1) ([[Tran et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22563403&sa=D&ust=1585016770857000){.c15}
    ]{.c16}[[PLoS
    One](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22563403&sa=D&ust=1585016770858000){.c15}]{.c14}[[,
    2012](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22563403&sa=D&ust=1585016770858000){.c15}]{.c16}[)]{.c8}
2.  Other studies with very limited power exist, such as a post-hoc
    analysis that found no secondary infections in medical staff from
    patients with influenza H1N1 treated with HFNC but was limited to
    only n=20
    ([[Rello](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&sa=D&ust=1585016770858000){.c15}
    ]{.c16}[[et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&sa=D&ust=1585016770859000){.c15}]{.c16}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&sa=D&ust=1585016770859000){.c15}
    ]{.c16}[[J Crit
    Care,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&sa=D&ust=1585016770859000){.c15}
    ]{.c14}[[2012](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&sa=D&ust=1585016770860000){.c15}]{.c16}^[\[b\]](#cmnt2){#cmnt_ref2}^);
    [ ]{.c22} 
3.  [Exhaled air distances are minimally increased with CPAP pressures
    up to 20 cm H2O and HFNC up to 60 LPM; device/interface leaks cause
    significant lateral air travel (]{.c0}[[Hui et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30705129&sa=D&ust=1585016770860000){.c15}
    ]{.c16 .c0}[[Eur Respir
    J,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30705129&sa=D&ust=1585016770861000){.c15}]{.c14
    .c0}[[ 2019](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30705129&sa=D&ust=1585016770861000){.c15}]{.c16
    .c0}[)]{.c0}

```{=html}
<!-- -->
```
3.  [Early intubation: ]{.c17}

```{=html}
<!-- -->
```
1.  We recommend [early consultation with anesthesia for possible
    intubation in the setting of rapidly progressive hypoxia. ]{.c8}

```{=html}
<!-- -->
```
1.  Case reports from China suggest high failure rates for non-invasive
    ventilation, including high-flow nasal oxygen ([[Zuo et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32102726&sa=D&ust=1585016770862000){.c15}
    ]{.c16}[[Chin Med Sci
    J](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32102726&sa=D&ust=1585016770862000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32102726&sa=D&ust=1585016770862000){.c15}]{.c16})

```{=html}
<!-- -->
```
2.  For patients maintained on Venturi mask, o[nce FiO2 = 60% and SpO2
    \< 92%, call for intubation if patient is a candidate for mechanical
    ventilation ]{.c8}

```{=html}
<!-- -->
```
1.  There is a COVID Airway Code Team[ with specific protocols for
    avoiding aerosolization.]{.c8}
2.  Many centers suggest Rapid Sequence Intubation when fully paralyzed,
    without ambu-bag (which generates aerosols) and highly experienced
    operators ([e.g.]{.c22}[, anesthesia attending). ]{.c8}

```{=html}
<!-- -->
```
3.  Consider additional indications for intubation (tachypnea, work of
    breathing).

 

3.  [Initial Mechanical Ventilation]{.c11} {#h.welz4k559gib style="display:inline"}
    --------------------------------------

```{=html}
<!-- -->
```
1.  [Intubations outside of ICU:]{.c17}

```{=html}
<!-- -->
```
1.  S[hould be attended by the Resource RT, who can facilitate early and
    appropriate ventilator settings with non-intensivists.]{.c8}
2.  [Use "Mechanical Ventilation with Sedation" orderset.]{.c8}

```{=html}
<!-- -->
```
2.  [Initiate Volume Control (AC/VC) mode ]{.c17}
3.  [Initial tidal volume (Vt):]{.c33}[ ]{.c8}

```{=html}
<!-- -->
```
1.  [Vt = 6 ml/kg (based on ideal body weight \[IBW\] from ARDSnet
    table, see table below)]{.c8}

```{=html}
<!-- -->
```
1.  [IBW men (kg) = 50 + 2.3 (height in inches -- 60)]{.c8}
2.  [IBW women (kg) = 45.5 + 2.3 (height in inches -- 60)]{.c8}

[![](media/image4.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 487.00px; height: 346.50px;"}

4.  [Initial respiratory rate 16-24, higher if acidosis present.]{.c17}
5.  [Initial PEEP based on BMI:]{.c17}

```{=html}
<!-- -->
```
1.  [BMI \< 35: PEEP 10]{.c8}
2.  [BMI 35 to 50: PEEP 12]{.c8}
3.  [BMI \> 50: PEEP 15]{.c8}

```{=html}
<!-- -->
```
6.  [Initial FiO2: ]{.c17}

```{=html}
<!-- -->
```
1.  100% on intubation then rapidly wean to SpO2 92-96% ([[Barrot et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&sa=D&ust=1585016770866000){.c15}
    ]{.c16}[[N Engl J
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&sa=D&ust=1585016770867000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&sa=D&ust=1585016770867000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&sa=D&ust=1585016770867000){.c15}]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&sa=D&ust=1585016770867000){.c15}]{.c16}[)]{.c8}

```{=html}
<!-- -->
```
7.  [Obtain STAT portable CXR to confirm endotracheal tube
    location:]{.c33}[ ]{.c8}

```{=html}
<!-- -->
```
1.  [Order and page radiology at time of intubation ]{.c8}
2.  [Prioritize CXR and vent titration over procedures (such as central
    venous catheter placement) if possible. ]{.c8}

```{=html}
<!-- -->
```
8.  [Within 30 minutes of intubation, obtain an ABG]{.c33}[ (preferred)
    or a VBG and adjust ventilation and oxygenation as needed]{.c17}

[]{.c8}

4.  [PEEP and Mechanics]{.c11} {#h.mcb6j64zp5u6 style="display:inline"}
    --------------------------

```{=html}
<!-- -->
```
1.  [If patients supported by Hamilton G5 Ventilator (most common),
    perform the following within 10 minutes of intubation:]{.c17}

```{=html}
<!-- -->
```
1.  Determine best PEEP following intubation while paralyzed[ using
    Pressure-Volume (PV) tool]{.c8}

```{=html}
<!-- -->
```
1.  This is a departure from use of Best PEEP Trials.[ PV tool is the
    preferred method due to widespread familiarity with RT staff,
    institutional experience, time constraints, and minimizing provider
    exposure]{.c8}

```{=html}
<!-- -->
```
2.  Recommend maintaining this PEEP for initial care unless titration is
    required based on clinical parameters ([e.g.]{.c22}[, hypoxia,
    elevated Ppl, etc)]{.c8}
3.  [If PEEP titration is required based on change in clinical status,
    recommend using PV tool to assess new PEEP. If this is not possible
    (no knowledgeable user available or patient inadequately sedated)
    then recommend PEEP titration by the Lower PEEP ARDSnet table (see
    below)]{.c8}

```{=html}
<!-- -->
```
2.  [If patients ]{.c33}[not]{.c33 .c22 .c42}[ supported by Hamilton G5
    Ventilator, perform the following within 10 minutes of
    intubation]{.c33}[:]{.c8}

```{=html}
<!-- -->
```
1.  [Initiate PEEP based on BMI ]{.c8}
2.  If there are changes in clinical parameters
    ([e.g.,]{.c22}[ hypoxia), titrate PEEP according to ARDSnet Lower
    PEEP table (below).]{.c8}
3.  Current recommendations are to use ARDSnet Lower PEEP table. This
    table is selected primarily to avoid doing initial harm to patients
    with poor lung compliance and was chosen following joint MGH and BWH
    discussion.[![](media/image3.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 495.50px; height: 126.21px;"}

[]{.c8}

3.  [After best PEEP determined, obtain]{.c33} [respiratory
    mechanics]{.c33}[:]{.c8}

```{=html}
<!-- -->
```
1.  Plateau pressure (with goal \< 30, management below)
2.  [Static compliance]{.c8}

```{=html}
<!-- -->
```
4.  [Obtain arterial blood gas: ]{.c17}

```{=html}
<!-- -->
```
1.  Goal pH 7.25 to 7.45
2.  [Calculate P/F ratio from initial post-intubation ABG]{.c8}

```{=html}
<!-- -->
```
5.  [Routine esophageal balloon use is not recommended]{.c17}

[]{.c8}

5.  [Targeting Sedation for Ventilator Synchrony]{.c11} {#h.nhqe52dtgmrn style="display:inline"}
    ---------------------------------------------------

```{=html}
<!-- -->
```
1.  [Initially target ]{.c33}[RASS -2 to -3 (see table
    below)]{.c33}[:]{.c33}

```{=html}
<!-- -->
```
1.  [Maintain deep sedation immediately post-intubation while paralyzed
    (assume 60 minutes for Rocuronium, 10 minutes for
    succinylcholine)]{.c8}

```{=html}
<!-- -->
```
1.  [Preferred initial sedation regimen]{.c42}:[ ]{.c0 .c35 .c80 .c94}

```{=html}
<!-- -->
```
1.  Fentanyl/Hydromorphone (boluses +/- infusion) + Propofol: target
    analgosedation and optimize analgesia first while decreasing
    sedative requirements
2.  [Measure triglycerides and lipase every third day on propofol or
    earlier if other reasons for hypertriglyceridemia]{.c8}

```{=html}
<!-- -->
```
2.  [Adjunct agent:]{.c42}[ Midazolam]{.c8}
3.  [Use dexmedetomidine only when nearing extubation]{.c41}

```{=html}
<!-- -->
```
2.  [Target ventilator synchrony: ]{.c33}Ventilator-induced lung injury
    (VILI) is common in patients who are not synchronous with the
    ventilator and can cause significant lasting damage

```{=html}
<!-- -->
```
1.  Once at target RASS after paralytics have worn off, assess patient
    synchrony with the ventilator ([e.g.]{.c22}[, signs of
    breath-stacking, double triggering, other ventilator alarms).]{.c8}

```{=html}
<!-- -->
```
1.  Titrate sedatives/analgesics to ventilator synchrony allowing for
    deeper RASS.
2.  If patient remains dyssynchronous despite deep sedation (RASS -5),
    initiate continuous paralytics (ensure BIS 40 to 60 prior to
    initiating and during paralysis)[.]{.c8}

[![](media/image5.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 314.51px; height: 337.50px;"}

[]{.c8}

6.  [General Management of Ventilated ARDS Patients]{.c11} {#h.f3ug6fi0aj01 style="display:inline"}
    ------------------------------------------------------

```{=html}
<!-- -->
```
1.  [Consider whether patient requires daily CXR: ]{.c17}

```{=html}
<!-- -->
```
1.  [CXR clearly indicated for: ]{.c8}

```{=html}
<!-- -->
```
1.  [Clinical change ]{.c8}
2.  [Concern for displaced ET tube:]{.c8}

```{=html}
<!-- -->
```
1.  [Sudden increase in peak inspiratory pressure or resistance]{.c8}
2.  [Decreased, unilateral breath sounds (usually on the right)]{.c8}
3.  [RN or RT concern for change in depth of ET tube at teeth ]{.c8}

```{=html}
<!-- -->
```
2.  [COVID-19 ICU Bundle:]{.c17}

```{=html}
<!-- -->
```
1.  Ventilated patients should all have a daily ICU "Bundle" of best
    practices. See [[Addendum 1](#h.9um4ryva0zlb){.c15}]{.c16} for a
    proposed "[COVID-19 ICU Bundle".]{.c8}

```{=html}
<!-- -->
```
3.  [Ventilator consults:]{.c17}

```{=html}
<!-- -->
```
1.  [If you need additional assistance managing ventilator choices, you
    can request a pulmonary phone/in-person consult (pager 11957).]{.c8}

[]{.c8}

7.  [Managing Ventilation]{.c11} {#h.qrh9t96165ug style="display:inline"}
    ----------------------------

```{=html}
<!-- -->
```
1.  [Follow ARDSnet ventilation where possible:]{.c33}[ ]{.c8}

```{=html}
<!-- -->
```
1.  [Tidal volumes should be 4-6 cc/kg using IBW (see table above) to
    minimize volumes (and thus ventilator injury).]{.c8}

```{=html}
<!-- -->
```
2.  [Minute ventilation (respiratory rate x tidal volume) typically
    drives pH and PCO2:]{.c17}

```{=html}
<!-- -->
```
1.  [Titrate ventilatory parameters to pH, not PCO2.]{.c8}
2.  [To achieve low tidal volumes, we tolerate hypercapnia (functionally
    no limitation unless clinical sequelae) and acidemia (pH \>
    7.2).]{.c8}
3.  [Because tidal volumes are low, the respiratory rate often has to be
    high to accommodate; typical RR is 20-35 breaths/minute.]{.c8}

```{=html}
<!-- -->
```
3.  [pH goal is normally 7.25-7.45:]{.c17}

```{=html}
<!-- -->
```
1.  [If pH \> 7.45, decrease respiratory rate]{.c8}
2.  [If pH 7.15-7.30, then increase respiratory rate until pH \> 7.30,
    or PaCO2 \< 25 (maximum RR= 35 breaths/minute)]{.c8}
3.  [If pH \< 7.15, then increase respiratory rate to 35
    breaths/minute]{.c8}
4.  [If pH still \< 7.15, then perform the following:]{.c8}

```{=html}
<!-- -->
```
1.  [Tidal volume may be increased by 1 mL/kg until pH \> 7.15 (until
    plateau pressure reaches 30 cm H2O or tidal volume reaches 8
    cc/kg)]{.c8}
2.  [Deep sedation advancing to RASS -5 if needed]{.c8}
3.  [If no improvement, initiate continuous paralysis]{.c8}
4.  [If still no improvement, initiate prone ventilation (may improve
    V/Q matching and better ventilation)]{.c8}

[]{.c8}

8.  [Managing Oxygenation]{.c11} {#h.4wvmhdtgo9di style="display:inline"}
    ----------------------------

```{=html}
<!-- -->
```
1.  [Minimizing oxygen toxicity: ]{.c17}

```{=html}
<!-- -->
```
1.  [PEEP and Fi02 drive oxygenation ]{.c8}
2.  The goal is to deliver a partial pressure of oxygen to perfuse
    tissues (PaO2 \> 75, Sp02 \>92%) while limiting lung injury from
    high distending pressures (Ppl \< 30) and hyperoxia ([FiO2 \<
    75]{.c33}, SpO2 \< 96%)[.]{.c8}
3.  Lower limit goals for PaO2 / SpO2 are widely debated (and discussed
    in [Rationale]{.c22});[ PaO2 \> 55 and SpO2 \>88% are also commonly
    used at BWH. ]{.c8}

[]{.c8}

2.  [PEEP management:]{.c17}

```{=html}
<!-- -->
```
1.  [Initial PEEP should be set as explained in section 4 above. ]{.c8}
2.  [If patient is hypoxic on Vt = 6 ml/kg and ideal PEEP from PV tool
    (or PEEP determination from ARDSnet table for non-Hamilton G5
    ventilators), perform the following:]{.c8}

```{=html}
<!-- -->
```
1.  Deep sedation,[ ]{.c33}[advancing to RASS -5 if needed; if no
    improvement then:]{.c8}
2.  Initiate continuous paralysis[ ]{.c33}[(cisatracurium bolus 0.2mg/kg
    followed by infusion at 0-5 mcg/kg/min titrated to
    patient-ventilator synchrony); if no improvement then:]{.c8}
3.  Initiate prone[ ]{.c33}ventilation (see below); high consideration
    for use early[ in severe ARDS (\<36 hours from ARDS onset, start
    discussion of proning when P:F \< 150, prone within 12 hours of
    FiO2 \> 75%)]{.c8}

```{=html}
<!-- -->
```
3.  [Checking plateau pressure:]{.c17}

```{=html}
<!-- -->
```
1.  [Check plateau pressure with every change in tidal volume, PEEP, or
    clinical deterioration (worsening oxygenation) but not as part of
    routine practice]{.c8}

```{=html}
<!-- -->
```
1.  [If plateau pressure is \> 30 cm H20, then decrease tidal volume by
    1 ml/kg (minimum 4 mL/kg)]{.c8}
2.  [If plateau pressure is \< 25 H20 and tidal volume \< 6 mL/kg, then
    increase tidal volume by 1 mL/kg until plateau pressure is \> 25 cm
    H2O or tidal volume = 6 mL/kg]{.c8}
3.  [If plateau pressure is \< 30 cm H20 and patient is breath stacking
    or dyssynchronous, then increase tidal volume in mL/kg increments to
    7 mL/kg or 8 mL/kg so long as plateau pressure is \< 30 cm H20]{.c8}

```{=html}
<!-- -->
```
4.  [Adjusting Fi02:]{.c17}

```{=html}
<!-- -->
```
1.  [Adjust Fi02 after optimizing PEEP  ]{.c8}
2.  [Goal FiO2 \< 75%; if FiO2 \> 75%; patient requires ventilator
    optimization. If you need assistance, pulmonary consultation is
    available (pager 11957)]{.c8}
3.  [It is reasonable to put a desaturating patient temporarily on 100%
    Fi02, but remember to wean oxygen as rapidly as possible]{.c8}

```{=html}
<!-- -->
```
5.  [Rationale]{.c33 .c22}[: ]{.c8}

```{=html}
<!-- -->
```
1.  [Avoiding hyperoxia: ]{.c22}Extensive mammalian animal data
    demonstrates that hyperoxic injury occurs at an FiO2 ≥ 75% (at sea
    level) with the rate of injury increasing as FiO2 exceeds that
    threshold. In multiple mammalian models, an FiO2 of 100% for 48 to
    72 hours is associated with nearly 100% mortality rate. In lung
    injury models, the time to death is markedly attenuated. In an
    effort to reduce the potential for hyperoxic injury, the threshold
    of FiO2 ≥ 75% triggers progressive intervention throughout this
    protocol: increased sedation, paralysis, proning and ECMO
    consultation. For a review of hyperoxic acute lung injury, see
    [[Kallet and
    Matthay,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23271823&sa=D&ust=1585016770883000){.c15}
    ]{.c16}[[Respir
    Care](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23271823&sa=D&ust=1585016770883000){.c15}]{.c14}[[,
    2013](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23271823&sa=D&ust=1585016770884000){.c15}]{.c16}.[ ]{.c8}
2.  [Setting the lower oxygen limits: ]{.c22}There is debate on the
    proper PaO2 goal, and our rationale relies on evidence for lack of
    benefit from conservative PaO2 goals in clinical trials
    ([i.e.]{.c22}, PaO2 \> 55) and past association between lower PaO2
    and cognitive impairment, although the evidence is certainly not
    definitive (mean PaO2 71 \[IQR 67-80\] for cognitively impaired
    survivors versus mean PaO2 86 \[IQR, 70-98\] in non-impaired
    survivors of ARDS ([[Mikkelsen et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22492988&sa=D&ust=1585016770884000){.c15}
    ]{.c16}[[Am J Respir Crit Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22492988&sa=D&ust=1585016770885000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22492988&sa=D&ust=1585016770885000){.c15}
    ]{.c16}[[2012](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22492988&sa=D&ust=1585016770885000){.c15}]{.c16}^[\[c\]](#cmnt3){#cmnt_ref3}^).
    In the LOCO[2]{.c70} multi-center, randomized clinical trial,
    patients with ARDS were randomized to their PaO2 55-70, SpO2 88-92%;
    or PaO2 90-105, SpO2 \>95%); the trial was stopped after enrollment
    of 205 patients due to futility and safety concerns (44% mortality
    in conservative oxygen group versus 30%; ([[Barrot et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&sa=D&ust=1585016770886000){.c15}
    ]{.c16}[[New Eng J
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&sa=D&ust=1585016770886000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&sa=D&ust=1585016770886000){.c15}
    ]{.c16}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&sa=D&ust=1585016770886000){.c15}]{.c16}^[\[d\]](#cmnt4){#cmnt_ref4}^).

[]{.c85 .c45 .c75}

9.  [Proning and Pulmonary Vasodilators]{.c11} {#h.wgrateeto9z4 style="display:inline"}
    ------------------------------------------

```{=html}
<!-- -->
```
1.  [Prone early:]{.c17}

```{=html}
<!-- -->
```
1.  We recommend early proning in severe ARDS without vasodilator trial
    (a departure from our typical practice for ARDS not due to
    COVID-19): \< 36 hours from ARDS onset, start discussion of prone
    when P:F \< 150, prone within 12 hours of FiO2 \> 75% ([[Guérin et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&sa=D&ust=1585016770888000){.c15}
    ]{.c16}[[N Engl J
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&sa=D&ust=1585016770888000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&sa=D&ust=1585016770888000){.c15}
    ]{.c16}[[2013](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&sa=D&ust=1585016770888000){.c15}]{.c16}).[ ]{.c87}

```{=html}
<!-- -->
```
2.  [Eligibility criteria for proning:]{.c17}

```{=html}
<!-- -->
```
1.  [Eligibility may vary depending on resources and staffing. Currently
    we recommend: ]{.c8}

```{=html}
<!-- -->
```
1.  [Age \< 75]{.c8}
2.  No high grade shock (either single agent norepinephrine 20 mcg/min
    or norepinephrine \< 15 mcg/min[ and vasopressin)]{.c8}
3.  [Not on CRRT or at risk of impending renal failure (due to
    difficulties in maintaining dialysis access while proned)]{.c8}
4.  The o[nly absolute contraindications to proned ventilation are
    spinal cord injury and open chest; BMI and patient size are not
    contraindications]{.c8}

```{=html}
<!-- -->
```
3.  [To initiate prone ventilation outside of MICU and 11C:]{.c17}

```{=html}
<!-- -->
```
1.  [Discuss with the PCCM Consultation team assigned to that unit]{.c8}
2.  [ICU charge nurse to contact MICU charge nurse for nursing
    assistance]{.c8}

```{=html}
<!-- -->
```
4.  [Managing a proned patient: ]{.c17}

```{=html}
<!-- -->
```
1.  Proning protocol is available at the MICU sharepoint
2.  [Maintain deep sedation with target RASS -4 to -5 while
    proned.]{.c8}
3.  [1 hour post-initiation of prone ventilation:]{.c8}

```{=html}
<!-- -->
```
1.  Adjust oxygen parameters: re-assess lung mechanics (plateau pressure
    and P-V tool to determine optimal PEEP) and adjust PEEP and titrate
    FiO2 as in [["Managing Ventilation"
    section](#h.qrh9t96165ug){.c15}]{.c16}[ of this chapter.]{.c8}
2.  [Assess tidal volume and adjust ventilation parameters as in section
    6]{.c8}

```{=html}
<!-- -->
```
1.  If Vt \< 6 ml/kg, may increase to maximum limit of 8 ml/kg while Ppl
    \< 30[ (preferred maximum is 6 ml/kg)]{.c8}

```{=html}
<!-- -->
```
4.  [If patient demonstrates improvement on proning then
    recommend:]{.c8}

```{=html}
<!-- -->
```
1.  [Discontinuing of continuous neuromuscular blockade and re-assess
    ventilator dyssynchrony; re-institute if dyssynchronous]{.c8}
2.  [Return to supine ventilation when following criteria are met:]{.c8}

```{=html}
<!-- -->
```
1.  [Ppl \< 25]{.c8}
2.  [FiO2 \< 50%]{.c8}
3.  [pH \> 7.3]{.c8}
4.  [P:F \> 200]{.c8}

```{=html}
<!-- -->
```
5.  [Repositioning and skin care while proned: ]{.c8}

```{=html}
<!-- -->
```
1.  [Currently we recommend continuing proning as per the MICU proning
    protocol. This may change in the future depending on availability of
    PPE and staffing.]{.c8}

```{=html}
<!-- -->
```
5.  [Escalation if still hypoxic:]{.c17}

```{=html}
<!-- -->
```
1.  If hypoxia (PaO2 \< 55 with FiO2 \> 75%) persists after proning;
    then initiate continuous inhaled epoprostenol (see [["COVID-19
    Therapies and Clinical Trials"
    chapter](#h.kx686gedgtzg){.c15}]{.c16}[).]{.c8}
2.  If FiO2 \> 75% despite above, recommend consultation with ECMO team
    (see [["ECMO consultation"
    section](#h.24j39tc7pjup){.c15}]{.c16}[ of this chapter).]{.c8}

[ ]{.c8}

10. [ECMO consultation]{.c11} {#h.24j39tc7pjup style="display:inline"}
    -------------------------

```{=html}
<!-- -->
```
1.  [Refractory Hypoxemia:]{.c17}

```{=html}
<!-- -->
```
1.  If despite PEEP optimization, paralysis, prone ventilation,
    optimizing volume status, pulmonary vasodilators (when available)
    the patient meets the following criteria, then consider ECMO consult
    (pager 35010[):]{.c8}

```{=html}
<!-- -->
```
1.  [Ppl \> 30]{.c8}
2.  [FiO2 \> 75%]{.c8}
3.  [P:F \< 80]{.c8}

```{=html}
<!-- -->
```
2.  [Candidacy:]{.c17}

```{=html}
<!-- -->
```
1.  Final ECMO guidelines for COVID-19 patients remain under
    development^[\[e\]](#cmnt5){#cmnt_ref5}^. Examples of common
    considerations include:

```{=html}
<!-- -->
```
1.  [Patient age \< 65]{.c8}
2.  [Mechanical ventilation duration \< 7 days]{.c8}
3.  [BMI \< 35 and patient body weight \< 150 kg]{.c8}
4.  [CrCl \> 30]{.c8}
5.  [No multiorgan failure or high grade shock (can be on single
    pressor; norepinephrine \< 15 mcg/min)]{.c8}
6.  [No active solid or liquid malignancy]{.c8}
7.  [Absolute neutrophil count \> 500]{.c8}
8.  [Platelets \> 50,000]{.c8}
9.  [Able to tolerate anticoagulation on initiation (no active
    hemorrhage)]{.c8}
10. [No evidence of irreversible neurological injury]{.c8}
11. [Able to perform ADLs at baseline prior to illness]{.c8}

[]{.c8}

[Chapter 3: COVID-19 Therapies and Clinical Trials]{.c23 .c49} {#h.kx686gedgtzg .c44}
==============================================================

^[\[f\]](#cmnt6){#cmnt_ref6}^

[]{.c75 .c81 .c22 .c66 .c80}

1.  [Note: ]{.c11} {#h.cjp7h4q36i0a style="display:inline"}
    --------------

```{=html}
<!-- -->
```
1.  [The anti-viral and anti-inflammatory section below written by our
    critical care group is meant to provide a summary of the literature.
    This section does not represent the views or recommendations of the
    BWH Division of Infectious Disease. The separate BWH Infectious
    Disease guidelines and ID consultation service take precedence over
    the information from the literature below.]{.c75 .c81 .c22 .c66
    .c80}

[]{.c75 .c81 .c22 .c66 .c80}

2.  [Clinical trials ]{.c11} {#h.hf0jef6dlsvm style="display:inline"}
    ------------------------

```{=html}
<!-- -->
```
1.  [Consult Infectious Disease for:]{.c17}

```{=html}
<!-- -->
```
1.  P[atients with +COVID-19 PCR; and clinical history and any chest
    imaging suspicious for COVID-19. ]{.c8}
2.  [Re-consult if the patient develops ARDS (mechanically ventilated
    with P/F ratio \< 300) or shock/cytokine syndrome. ]{.c8}

```{=html}
<!-- -->
```
2.  [Current trials:]{.c17}

```{=html}
<!-- -->
```
1.  [ID teams are enrolling for clinical trials of Remdesivir and
    possibly other antiviral agents.]{.c8}
2.  ID and the PETAL network are coordinating to enroll for clinical
    trials of host-response modifying therapies (see  [["Systemic
    Corticosteroids"](#h.x05c129ivxrw){.c15}]{.c16} and [["Anti-IL6
    agents"](#h.m6l0vgre9d0s){.c15}]{.c16}[ sections of this
    chapter).]{.c8}

```{=html}
<!-- -->
```
3.  [Monitor for drug-drug interactions:]{.c17}

```{=html}
<!-- -->
```
1.  [Patients may arrive at the ICU already enrolled in a COVID-19
    clinical trial.  Verify that ICU treatment regimen does not add
    harmful drug interactions with study agents.]{.c8}

[]{.c8}

3.  [Antibiotic stewardship]{.c11} {#h.8vhrbtln428m style="display:inline"}
    ------------------------------

```{=html}
<!-- -->
```
1.  [Antibiotic choice:]{.c17}

```{=html}
<!-- -->
```
1.  [Antibiotics should reflect IDSA guidelines, presumed source, and
    MDRO risk. For a presumed pulmonary source: ]{.c8}

```{=html}
<!-- -->
```
1.  [Without risk factors for MRSA or Pseudomonas (i.e. living in
    community, no prior MDROs): ]{.c8}

```{=html}
<!-- -->
```
1.  Ceftriaxone +[ ]{.c22}[Azithromycin  ]{.c8}

```{=html}
<!-- -->
```
2.  [With risk factors for MRSA or Pseudomonas (i.e. chronic
    hospitalization, prior MDR infections): ]{.c8}

```{=html}
<!-- -->
```
1.  Vancomycin +[ ]{.c22}[Cefepime, and consider Ciprofloxacin if high
    concern for Pseudomonas]{.c8}

```{=html}
<!-- -->
```
3.  See special dispensations for oncology patients in [["Considerations
    for Oncology Patients" section](#h.aayfijcxre19){.c15}]{.c16} within
    [["Other Guidance" chapter](#h.l3i6lcz3jr27){.c15}]{.c16}.

```{=html}
<!-- -->
```
2.  [Formulation:]{.c17}

```{=html}
<!-- -->
```
1.  [Give oral antibiotics (Azithromycin, Levofloxacin, Ciprofloxacin)
    when possible to reduce volume load, unless concerns for poor oral
    absorption]{.c8}

```{=html}
<!-- -->
```
3.  [Coinfection:]{.c17}

```{=html}
<!-- -->
```
1.  [If concurrent influenza give Oseltamivir]{.c8}
2.  [Given lymphopenia consider Pneumocystis and treat accordingly]{.c8}

```{=html}
<!-- -->
```
4.  [Discontinuation:]{.c17}

```{=html}
<!-- -->
```
1.  [Antibiotics should be discontinued as soon as possible (within 48h)
    if:]{.c8}

```{=html}
<!-- -->
```
1.  [Clinical status is not deteriorating, cultures do not reveal
    pathogens at 48h, and procalcitonin and WBC are relatively stable
    from 0 to 48h]{.c8}

```{=html}
<!-- -->
```
1.  [Clinical judgement should prevail over any specific lab value]{.c8}

```{=html}
<!-- -->
```
5.  [Rationale]{.c33 .c22}[: ]{.c33}Clinical reports indicate that rates
    of bacterial superinfection of COVID19 are low (10-20%), but when
    present increase mortality risk. Anecdotal reports suggest less MRSA
    superinfection than with influenza. Unnecessary antibiotics carry
    risks of fluid overload and drug-resistance, as well as the
    possibility that antibiotics may become a limited resource. ([[Zhou
    et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770904000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770904000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770904000){.c15}]{.c16}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770905000){.c15}]{.c16};
    [[Yang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016770905000){.c15}
    ]{.c16}[[Lancet Respir
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016770905000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016770905000){.c15}]{.c16};
    [[Lippi and
    Plebani,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&sa=D&ust=1585016770906000){.c15}
    ]{.c16}[[Clinica Chimica
    Acta](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&sa=D&ust=1585016770906000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&sa=D&ust=1585016770906000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&sa=D&ust=1585016770906000){.c15}]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&sa=D&ust=1585016770907000){.c15}]{.c16};
    [[WHO,](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770907000){.c15}
    ]{.c16}[[COVID-19 Interim
    guidance](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770908000){.c15}]{.c14}[[,
    March
    2020](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770908000){.c15}]{.c16})

[ ]{.c17}

4.  Metered-dose inhalers (MDIs) vs. nebulizers {#h.eudti5z0ojjo style="display:inline"}
    -------------------------------------------

```{=html}
<!-- -->
```
1.  [N]{.c33}[on-intubated patients: ]{.c17}

```{=html}
<!-- -->
```
1.  [For COVID-19 Confirmed or PUI, use MDI (inhalers), not nebulizers,
    due to the increased aerosol risk. ]{.c8}
2.  [Because MDI supply is limited, only prescribe when needed.  ]{.c8}
3.  For non-COVID-19 Confirmed or PUI patient, use nebulizers even if on
    droplet precautions ([e.g.,]{.c22}[ influenza) because MDI supply is
    limited. ]{.c8}
4.  After a patient is COVID-neg (and no longer on COVID precautions per
    infection control): After the patient's current MDI runs out, switch
    to neb.

```{=html}
<!-- -->
```
2.  [Intubated patients]{.c33}[:]{.c33}[ ]{.c17}

```{=html}
<!-- -->
```
1.  The ventilator circuit is a closed system so nebulizers can be used
    when required ([e.g., ]{.c22}DuoNeb standing and albuterol PRN).

```{=html}
<!-- -->
```
3.  [Rationale]{.c33}[:]{.c33} Nebulization may aerosolize viral
    particles and contribute to disease transmission.  COVID-19 clinical
    reports do not indicate wheeze as a common symptom, and not all
    patients require bronchodilators ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770910000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770910000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770911000){.c15}]{.c16}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770911000){.c15}]{.c16};
    [[Yang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016770911000){.c15}
    ]{.c16}[[Lancet Repir
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016770911000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016770911000){.c15}]{.c16}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016770911000){.c15}]{.c16};
    [[Guan et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&sa=D&ust=1585016770912000){.c15}
    ]{.c16}[[N Engl J
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&sa=D&ust=1585016770912000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&sa=D&ust=1585016770912000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&sa=D&ust=1585016770912000){.c15}]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&sa=D&ust=1585016770913000){.c15}]{.c16};
    [[WHO,](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770913000){.c15}
    ]{.c16}[[COVID-19 Interim
    guidance](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770913000){.c15}]{.c14}[[,
    March
    2020](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770914000){.c15}]{.c16}[)]{.c8}

[]{.c17}

5.  [Airway Clearance  ]{.c11} {#h.8pktimpr5u6o style="display:inline"}
    --------------------------

```{=html}
<!-- -->
```
1.  [Management principles:]{.c17}

```{=html}
<!-- -->
```
1.  [Reports from Wuhan and Italy indicate that some patients develop
    very thick secretions causing dangerous mucus plugging. However,
    nebulizers and airway clearance techniques may aerosolize
    secretions]{.c8}
2.  Airway clearance should be used only in selected ventilated
    patients[ ]{.c33 .c22}(closed circuit)[ ]{.c22}with extremely thick
    secretions to avoid mucus plugging that would require bronchoscopy

```{=html}
<!-- -->
```
2.  [For t]{.c33}[hinning secretions:]{.c17}

```{=html}
<!-- -->
```
1.  Anecdotal reports suggest Dornase alfa may be particularly effective
    in thinning secretions in COVID-19 patients. However, data for
    Dornase alfa in non-CF patients is poor. For now we
    recommend:^[\[g\]](#cmnt7){#cmnt_ref7}[\[h\]](#cmnt8){#cmnt_ref8}^

```{=html}
<!-- -->
```
1.  Consideration of [Dornase alfa 2.5mg nebulizer once daily ]{.c8}

```{=html}
<!-- -->
```
1.  [Can cause bronchoconstriction and mucosal bleeding ]{.c8}
2.  [Pre-treat with albuterol 2.5mg, just prior to delivery]{.c8}
3.  Avoid in setting of bloody secretions

```{=html}
<!-- -->
```
2.  Alternative: Nebulized [hypertonic (3-7%) saline once daily]{.c8}

```{=html}
<!-- -->
```
1.  [Side effects can include bronchoconstriction]{.c8}

```{=html}
<!-- -->
```
1.  [Start with 3% to assess response and bronchoconstriction]{.c8}
2.  Pre-treat with albuterol 2.5mg just prior to delivery

```{=html}
<!-- -->
```
3.  Avoid N-acetylcysteine due to frequent dosing requirements

```{=html}
<!-- -->
```
3.  [Airway clearance:  ]{.c33}

```{=html}
<!-- -->
```
1.  Continue chest PT vests if patient uses at home ([e.g.,]{.c22} CF
    patients) with appropriate isolation precautions[. Bronchiectasis
    patients may be considered on a case-by-case basis. ]{.c8}
2.  Avoid oscillating positive expiratory pressure devices (Aerobika or
    Acapella) and cough assist (MIE).

```{=html}
<!-- -->
```
6.  [Inhaled Pulmonary Vasodilators]{.c11} {#h.ym3ao1e1uli3 style="display:inline"}
    --------------------------------------

```{=html}
<!-- -->
```
1.  [Indications for use:]{.c17}

```{=html}
<!-- -->
```
1.  [Inhaled vasodilators should not be routinely used except in two
    circumstances]{.c8}

```{=html}
<!-- -->
```
1.  As a rescue strategy in already prone ventilated patients (see
    [["Respiratory Support for COVID-19 Patients"
    chapter](#h.hu2czim2nti8){.c15}]{.c16}[). ]{.c8}

```{=html}
<!-- -->
```
1.  There is no evidence of survival benefit of inhaled vasodilators in
    ARDS, and there are risks of viral aerosolization when connecting
    the device  ([[Fuller et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25742022&sa=D&ust=1585016770920000){.c15}
    ]{.c16}[[Chest](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25742022&sa=D&ust=1585016770920000){.c15}]{.c14}[[,
    2015](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25742022&sa=D&ust=1585016770920000){.c15}]{.c16};
    [[Gebistorf et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770921000){.c15}
    ]{.c16}[[Cochrane Database Syst
    Rev](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770921000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770921000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770921000){.c15}]{.c14}[[2016](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770922000){.c15}]{.c16};
    [[Afshari et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28806480&sa=D&ust=1585016770922000){.c15}
    ]{.c16}[[Cochrane Database Syst
    Rev](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28806480&sa=D&ust=1585016770922000){.c15}]{.c14}[[,
    2017](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28806480&sa=D&ust=1585016770923000){.c15}]{.c16}[)]{.c8}

```{=html}
<!-- -->
```
2.  To reduce RV afterload in hemodynamically significant RV failure in
    consultation with cardiology

```{=html}
<!-- -->
```
2.  [Instructions for use:]{.c17}

```{=html}
<!-- -->
```
1.  [If inhaled vasodilators are used, they should reevaluated at 4
    hours  ]{.c8}

```{=html}
<!-- -->
```
1.  [Inhaled Epoprostenol:]{.c42 .c0}[ ]{.c59 .c42 .c75 .c0 .c57}

```{=html}
<!-- -->
```
1.  [S]{.c0}[tart continuous nebulization at 0.05mcg/kg/min based on IBW
     ]{.c8 .c0}

```{=html}
<!-- -->
```
1.  [If no improvement in P/F ratio in 2 hours, wean off by decreasing
    0.01mcg/kg/min every ]{.c0}[hour]{.c0}[ ]{.c8 .c0}

```{=html}
<!-- -->
```
2.  [Inhaled Nitric Oxide (iNO):]{.c41}

```{=html}
<!-- -->
```
1.  Strong consideration in refractory ARDS that does not respond to
    inhaled epoprostenol. [ ]{.c8}

```{=html}
<!-- -->
```
1.  Limited [in vitro]{.c22} data notes that iNO at high doses inhibits
    replication of SARS-CoV, but this has not been studied [in
    vivo]{.c22}. ([[Akerstrom et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&sa=D&ust=1585016770925000){.c15}
    ]{.c16}[[J
    Virol](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&sa=D&ust=1585016770926000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&sa=D&ust=1585016770926000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&sa=D&ust=1585016770926000){.c15}]{.c14}[[2005](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&sa=D&ust=1585016770926000){.c15}]{.c16}; [[Gebistorf
    et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770927000){.c15}
    ]{.c16}[[Cochrane Database Syst
    Rev](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770927000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770927000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770928000){.c15}]{.c14}[[2016](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016770928000){.c15}]{.c16}[)]{.c8}
2.  iNO may be included in future trial protocols[, such as early
    initiation in milder disease (non-intubated). ]{.c8}

[]{.c8}

7.  S[ystemic Corticosteroids]{.c11} {#h.x05c129ivxrw style="display:inline"}
    --------------------------------

```{=html}
<!-- -->
```
1.  [Data on ]{.c33}[corticosteroids for COVID-19: ]{.c33}[ ]{.c24 .c22}

```{=html}
<!-- -->
```
1.  [Most studies show negative effects of corticosteroids on similar
    viruses]{.c8}

```{=html}
<!-- -->
```
1.  There is no clinical evidence of net benefit from steroids in
    SARS-CoV, MERS-CoV or influenza infection, and observational data
    show increased mortality, more secondary infections, impaired viral
    clearance and more adverse effects in survivors
    ([e.g.,]{.c22} psychosis, diabetes, avascular necrosis) ([[Lee et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&sa=D&ust=1585016770930000){.c15}]{.c16}[[ J
    Clin
    Virol](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&sa=D&ust=1585016770930000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&sa=D&ust=1585016770931000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&sa=D&ust=1585016770931000){.c15}]{.c14}[[2004](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&sa=D&ust=1585016770931000){.c15}]{.c16};
    [[Stockman et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16968120&sa=D&ust=1585016770931000){.c15}
    ]{.c16}[[PLoS
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16968120&sa=D&ust=1585016770932000){.c15}]{.c14}[[,
    2006](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16968120&sa=D&ust=1585016770932000){.c15}]{.c16};
    [[Arabi](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&sa=D&ust=1585016770932000){.c15}]{.c16}[[ et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&sa=D&ust=1585016770933000){.c15}
    ]{.c16}[[Am J Respir Crit Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&sa=D&ust=1585016770933000){.c15}]{.c14}[[,
    201](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&sa=D&ust=1585016770933000){.c15}]{.c16}[[8](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&sa=D&ust=1585016770933000){.c15}]{.c16};
    [[WHO,](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770934000){.c15}
    ]{.c16}[[COVID-19 Interim
    guidance](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770934000){.c15}]{.c14}[[,
    March
    2020](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770935000){.c15}]{.c16};
    [[Wu et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770935000){.c15}
    ]{.c16}[[JAMA Int
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770935000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770936000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770936000){.c15}]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770936000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
2.  However, a new retrospective cohort (201 patients, 84 \[42%\] of
    whom developed ARDS) demonstrated that among patients with ARDS,
    methylprednisolone decreased risk of death (HR, 0.38; 95% CI,
    0.20-0.72) ([[Wu et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770937000){.c15}
    ]{.c16}[[JAMA Int
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770937000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770937000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770938000){.c15}]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016770938000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
2.  [Recommendation]{.c33}[:]{.c8}

```{=html}
<!-- -->
```
1.  [We recommend against using steroids for COVID-19 except as part of
    a clinical trial]{.c17}

```{=html}
<!-- -->
```
1.  This is in line with WHO guidance
    ([[WHO,](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770939000){.c15}
    ]{.c16}[[COVID-19 Interim
    guidance](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770939000){.c15}]{.c14}[[,
    March
    2020](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770939000){.c15}]{.c16}).

```{=html}
<!-- -->
```
3.   [Use corticosteroids if required for other indications:]{.c17}

```{=html}
<!-- -->
```
1.  [ Use the lowest dose for the shortest duration:]{.c8}

```{=html}
<!-- -->
```
1.  [Asthma or COPD exacerbation]{.c8}

```{=html}
<!-- -->
```
1.  [40mg prednisone PO or 30mg methylprednisolone IV, once daily x 3-5
    days]{.c8}

```{=html}
<!-- -->
```
2.  [Shock with history of chronic steroid use \> 10mg prednisone
    daily:]{.c8}

```{=html}
<!-- -->
```
1.  [50mg hydrocortisone IV Q6H until improvement in shock ]{.c8}

```{=html}
<!-- -->
```
3.  [Multipressor shock without history of chronic steroid use]{.c8}

```{=html}
<!-- -->
```
1.  [50mg hydrocortisone IV Q6H until improvement in shock ]{.c8}

```{=html}
<!-- -->
```
8.  [Anti-IL6 Agents (Tocilizumab, Siltuximab)  ]{.c11} {#h.m6l0vgre9d0s style="display:inline"}
    ---------------------------------------------------

```{=html}
<!-- -->
```
1.  [Pathophysiology:]{.c17}

```{=html}
<!-- -->
```
1.  IL-6 activates T cells and macrophages, among other cell types (see
    [["Cytokine Activation Syndrome"
    section](#h.7i62kagnynf0){.c15}]{.c16} in [["Shock"
    chapter](#h.dpe5gr1hwjp){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
1.  IL-6 inhibitors are approved for cytokine activation syndrome
    complications related to Chimeric Antigen Receptor T cell (CAR-T)
    therapy ([[Brudno and
    Kochenderfer,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&sa=D&ust=1585016770941000){.c15}
    ]{.c16}[[Blood
    Rev](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&sa=D&ust=1585016770941000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&sa=D&ust=1585016770941000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&sa=D&ust=1585016770942000){.c15}]{.c14}[[2019](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&sa=D&ust=1585016770942000){.c15}]{.c16};
    [[Rubin et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&sa=D&ust=1585016770942000){.c15}
    ]{.c16}[[Brain](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&sa=D&ust=1585016770942000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&sa=D&ust=1585016770943000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&sa=D&ust=1585016770943000){.c15}]{.c14}[[20](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&sa=D&ust=1585016770943000){.c15}]{.c16}[[19](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&sa=D&ust=1585016770943000){.c15}]{.c16}[).]{.c8}
2.  [IL-6 levels are reported to correlate with severe COVID-19 ]{.c8}
3.  [While patients have peripheral lymphopenia, BAL fluid is often
    lymphocytic, suggesting that IL-6 inhibition and prevention of T
    cell activation may be protective.]{.c8}

```{=html}
<!-- -->
```
2.  [Recommendation:]{.c33}

```{=html}
<!-- -->
```
1.  [We do not recommend routine use at this time ]{.c8}

```{=html}
<!-- -->
```
1.  There are anecdotal reports of benefit of tocilizumab in COVID-19
    patients but no rigorous studies are available (Anecdotal reports
    from Italy^[\[i\]](#cmnt9){#cmnt_ref9}^; [[National Health
    Commission & State Administration of Traditional Chinese
    Medicine,](https://www.google.com/url?q=http://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf&sa=D&ust=1585016770945000){.c15}
    ]{.c16}[[Diagnosis and Treatment Protocol for Novel Coronavirus
    Pneumonia \[Trial Version
    7\]](https://www.google.com/url?q=http://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf&sa=D&ust=1585016770945000){.c15}]{.c14}[[,
    March
    2020](https://www.google.com/url?q=http://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf&sa=D&ust=1585016770945000){.c15}]{.c16}^[\[j\]](#cmnt10){#cmnt_ref10}^[)]{.c8}

```{=html}
<!-- -->
```
2.  For severe cytokine activation syndrome cases (see [["Other
    Guidance" chapter](#h.l3i6lcz3jr27){.c15}]{.c16}[):]{.c8}

```{=html}
<!-- -->
```
1.  Consult Infectious Disease team for enrollment in a clinical trial
    based on CRP and IL-6 levels.^[\[k\]](#cmnt11){#cmnt_ref11}^

```{=html}
<!-- -->
```
1.  Exercise caution if [secondary infection is clinically suspected,
    including sepsis, pneumocystis or bacterial pneumonia. ]{.c8}

```{=html}
<!-- -->
```
3.  [Dosing regimens]{.c33}[: ]{.c33}

```{=html}
<!-- -->
```
1.  [Tocilizumab 4-8mg/kg (suggested dose 400mg) IV x1 (anti-IL6R
    mAb)]{.c8}

```{=html}
<!-- -->
```
1.  [Dose can be repeated 12h later if inadequate response to the first
    dose.  Total dose should be no more than 800mg. Tocilizumab should
    not be administered more than twice. ]{.c8}
2.  [Common adverse effects include: ]{.c8}

```{=html}
<!-- -->
```
1.  [Transaminitis (AST, ALT) \> 22%]{.c8}
2.  [Infusion reaction 4-20%]{.c8}
3.  [Hypercholesterolemia 20%]{.c8}
4.  [Upper respiratory tract infection 7%]{.c8}
5.  [Neutropenia 2-7%]{.c8}

```{=html}
<!-- -->
```
2.  [Alternative: Siltuximab 11mg/kg IV x1 (anti-IL6 mAb)]{.c8}

```{=html}
<!-- -->
```
1.  [Common adverse effects include: ]{.c8}

```{=html}
<!-- -->
```
1.  [Edema \>26%]{.c8}
2.  [Upper respiratory infection \>26%]{.c8}
3.  [Pruritus / skin rash 28%]{.c8}
4.  [Hyperuricemia 11%]{.c8}
5.  [Lower respiratory tract infection 8%]{.c8}
6.  [Thrombocytopenia 8%]{.c8}
7.  [Hypotension 4% ]{.c8}

[]{.c8}

9.  [Hydroxychloroquine and Chloroquine]{.c11} {#h.wr1agkjgho7b style="display:inline"}
    ------------------------------------------

```{=html}
<!-- -->
```
1.  [Pathophysiology:]{.c17 .c0}

```{=html}
<!-- -->
```
1.  [Hydroxychloroquine (HQ) is an anti-malarial 4-aminoquinoline shown
    to have in vitro (but not yet in-vivo) activity against diverse RNA
    viruses including SARS-CoV-1
    (]{.c0}[[T](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32147496&sa=D&ust=1585016770949000){.c15}]{.c16
    .c0}[[ouret and de
    Lamballerie,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32147496&sa=D&ust=1585016770950000){.c15}
    ]{.c16}[[Antivir
    Res](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32147496&sa=D&ust=1585016770950000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32147496&sa=D&ust=1585016770950000){.c15}]{.c16
    .c0}[). ]{.c8 .c0}
2.  [HQ is thought to act through multiple mechanisms (]{.c0}[[Devaux et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171740&sa=D&ust=1585016770950000){.c15}
    ]{.c16 .c0}[[Int J Antimicrob
    Agent](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171740&sa=D&ust=1585016770951000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171740&sa=D&ust=1585016770951000){.c15}]{.c16
    .c0}[):]{.c8 .c0}

```{=html}
<!-- -->
```
1.  [Inhibition of viral entry.]{.c33 .c0}[ HQ inhibits synthesis of
    sialic acids and interferes with protein glycosylation, which may
    disrupt interactions necessary for viral attachment and entry
    (]{.c0}[[Vincent et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16115318&sa=D&ust=1585016770951000){.c15}
    ]{.c16 .c0}[[Virol
    J](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16115318&sa=D&ust=1585016770951000){.c15}]{.c14
    .c0}[[,
    2005](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16115318&sa=D&ust=1585016770951000){.c15}]{.c16
    .c0}[; ]{.c0}[[Olofsson et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15766653&sa=D&ust=1585016770952000){.c15}
    ]{.c16 .c0}[[Lancet Infect
    Dis,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15766653&sa=D&ust=1585016770952000){.c15}]{.c14
    .c0}[[ 2005](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15766653&sa=D&ust=1585016770952000){.c15}]{.c16
    .c0}[).]{.c8 .c0}
2.  [Inhibition of viral release into the host cell.]{.c33 .c0}[ HQ
    blocks endosomal acidification, which activates endosomal proteases.
    These proteases are required to initiate coronavirus/endosome fusion
    that releases viral particles into the cell (]{.c0}[[Yang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15140961&sa=D&ust=1585016770952000){.c15}
    ]{.c16 .c0}[[J
    Virol](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15140961&sa=D&ust=1585016770952000){.c15}
    ]{.c14
    .c0}[[2004](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15140961&sa=D&ust=1585016770953000){.c15}]{.c16
    .c0}[).]{.c8 .c0}
3.  [Reduction of viral infectivity.]{.c33 .c0}[ HQ has been shown to
    inhibit protein glycosylation and proteolytic maturation of viral
    proteins. Studies on other RNA viruses have shown a resulting
    accumulation of non-infective viral particles, or an inability of
    viral particles to bud out of the host cell (]{.c0}[[Savarino et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15076236&sa=D&ust=1585016770953000){.c15}
    ]{.c16 .c0}[[J Acquir Immune Defic
    Syndr](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15076236&sa=D&ust=1585016770953000){.c15}]{.c14
    .c0}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15076236&sa=D&ust=1585016770953000){.c15}
    ]{.c16
    .c0}^[\[l\]](#cmnt12){#cmnt_ref12}[\[m\]](#cmnt13){#cmnt_ref13}^[[2004](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15076236&sa=D&ust=1585016770953000){.c15}]{.c16
    .c0}[;]{.c0}^[\[n\]](#cmnt14){#cmnt_ref14}[\[o\]](#cmnt15){#cmnt_ref15}^[ ]{.c0}[[Klumperman
    et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/8083990&sa=D&ust=1585016770954000){.c15}
    ]{.c16 .c0}[[J
    Virol](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/8083990&sa=D&ust=1585016770954000){.c15}]{.c14
    .c0}[[,
    1994](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/8083990&sa=D&ust=1585016770954000){.c15}]{.c16
    .c0}[).]{.c8 .c0}
4.  [Immune modulation.]{.c33 .c0}[ HQ reduces toll-like receptors and
    cGAS-STING signaling. It has been shown to reduce release of a
    number of pro-inflammatory cytokines from several immune cell types
    (]{.c0}[[Schrezenmeier and
    Dorner,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32034323&sa=D&ust=1585016770954000){.c15}
    ]{.c16 .c0}[[Nat Rev
    Rheum](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32034323&sa=D&ust=1585016770955000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32034323&sa=D&ust=1585016770955000){.c15}]{.c16
    .c0}[).]{.c0}

```{=html}
<!-- -->
```
2.  [Data:]{.c33 .c0}

```{=html}
<!-- -->
```
1.  [An ]{.c0}[expert consensus group out of China ]{.c0}[suggests that
    Chloroquine ]{.c0}[improved lung imaging and shortened disease
    course (]{.c0}[[Zhonghua et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32075365&sa=D&ust=1585016770955000){.c15}
    ]{.c16
    .c0}[[CMAPH](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32075365&sa=D&ust=1585016770956000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32075365&sa=D&ust=1585016770956000){.c15}]{.c16
    .c0}[). Chloroquine will be included in the next treatment
    guidelines from the National Health Commission, but the specific
    data on which this is based is not available yet (]{.c0}[[Gao et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32074550&sa=D&ust=1585016770956000){.c15}
    ]{.c16 .c0}[[Biosci
    Trends](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32074550&sa=D&ust=1585016770956000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32074550&sa=D&ust=1585016770957000){.c15}]{.c16
    .c0}[).]{.c0}
2.  [Hydroxychloroquine was found to be more potent than chloroquine in
    inhibiting SARS-CoV-2 in vitro (]{.c0}[[Yao et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32150618&sa=D&ust=1585016770957000){.c15}
    ]{.c16 .c0}[[Clin Infect
    Dis](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32150618&sa=D&ust=1585016770957000){.c15}]{.c14
    .c0}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32150618&sa=D&ust=1585016770958000){.c15}]{.c16
    .c0}[)]{.c0}

```{=html}
<!-- -->
```
3.  [Recommendation:]{.c17 .c0}

```{=html}
<!-- -->
```
1.  [Strong consideration of h]{.c0}[ydroxychloroquine in patients who
    require supplemental oxygen who are not candidates for other
    clinical trials.]{.c0}^[\[p\]](#cmnt16){#cmnt_ref16}^

```{=html}
<!-- -->
```
4.  [Dosing ]{.c33 .c0}[(from published literature)]{.c33 .c0
    .c22}[:]{.c17 .c0}

```{=html}
<!-- -->
```
1.  [Hydroxychloroquine: ]{.c8 .c0}

```{=html}
<!-- -->
```
1.  [400mg PO BID on the first day, ]{.c0}[followed by 200mg ]{.c0}[q12
    (q8h if concerns for absorption) for 5-10 days]{.c8 .c0}

```{=html}
<!-- -->
```
2.  [Chloroquine (not available at BWH):]{.c8 .c0}

```{=html}
<!-- -->
```
1.  [Second line agent (increased toxicity compared to
    Hydroxychloroquine)]{.c8 .c0}
2.  [500mg Chloroquine phosphate 500mg PO BID for 10
    days]{.c0}^[\[q\]](#cmnt17){#cmnt_ref17}^

```{=html}
<!-- -->
```
1.  [Common adverse reactions include: ]{.c8 .c0}

```{=html}
<!-- -->
```
1.  [Prolonged QT interval and risk of Torsade de pointes]{.c8 .c0}
2.  [Cardiomyopathy]{.c8 .c0}
3.  [Bone marrow suppression]{.c8 .c0}

```{=html}
<!-- -->
```
2.  [Contraindicated in epilepsy and porphyria]{.c8 .c0}

```{=html}
<!-- -->
```
5.  [Monitoring]{.c17 .c0}

```{=html}
<!-- -->
```
1.  [If hydroxychloroquine is being administered with azithromycin,
    there should be vigilant QTc monitoring:]{.c8 .c0}

```{=html}
<!-- -->
```
1.  [Obtain baseline ECG and daily ECG]{.c8 .c0}
2.  [Discontinue all other QT prolonging agents]{.c8 .c0}
3.  [Maintain continuous telemetry while under treatment ]{.c8 .c0}
4.  [Do not start if QTc \>500 or 550 with pacing or BBB. ]{.c8 .c0}
5.  [Discontinue if there is an increase in PVCs or non-sustained PMVT.
    ]{.c8 .c0}

```{=html}
<!-- -->
```
2.  [There is a reported risk of hydroxychloroquine induced
    cardiomyopathy. Case series and reports have found this to be a
    long-term (years) and dose-dependent phenomenon. Given the
    anticipated short duration in COVID-19, it is not an expected risk
    (]{.c0}[[Nord et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15079764&sa=D&ust=1585016770961000){.c15}
    ]{.c16 .c0}[[Semin Arthritis
    Rheum](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15079764&sa=D&ust=1585016770962000){.c15}]{.c14
    .c0}[[,
    2004](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15079764&sa=D&ust=1585016770962000){.c15}]{.c16
    .c0}[). ]{.c0}^[\[r\]](#cmnt18){#cmnt_ref18}^

[]{.c17 .c0}

[]{.c8 .c0}

10. Angiotensin Converting Enzyme Inhibitors (ACE-I) and [Angiotensin II Receptor Blockers (ARB)]{.c11} {#h.uebugzw0ifj style="display:inline"}
    ---------------------------------------------------------------------------------------------------

```{=html}
<!-- -->
```
1.  [Pathophysiology:]{.c17}

```{=html}
<!-- -->
```
1.  SARS-CoV-2, the virus that causes COVID-19, enters the same cell
    entry receptor as SARS-CoV: angiotensin converting enzyme II (ACE2)
    ([[Paules et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31971553&sa=D&ust=1585016770963000){.c15}]{.c16}[[,
    JAMA,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31971553&sa=D&ust=1585016770963000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31971553&sa=D&ust=1585016770964000){.c15}]{.c16}[).
    SARS-CoV-2 is thought to have a higher affinity to ACE2 than
    SARS-CoV. ]{.c8}

```{=html}
<!-- -->
```
1.  ACE2 is expressed in the heart, lungs, vasculature, and kidneys.
     ACEi and ARBs in animal models increase the expression of ACE2
    ([[Zheng et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32139904&sa=D&ust=1585016770964000){.c15}
    ]{.c16}[[Nat Rev
    Cardiol](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32139904&sa=D&ust=1585016770965000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32139904&sa=D&ust=1585016770965000){.c15}]{.c16})[,
    though this has not been confirmed in human studies. This has led to
    the hypothesis that ACE-I and ARBs, might worsen myocarditis or
    precipitate ACS. ]{.c8}
2.  It has also been hypothesized that the upregulation of ACE2 is
    therapeutic in COVID-19 and that ARBs might be protective in during
    infection ([[Gurwitz
    D,](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32129518&sa=D&ust=1585016770965000){.c15}
    ]{.c16}[[Drug Dev
    Res](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32129518&sa=D&ust=1585016770966000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32129518&sa=D&ust=1585016770966000){.c15}]{.c16}).^[\[s\]](#cmnt19){#cmnt_ref19}^

```{=html}
<!-- -->
```
2.  [Recommendation:]{.c33 .c0 .c35}

```{=html}
<!-- -->
```
1.  [For ]{.c0 .c35}[outpatients]{.c0 .c35}[: ]{.c23 .c0 .c35}

```{=html}
<!-- -->
```
1.  [We recommend ]{.c0 .c35}[against discontinuing]{.c0
    .c35}[ outpatient ACEi/ARBs. ]{.c23 .c0 .c35}

```{=html}
<!-- -->
```
2.  [For ]{.c0 .c35}[inpatients]{.c0 .c35}[:]{.c23 .c0 .c35}

```{=html}
<!-- -->
```
1.  [We recommend against routine discontinuation of ACEi/ARBs, unless
    otherwise indicated (]{.c0 .c35}[e.g.,]{.c0 .c22 .c35}[ acute kidney
    injury, hypotension, shock, etc). ]{.c0 .c35}

```{=html}
<!-- -->
```
3.  [Rationale]{.c23 .c0 .c35}

```{=html}
<!-- -->
```
1.  [The American College of Cardiology, American Heart Association and
    Heart Failure Society of America joint statement recommends against
    discontinuing ACE-I and ARBs in patients with COVID-19 (]{.c0
    .c35}[[Bozkurt et
    al,](https://www.google.com/url?q=http://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19&sa=D&ust=1585016770967000){.c15}]{.c16
    .c0 .c35}[[ HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS
    Antagonists in
    COVID-19,](https://www.google.com/url?q=http://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19&sa=D&ust=1585016770968000){.c15}
    ]{.c14 .c0
    .c35}[[2020](https://www.google.com/url?q=http://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19&sa=D&ust=1585016770968000){.c15}]{.c16
    .c0 .c35}[). This remains an area of investigation and it is unclear
    how these medications affect patients with COVID-19.]{.c23 .c0 .c35}

[]{.c59 .c0 .c35 .c80 .c93}

11. Non-steroidal anti-inflammatory drugs (NSAIDs) {#h.msot2gdaj2bg style="display:inline"}
    ----------------------------------------------

```{=html}
<!-- -->
```
1.  [Pathophysiology:]{.c17}

```{=html}
<!-- -->
```
1.  SARS-CoV-2 binds to cells via ACE2. ACE2 is upregulated by ibuprofen
    in animal models, and this might contribute (see [["Angiotensin
    Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor
    Blockers (ARB)" section](#h.uebugzw0ifj){.c15}]{.c16}[ of this
    chapter).]{.c8}

[]{.c8}

2.  [Recommendation:]{.c17}

```{=html}
<!-- -->
```
1.  Consider acetaminophen instead of NSAIDs if possible; risk / benefit
    should be discussed with patients and treatment tea[m. ]{.c8}

```{=html}
<!-- -->
```
1.  Reports from France indicate possible increase in mortality with
    ibuprofen in COVID-19 infection, but these reports have not been
    corroborated ([[Fang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&sa=D&ust=1585016770970000){.c15}
    ]{.c16}[[Lancet Respir
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&sa=D&ust=1585016770970000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&sa=D&ust=1585016770970000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&sa=D&ust=1585016770971000){.c15}]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&sa=D&ust=1585016770971000){.c15}]{.c16};
    [[Day
    M,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32184201&sa=D&ust=1585016770971000){.c15}
    ]{.c16}[[BMJ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32184201&sa=D&ust=1585016770971000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32184201&sa=D&ust=1585016770972000){.c15}]{.c16}[).
    ]{.c8}
2.  WHO clarified on 3/20/20 it does not recommend avoiding NSAIDs as of
    3/18/20
    ([[WHO,](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770972000){.c15}
    ]{.c16}[[COVID-19 Interim
    guidance](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770973000){.c15}]{.c14}[[,
    March
    2020](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016770973000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
12. Blood Products[ ]{.c11} {#h.p7atxkt2b3sh style="display:inline"}
    -----------------------

```{=html}
<!-- -->
```
1.  [Recommendation:]{.c17}

```{=html}
<!-- -->
```
1.  R[estrictive transfusion strategy (Hct \> 21, Hgb \> 7) is
    recommended unless the patient is actively bleeding or there is
    concern for acute coronary syndrome.]{.c8}

```{=html}
<!-- -->
```
1.  [Parsimony is encouraged given limited supplies (blood drives are
    limited by social distancing)]{.c8}
2.  Acute coronary syndrome[: Hgb \> 10]{.c8}
3.  [Oncology patients: if possible, reduce threshold to Hgb \>7]{.c8}
4.  All others: Hgb \> 7
5.  Massive transfusion protocol, as a very limited resource, will need
    to be activated only by the ICU attending 

```{=html}
<!-- -->
```
2.  [Other blood products:]{.c8}

```{=html}
<!-- -->
```
1.  [Treat bleeding not numbers]{.c8}
2.  [FFP or 4 factor-PCC (lower volume) for active bleeding in setting
    of known or suspected coagulation abnormalities]{.c8}
3.  [Warfarin reversal: use 4 factor-PCC given longer effect and lower
    volume]{.c8}
4.  [Platelets: goal \> 30K unless actively bleeding]{.c8}

```{=html}
<!-- -->
```
2.  [Rationale]{.c33 .c22}: Volume overload is of particular concern in
    patients with COVID-19 so transfusions may be harmful. Randomized
    controlled trials of ICU patients have shown that a conservative
    transfusion strategy (Hgb \> 7) is associated with less pulmonary
    edema, fewer cardiac events, fewer transfusions (likely fewer
    transfusion reactions) and no evidence of harm compared to a liberal
    transfusion strategy. ([[Hébert et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&sa=D&ust=1585016770976000){.c15}
    ]{.c16}[[N Engl J
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&sa=D&ust=1585016770976000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&sa=D&ust=1585016770976000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&sa=D&ust=1585016770976000){.c15}]{.c14}[[1999](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&sa=D&ust=1585016770977000){.c15}]{.c16};
    [[Holst et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25270275&sa=D&ust=1585016770977000){.c15}
    ]{.c16}[[N Engl J
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25270275&sa=D&ust=1585016770977000){.c15}]{.c14}[[,
    2014](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25270275&sa=D&ust=1585016770977000){.c15}]{.c16};
    [[Gajic et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16617262&sa=D&ust=1585016770978000){.c15}
    ]{.c16}[[Crit Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16617262&sa=D&ust=1585016770978000){.c15}]{.c14}[[,
    2006](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16617262&sa=D&ust=1585016770978000){.c15}]{.c16}).

[]{.c8}

[Chapter 4: Cardiac Complications of COVID-19]{.c23 .c49} {#h.6zfga8b63w2s .c44 .c0}
=========================================================

1.  [Acute Cardiac Injury]{.c11} {#h.sxzvrsrmkd1g style="display:inline"}
    ----------------------------

```{=html}
<!-- -->
```
1.  [Definition:]{.c17}

```{=html}
<!-- -->
```
1.  Defined in studies as troponin \> 99[th]{.c64} percentile, or
    abnormal EKG or echocardiographic findings ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770979000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770979000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770979000){.c15}]{.c16}[).
    Non-specific. ]{.c8}

```{=html}
<!-- -->
```
2.  [Incidence]{.c33}[:]{.c8}

```{=html}
<!-- -->
```
1.  Incidence of 7-22% in hospitalized patients with COVID-19 in China
    ([[Ruan et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770980000){.c15}
    ]{.c16}[[Intensive Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770980000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770981000){.c15}]{.c16}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770981000){.c15}]{.c16};
    [[Wang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770981000){.c15}
    ]{.c16}[[JAMA](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770981000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770982000){.c15}]{.c16};
    [[Chen et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&sa=D&ust=1585016770982000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&sa=D&ust=1585016770982000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&sa=D&ust=1585016770982000){.c15}]{.c16}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&sa=D&ust=1585016770983000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
3.  [Prognostic implications: ]{.c17}

```{=html}
<!-- -->
```
1.  ACI is higher in non-survivors (59%, n=32) than survivors (1%, n=1)
    ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770983000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770983000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770984000){.c15}]{.c16}[).]{.c8}
2.  ACI is higher in ICU patients (22%, n=22) compared to non-ICU
    patients (2%, n=2) ([[Wang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770984000){.c15}
    ]{.c16}[[JAMA](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770984000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770985000){.c15}]{.c16}[)]{.c8}

```{=html}
<!-- -->
```
4.  [Time course:]{.c17}

```{=html}
<!-- -->
```
1.  [Troponin rise and acute cardiac injury tend to be late
    manifestations. ]{.c8}

```{=html}
<!-- -->
```
1.  Troponin increased rapidly from \~14 days from illness onset, after
    the onset of respiratory failure ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770986000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770986000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770986000){.c15}]{.c16}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770986000){.c15}]{.c16}).
    ^[\[t\]](#cmnt20){#cmnt_ref20}[\[u\]](#cmnt21){#cmnt_ref21}[\[v\]](#cmnt22){#cmnt_ref22}[\[w\]](#cmnt23){#cmnt_ref23}^
2.  Among non-survivors, a steady rise in troponin I levels was observed
    throughout the disease course from day 4 of illness through day 22
    ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770987000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770987000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016770988000){.c15}]{.c16}).

```{=html}
<!-- -->
```
5.  [Mechanism:]{.c17}

```{=html}
<!-- -->
```
1.  The mechanism is unknown, though several have been proposed, based
    on very limited data outside of case series and reports ([[Ruan et
    al,](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770988000){.c15}
    ]{.c16}[[Intensive Care
    Med](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770989000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016770989000){.c15}]{.c16};
    [[Hu et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&sa=D&ust=1585016770989000){.c15}
    ]{.c16}[[Eur Heart
    J](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&sa=D&ust=1585016770989000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&sa=D&ust=1585016770990000){.c15}]{.c16};
    [[Zeng et
    al,](https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&sa=D&ust=1585016770990000){.c15}
    ]{.c16}[[Preprints](https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&sa=D&ust=1585016770990000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&sa=D&ust=1585016770990000){.c15}]{.c16}[)]{.c8}

```{=html}
<!-- -->
```
1.  Possible direct toxicity through viral invasion into cardiac
    myocytes ([i.e.]{.c22}[, myocarditis)]{.c8}
2.  [Acute coronary syndrome and demand ischemia]{.c8}
3.  Stress or cytokine-mediated cardiomyopathy ([i.e.,
    ]{.c22}[Takotsubo's)]{.c8}

[]{.c8}

2.  [Cardiovascular Testing ]{.c11} {#h.es6b8f4xqski style="display:inline"}
    -------------------------------

```{=html}
<!-- -->
```
1.  [Troponin: ]{.c17}

```{=html}
<!-- -->
```
1.  [ICU patients: Check hsTrop daily and SCvO2 daily]{.c8}
2.  [Inpatients: Check hsTrop every other day ]{.c8}

```{=html}
<!-- -->
```
1.  [If hsTrop \> 200 ng/L]{.c8}

```{=html}
<!-- -->
```
1.  [Obtain 12-lead ECG]{.c8}
2.  [Perform point-of-care US (POCUS) if you are trained to do so ]{.c8}
3.  [If no new ECG or echocardiographic abnormalities, continue to
    monitor every other day hsTrop]{.c8}

```{=html}
<!-- -->
```
2.  [Telemetry: ]{.c17}

```{=html}
<!-- -->
```
1.  [Telemetry should be used for all critically-ill patients]{.c8}
2.  [At BWH, COVID-19 floor patients also have telemetry. ]{.c8}
3.  For hospitals, with resource-limitations, telemetry is most
    important for patients who meet AHA criteria ([[Sandau et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28974521&sa=D&ust=1585016770993000){.c15}
    ]{.c16}[[Circulation,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28974521&sa=D&ust=1585016770994000){.c15}
    ]{.c14}[[2017](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28974521&sa=D&ust=1585016770994000){.c15}]{.c16})[.
    ]{.c8}

```{=html}
<!-- -->
```
3.  [ECGs: ]{.c17}

```{=html}
<!-- -->
```
1.  [Daily ECGs are reasonable for individuals with severe
    COVID-19.]{.c8}

```{=html}
<!-- -->
```
1.  [When possible, print ECGs from the in-room monitor to minimize
    contamination of equipment.]{.c8}

```{=html}
<!-- -->
```
4.  [TTE:]{.c17}

```{=html}
<!-- -->
```
1.  [Do not order routine TTEs on COVID-19 patients.]{.c8}

```{=html}
<!-- -->
```
1.  [Cardiology consult or a trained provider should perform POCUS
    if:]{.c8}

```{=html}
<!-- -->
```
1.  [Significant troponin elevation or decline in ScvO2/MvO2]{.c8}
2.  [Shock]{.c8}
3.  New[ heart failure (not pre-existing heart failure) ]{.c8}
4.  New persistent[ ]{.c22}[arrhythmia]{.c8}
5.  [Significant ECG changes]{.c8}

```{=html}
<!-- -->
```
2.  [If abnormalities are identified on POCUS (e.g. new reduction in
    LVEF \< 50%), a formal TTE should be obtained and cardiology
    consulted.]{.c8}

```{=html}
<!-- -->
```
1.  [Where possible order limited TTEs instead of full TTEs to conserve
    resources.]{.c8}

```{=html}
<!-- -->
```
5.  [Stress Testing: ]{.c17}

```{=html}
<!-- -->
```
1.  [Stress testing is likely not indicated in individuals with active
    COVID. ]{.c8}
2.  [Any question of possible stress testing should be directed to
    cardiology.]{.c8}

[]{.c8}

3.  [Arrhythmias]{.c11} {#h.rm4wr985h2i8 style="display:inline"}
    -------------------

```{=html}
<!-- -->
```
1.  [ ]{.c33 .c86 .c89}[Incidence:]{.c17}

```{=html}
<!-- -->
```
1.  Case series report the occurrence of unspecified arrhythmias in 17%
    of hospitalized patients with COVID-19 (n=23 of 138), with higher
    rate in ICU patients (44%, n=16) compared to non-ICU patients (7%,
    n=7) ([[Wang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770998000){.c15}
    ]{.c16}[[JAMA](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770998000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016770998000){.c15}]{.c16}[).]{.c8}
2.  [There are anecdotal reports of VT and VF as a late manifestation of
    COVID-19. No specific published findings were identified. ]{.c8}

```{=html}
<!-- -->
```
2.  [Workup:]{.c17}

```{=html}
<!-- -->
```
1.  [Telemetry, 12-lead EKG, cardiac troponin, NT-proBNP, TFT]{.c8}
2.  [ScvO2 if central line present (goal SCVO2 \> 60%)]{.c8}
3.  [POCUS to assess LV and RV function]{.c8}

```{=html}
<!-- -->
```
1.  [Obtain formal TTE if abnormalities of any of the above]{.c8}

```{=html}
<!-- -->
```
3.  [Treatment:]{.c17}

```{=html}
<!-- -->
```
1.  [Atrial fibrillation/atrial flutter ]{.c8}

```{=html}
<!-- -->
```
1.  [Beta blockade if no evidence of heart failure or shock]{.c8}

```{=html}
<!-- -->
```
1.  If significant heart failure or borderline BPs, use amiodarone.
    [There is no known increased concern for amiodarone lung
    toxicity]{.c8}

```{=html}
<!-- -->
```
2.  [ If unstable, synchronized DCCV with 200 Joules biphasic ]{.c8}

```{=html}
<!-- -->
```
2.  Ventricular tachycardia (VT[) ]{.c8}

```{=html}
<!-- -->
```
1.  [Unstable/pulseless: initiate ACLS]{.c8}
2.  [Stable:]{.c8}

```{=html}
<!-- -->
```
1.  [Cardiology consult (may represent evolving myocardial
    involvement)]{.c8}
2.  [Amiodarone 150mg IV x 1 or lidocaine 100mg IV x 1 ]{.c8}

[]{.c8}

4.  [Acute Coronary Syndromes]{.c11} {#h.13b1uhteftcc style="display:inline"}
    --------------------------------

```{=html}
<!-- -->
```
1.  [Incidence:]{.c17}

```{=html}
<!-- -->
```
1.  [There is no current available data on the incidence of ACS in
    COVID. However, we presume that due to the presence of ACE2
    receptors on the endothelium, and the known increased risk of ACS in
    influenza that there is a possible increased incidence of ACS among
    COVID-19 patients.]{.c8}

```{=html}
<!-- -->
```
1.  The incidence of ACS is about 6 times as high within seven days of
    an influenza diagnosis than during control interval - incidence
    ratio 6.05 (95% CI, 3.86 to 9.50) ([[Kwong et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29365305&sa=D&ust=1585016771001000){.c15}
    ]{.c16}[[NEJM](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29365305&sa=D&ust=1585016771002000){.c15}]{.c14}[[,
    2018](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29365305&sa=D&ust=1585016771002000){.c15}]{.c16})^[\[x\]](#cmnt24){#cmnt_ref24}[\[y\]](#cmnt25){#cmnt_ref25}^[.]{.c8}

```{=html}
<!-- -->
```
2.  [Workup:]{.c17}

```{=html}
<!-- -->
```
1.  [Elevated troponin/ECG changes alone may not be able to discriminate
    between:]{.c8}

```{=html}
<!-- -->
```
1.  [Coronary thrombosis ]{.c8}
2.  [Demand-related ischemia ]{.c8}
3.  [Myocarditis]{.c8}

```{=html}
<!-- -->
```
2.  [Determination of ACS will rely on all evidence available: ]{.c8}

```{=html}
<!-- -->
```
1.  [Symptoms (if able to communicate)]{.c8}

```{=html}
<!-- -->
```
1.  [New dyspnea, chest pain, anginal equivalents]{.c8}

```{=html}
<!-- -->
```
2.  Regional[ ECG changes]{.c8}
3.  Rate of change of Troponin changes ([i.e.]{.c22}[, acute rise
    suggests ACS)]{.c8}
4.  Echo findings ([e.g.]{.c22}[, new RWMA)]{.c8}

```{=html}
<!-- -->
```
3.  [When in doubt, request a cardiology consult.]{.c8}

```{=html}
<!-- -->
```
3.  [Management:]{.c17}

```{=html}
<!-- -->
```
1.  [Medical management of ACS should be coordinated with
    cardiology]{.c8}

```{=html}
<!-- -->
```
1.  [Treat with full dose aspirin, clopidogrel (if not bleeding),
    heparin, oxygen (if hypoxemic), statin, nitrates (if hypertensive),
    and opioids (if persistent pain during medical management).]{.c8}

```{=html}
<!-- -->
```
1.  [Beta blockers should be used with caution given possible
    concomitant myocarditis/decompensated heart failure.]{.c8}

```{=html}
<!-- -->
```
2.  [As of the time of this writing, the cath lab will take COVID-19
    patients, even if ventilated. ]{.c8}

```{=html}
<!-- -->
```
1.  [If resources become constrained and door-to-balloon time is no
    longer adequate, cardiology may decide to use lytic medications for
    COVID-19 STEMI patients in lieu of PCI.]{.c8}

[]{.c8}

5.  [Pericarditis and Myocarditis]{.c11} {#h.txp16938ptwl style="display:inline"}
    ------------------------------------

```{=html}
<!-- -->
```
1.  [Incidence:]{.c17}

```{=html}
<!-- -->
```
1.  Myocarditis and pericarditis are potential manifestations of
    COVID-19 and source of Acute Cardiac Injury, based on case
    reports/case series ([[Ruan et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771004000){.c15}
    ]{.c16}[[Intensive Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771005000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771005000){.c15}]{.c16}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771005000){.c15}]{.c16};
    [[Zeng et
    al,](https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&sa=D&ust=1585016771005000){.c15}
    ]{.c16}[[Preprints](https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&sa=D&ust=1585016771005000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&sa=D&ust=1585016771005000){.c15}]{.c16};
    [[Hu et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&sa=D&ust=1585016771006000){.c15}
    ]{.c16}[[Eur Heart
    J](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&sa=D&ust=1585016771006000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&sa=D&ust=1585016771006000){.c15}]{.c16}[)
    ]{.c8}
2.  [However, there is currently no evidence of proven pericarditis or
    myocarditis, either by biopsy or cMRI. ]{.c8}

```{=html}
<!-- -->
```
2.  [Diagnosis:]{.c17}

```{=html}
<!-- -->
```
1.  [Likely no role for endomyocardial biopsy]{.c8}
2.  [cMRI should be discussed on a case-by-case basis with a cardiology
    consult team.]{.c8}

```{=html}
<!-- -->
```
3.  [Management:]{.c17}

```{=html}
<!-- -->
```
1.  [Supportive for heart failure and direct viral treatments ]{.c8}
2.  The use of anti-inflammatory medications such as Colchicine and
    Ibuprofen should also be discussed with the cardiology consult team
    as this literature is evolving.

Chapter 5: Shock: Septic, Cardiogenic, and Cytokine Storm {#h.dpe5gr1hwjp .c44}
=========================================================

1.  [Undifferentiated Shock in COVID]{.c11} {#h.bdbn9kepy2bs style="display:inline"}
    ---------------------------------------

```{=html}
<!-- -->
```
1.  [Definition:]{.c17}

```{=html}
<!-- -->
```
1.  Acute onset of new and sustained hypotension (MAP \< 65 or SBP
    \< 90) with signs of hypoperfusion requiring IVF or vasopressors to
    maintain adequate blood pressure

```{=html}
<!-- -->
```
2.  [Time course:]{.c17}

```{=html}
<!-- -->
```
1.  Patients rarely present in shock on admission[ ]{.c8}

```{=html}
<!-- -->
```
1.  [Natural history seems to favor the development of shock after
    multiple days of critical illness. ]{.c8}

```{=html}
<!-- -->
```
3.  [Etiology:]{.c17}

```{=html}
<!-- -->
```
1.  [The range of reasons for shock is wide and more variable than for
    most patients and includes: ]{.c8}

```{=html}
<!-- -->
```
1.  [Cardiogenic shock]{.c8}
2.  [Secondary bacterial infection]{.c8}
3.  [Cytokine storm ]{.c8}

```{=html}
<!-- -->
```
4.  [Workup for new ]{.c33}[undifferentiated shock:]{.c33}

```{=html}
<!-- -->
```
1.  [Assess for severity of end organ damage:]{.c8}

```{=html}
<!-- -->
```
1.  [UOP,  Mental status, Lactate, BUN/creatinine, electrolytes,
    LFTs]{.c8}

```{=html}
<!-- -->
```
2.  [Obtain a FULL infectious workup, which includes all of the
    following:]{.c8}

```{=html}
<!-- -->
```
1.  Labs: CBC with differential. Note that most COVID patients are
    lymphopenic (83%).  However, new leukocytosis can occur and
    left-shift can be used as a part of clinical picture ([[Guan et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&sa=D&ust=1585016771010000){.c15}
    ]{.c16}[[N Engl J
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&sa=D&ust=1585016771010000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&sa=D&ust=1585016771010000){.c15}]{.c16}).
    Two sets of blood cultures, LFTs (for cholangitis/acalculous
    cholecystitis), urinalysis (with reflex to culture), sputum culture
    (if safely obtained via inline suctioning, do not perform
    bronchoscopy or sputum induction), procalcitonin at 0 and 48h (do
    not withhold early antibiotics on the basis of procalcitonin[),
    ]{.c22}urine Strep and legionella antigens
2.  [Portable CXR (avoid CT unless absolutely necessary)]{.c8}
3.  [Full skin exam]{.c8}

```{=html}
<!-- -->
```
3.  [Assess for cardiogenic shock]{.c8}

```{=html}
<!-- -->
```
1.  [Assess extremities: warm or cool on exam]{.c8}
2.  [Assess patient volume status: JVP, CVP, edema, CXR]{.c8}
3.  Assess pulse pressure: If \< 25% of the SBP, correlates highly with
    a reduction in cardiac index to less than 2.2 with a sensitivity of
    91% and a specificity of 83% ([[Stevenson and
    Perloff,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&sa=D&ust=1585016771011000){.c15}
    ]{.c16}[[JAMA](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&sa=D&ust=1585016771011000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&sa=D&ust=1585016771011000){.c15}]{.c16}[[ 1989](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&sa=D&ust=1585016771012000){.c15}]{.c16}[)]{.c8}
4.  [Perform POCUS if trained to do so]{.c8}

```{=html}
<!-- -->
```
1.  For TTE protocols see [["Cardiac Complications of COVID-19"
    chapter](#h.6zfga8b63w2s){.c15}]{.c16}[.]{.c8}

```{=html}
<!-- -->
```
5.  [Labs: Obtain an SCV02 or MV02 if the patient has central access,
    troponin x2, NT proBNP, A1c, lipid profile, TSH]{.c8}
6.  [EKG (and telemetry)]{.c8}
7.  [Calculate estimated Fick Cardiac Output]{.c8}

```{=html}
<!-- -->
```
1.  CO (Cardiac Output), L/min = VO[2]{.c70}/ \[(SaO[2]{.c70} -
    SvO[2]{.c70}[) x Hb x 13.4)\],]{.c8}

```{=html}
<!-- -->
```
1.  where VO[2]{.c70} = 125 mL O[2]{.c70}/min x BSA, where BSA =
    \[(Height, cm x Weight, kg)/ 3,600 \][½]{.c64}; in patients aged
    ≥70, use 110 mL O[2 ]{.c70}x BSA for VO[2]{.c65 .c70}

```{=html}
<!-- -->
```
2.  MDcalc online calculators: [[Fick
    CO](https://www.google.com/url?q=http://www.mdcalc.com/cardiac-output-ficks-formula&sa=D&ust=1585016771014000){.c15}]{.c16},
    [[BSA](https://www.google.com/url?q=http://www.mdcalc.com/body-mass-index-bmi-body-surface-area-bsa&sa=D&ust=1585016771015000){.c15}]{.c16}

```{=html}
<!-- -->
```
4.  [Assess for other causes of shock:]{.c8}

```{=html}
<!-- -->
```
1.  [Vasoplegia: ]{.c8}

```{=html}
<!-- -->
```
1.  [Run medication list for recent cardiosuppressive medications,
    vasodilatory agents, antihypertensives ]{.c8}

```{=html}
<!-- -->
```
2.  [Adrenal insufficiency:]{.c8}

```{=html}
<!-- -->
```
1.  [Unless high pretest probability of adrenal insufficiency, we
    recommend against routine cortisone stimulation testing]{.c8}

```{=html}
<!-- -->
```
3.  [Obstruction:]{.c8}

```{=html}
<!-- -->
```
1.  [PE (given the elevated risk of thrombosis)]{.c8}
2.  [Tamponade (given elevated risk of pericarditis)]{.c8}
3.  [Obstruction from PEEP]{.c8}

```{=html}
<!-- -->
```
4.  Cytokine storm[ ]{.c57}(see [["Cytokine Activation Syndrome"
    section](#h.7i62kagnynf0){.c15}]{.c16}[ in this chapter below)]{.c8}
5.  [Allergic reactions to recent medications]{.c8}
6.  [Neurogenic shock is uncommon in this context]{.c8}
7.  [Hypovolemia:]{.c8}

```{=html}
<!-- -->
```
1.  [Bleeding]{.c8}
2.  [Insensible losses from fever]{.c8}
3.  [Diarrhea/vomiting]{.c8}

[]{.c8}

2.  Differentiating Shock {#h.ebuidko2u3iz style="display:inline"}
    ---------------------

```{=html}
<!-- -->
```
1.  [[This
    video](https://www.google.com/url?q=https://www.khanacademy.org/science/health-and-medicine/circulatory-system-diseases/shock/v/differentiating-shock&sa=D&ust=1585016771018000){.c15}]{.c42
    .c84}[ is a helpful tutorial.]{.c8}

[]{.c24 .c22}

[]{.c24 .c22}

[]{#t.360bbd040a7d74c422f46692d8beb3d45d1de991}[]{#t.0}

  ---------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------
  [Type of Shock]{.c24 .c22}                                 [Cardiac Output]{.c24 .c22}                                                                                                                                                                                                                                       [SVR]{.c24 .c22}                                                                                                                                                                                                                                                  [CVP/Wedge]{.c24 .c22}                                                                                                                                                                                                                                                                [ScvO2, MvO2]{.c24 .c22}                                                                                                                                                                                                                                          [Other features]{.c33 .c22}
  [Cardiogenic]{.c24 .c22}                                   [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   [![](media/image2.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"}   [![](media/image2.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"}                       [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   []{.c81 .c33 .c22 .c66 .c80 .c88}
  [Distributive (sepsis,cytokine, anaphylaxis)]{.c24 .c22}   [![](media/image2.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"}   [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}                       [![](media/image2.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"}   []{.c24 .c22}
  [Obstructive]{.c24 .c22}                                   [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   [![](media/image2.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"}   [![](media/image2.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"}                       [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   []{.c24 .c22}
  [Hypovolemic]{.c24 .c22}                                   [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   [![](media/image2.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"}   [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}                       [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   []{.c24 .c22}
  [Neurogenic]{.c24 .c22}                                    [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}[/normal]{.c22 .c24}   [![](media/image1.png)]{style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"}   [Decreased HR]{.c24 .c22}
  ---------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------

[]{.c8}

[]{.c24 .c22}

3.  [Septic Shock and Secondary Infections ]{.c11} {#h.lydcfzsuv4hc style="display:inline"}
    ----------------------------------------------

```{=html}
<!-- -->
```
1.  [Incidence:]{.c17}

```{=html}
<!-- -->
```
1.  [The reported rates of sepsis and septic shock are not reported
    consistently in currently available case series]{.c8}

```{=html}
<!-- -->
```
1.  [Secondary bacterial infections are reported:]{.c8}

```{=html}
<!-- -->
```
1.  20% of non-survivors ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771035000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771035000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771035000){.c15}]{.c16}[)]{.c8}
2.  16% of non-survivors ([[Ruan et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771036000){.c15}
    ]{.c16}[[Intensive Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771036000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771036000){.c15}]{.c16}[)]{.c8}
3.  12-19% In H1N1 epidemic ([[MacIntyre et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30526505&sa=D&ust=1585016771037000){.c15}
    ]{.c16}[[BMC Infect
    Dis](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30526505&sa=D&ust=1585016771037000){.c15}]{.c14}[[,
    2018](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30526505&sa=D&ust=1585016771037000){.c15}]{.c16}[)
    ]{.c8}

```{=html}
<!-- -->
```
2.  [Concurrent Pneumocystis pneumonia has been reported in at least one
    case (possibly due to lymphopenia)]{.c8}

```{=html}
<!-- -->
```
2.  [Antibiosis:]{.c17}

```{=html}
<!-- -->
```
1.  Early empiric antibiotics should be initiated within 1 hour (see
    [["Antibiotic Stewardship"
    section](#h.8vhrbtln428m){.c15}]{.c16} within [["COVID-19 Therapies
    and Clinical Trials" chapter](#h.kx686gedgtzg){.c15}]{.c16})

```{=html}
<!-- -->
```
3.  [Conservative Fluid Management:]{.c17}

```{=html}
<!-- -->
```
1.  [Goal MAP \> 65mmHg]{.c8}
2.  Start Norepinephrine while determining the etiology of
    undifferentiated shock
3.  [We do not recommend conventional 30cc/kg resuscitation]{.c8}

```{=html}
<!-- -->
```
1.  [Give 250-500cc IVF and assess in 15-30 minutes for:]{.c8}

```{=html}
<!-- -->
```
1.  [Increase \> 2 in CVP]{.c8}
2.  [Increase in MAP or decrease in pressor requirement]{.c8}

```{=html}
<!-- -->
```
1.  [Use isotonic crystalloids; Lactated Ringer's solution is preferred
    where possible. Avoid hypotonic fluids, starches, or colloids]{.c8}

```{=html}
<!-- -->
```
2.  [Repeat 250-500cc IVF boluses; Use dynamic measures of fluid
    responsiveness]{.c8}

```{=html}
<!-- -->
```
1.  Pulse Pressure Variation: can be calculated in mechanically
    [ventilated patients without arrhythmia; PPV \>12% is sensitive and
    specific for volume responsiveness]{.c8}
2.  [Straight Leg Raise: raise legs to 45° w/ supine torso for at least
    one minute. A change in pulse pressure of \> 12% has sensitivity of
    60% & specificity of 85% for fluid responsiveness in mechanically
    ventilated patients; less accurate if spontaneously breathing]{.c8}
3.  [Ultrasound evaluation of IVC collapsibility should only be
    undertaken by trained personnel to avoid contamination of
    ultrasound]{.c8}

```{=html}
<!-- -->
```
3.  For further guidance, Conservative Fluid Management protocols are
    available from from FACCT Lite trial ([[Grissom et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&sa=D&ust=1585016771041000){.c15}]{.c16}[[ Crit
    Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&sa=D&ust=1585016771041000){.c15}]{.c14}[[,
    2015](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&sa=D&ust=1585016771042000){.c15}]{.c16})[.]{.c8}
4.  [Rationale]{.c22}: COVID-19 clinical reports indicate the majority
    of patients present with respiratory failure without shock. ARDS is
    mediated in part by pulmonary capillary leak, and randomized
    controlled trials of ARDS indicate that a conservative fluid
    strategy is protective in this setting ([[Grissom et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&sa=D&ust=1585016771042000){.c15}]{.c16}[[ Crit
    Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&sa=D&ust=1585016771043000){.c15}]{.c14}[[,
    2015](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&sa=D&ust=1585016771043000){.c15}]{.c16};
    [[Famous et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27513822&sa=D&ust=1585016771043000){.c15}
    ]{.c16}[[Am J Respir Crit Care
    Med,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27513822&sa=D&ust=1585016771043000){.c15}]{.c14}[[ 2017](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27513822&sa=D&ust=1585016771044000){.c15}]{.c16};
    [[Silversides et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27734109&sa=D&ust=1585016771044000){.c15}
    ]{.c16}[[Int Care
    Med,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27734109&sa=D&ust=1585016771044000){.c15}]{.c14}[[ 2017](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27734109&sa=D&ust=1585016771045000){.c15}]{.c16};
    [[WHO,](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016771045000){.c15}
    ]{.c16}[[COVID-19 Interim
    guidance](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016771045000){.c15}]{.c14}[[,
    March
    2020](https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&sa=D&ust=1585016771046000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
4.  [Pressor management]{.c17}

```{=html}
<!-- -->
```
1.  Unless new evidence emerges, standard choices for distributive shock
    ([i.e.]{.c22}[, norepinephrine then vasopressin) are recommended,
    with high vigilance for the development of cardiogenic shock,
    addressed in the next section.]{.c8}

```{=html}
<!-- -->
```
5.  [Corticosteroids]{.c17}

```{=html}
<!-- -->
```
1.  See [["Systemic Corticosteroids"
    section](#h.x05c129ivxrw){.c15}]{.c16} within [["COVID-19 Therapies
    and Clinical Trials" chapter](#h.kx686gedgtzg){.c15}]{.c16}[.]{.c8}

```{=html}
<!-- -->
```
1.  Stress dose hydrocortisone should still be considered in patients
    on \> 2 pressors[.]{.c22}

[]{.c8}

4.   Cardiogenic Shock {#h.ftupyxepmedz style="display:inline"}
    ------------------

[]{.c8}

6.  [Incidence: ]{.c17}

```{=html}
<!-- -->
```
1.  Heart failure or cardiogenic shock was observed in 23% (n=44 of 191)
    of hospitalized patients in one case series ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771048000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771049000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771049000){.c15}]{.c16}).
    Moreover, there were higher rates in non-survivors (52%, n=28)
    compared to survivors (12%, n=16).  Among 21 patients admitted to an
    ICU in Washington State 33% (n=7) developed a new cardiomyopathy
    ([[Arentz et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32191259&sa=D&ust=1585016771049000){.c15}
    ]{.c16}[[JAMA](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32191259&sa=D&ust=1585016771050000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32191259&sa=D&ust=1585016771050000){.c15}]{.c16}).
    Notably, these patients tended to be older with more comorbidities
    and had a high mortality (11 of the 21
    died)^[\[z\]](#cmnt26){#cmnt_ref26}[\[aa\]](#cmnt27){#cmnt_ref27}^[.]{.c8}
2.  Heart failure or myocardial damage contributed to death in 39%
    (n=29) of deaths in a series of 68 patients in Wuhan. Most (n=22
    of 29) had concomitant respiratory failure ([[Ruan et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771050000){.c15}
    ]{.c16}[[Intensive Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771051000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771051000){.c15}]{.c16}).

```{=html}
<!-- -->
```
7.  [Diagnosis:]{.c17}

```{=html}
<!-- -->
```
1.  Significant concern for cardiogenic shock if any of the following
    are present with evidence of hypoperfusion ([e.g.]{.c22}[, elevated
    lactate):]{.c8}

```{=html}
<!-- -->
```
1.  [Elevated NT-proBNP, or]{.c8}
2.  [CvO2 \< 60% (PvO2 \< 35 mm Hg), or]{.c8}
3.  [Echocardiogram with depressed LV and/or RV function]{.c8}

```{=html}
<!-- -->
```
8.  [Time course:]{.c17}

```{=html}
<!-- -->
```
1.  Cardiogenic shock may present late in the course of illness even
    after improvement of respiratory symptoms, and manifest as a
    precipitous clinical deterioration in the setting of an acute
    decline in LVEF (see [["Acute Cardiac Injury"
    section](#h.sxzvrsrmkd1g){.c15}]{.c16} in [["Cardiac Complications"
    chapter](#h.6zfga8b63w2s){.c15}]{.c16}).

```{=html}
<!-- -->
```
9.  [Etiology:]{.c17}

```{=html}
<!-- -->
```
1.  See [["Acute Cardiac Injury"
    section](#h.sxzvrsrmkd1g){.c15}]{.c16} in [["Cardiac Complications"
    chapter](#h.6zfga8b63w2s){.c15}]{.c16}[. ]{.c8}
2.  [Mechanism is unknown, potentially direct viral toxicity, ACS, or
    stress cardiomyopathy.]{.c8}

```{=html}
<!-- -->
```
10. [Workup:]{.c17}

```{=html}
<!-- -->
```
1.  Rule out ACS and complete the initial work up as described in
    [["Cardiac Complications" chapter](#h.6zfga8b63w2s){.c15}]{.c16}.
2.  Ongoing monitoring:

```{=html}
<!-- -->
```
1.  Labs[: Trend troponins to peak, SCvO2 (obtained by upper body CVC)
    or MvO2 q8-12h or with clinical change, Lactate q4-6h,  LFTs daily
    (for hepatic congestion)]{.c8}
2.  [Daily EKGs or prn with clinical deterioration]{.c8}
3.  [Trend troponin to peak]{.c8}

```{=html}
<!-- -->
```
3.  [All cardiogenic shock cases require cardiovascular consult]{.c8}

```{=html}
<!-- -->
```
1.  [PA catheters may be placed bedside by experienced providers, with
    preference for use only in mixed shock or complex cases with
    cardiology guidance]{.c8}

```{=html}
<!-- -->
```
11. [Medical management:]{.c17}

```{=html}
<!-- -->
```
1.  [Close collaboration with the cardiovascular consultation service is
    recommended]{.c8}
2.  [Goals: MAPs 65-75, CVP 6-14, PCWP 12-18, PAD 20-25, SVR 800-1000,
    SCvO2 \> 60%, CI \> 2.2]{.c8}

```{=html}
<!-- -->
```
1.  [Note: Achieving MAP goal is first priority, then optimize other
    parameters]{.c8}

```{=html}
<!-- -->
```
3.  [How to achieve goals:]{.c8}

```{=html}
<!-- -->
```
1.  [Continue titration of norepinephrine gtt for goal MAP 65-75]{.c8}
2.  [Initiate diuretic therapy for CVP \> 14, PCWP \>18, PAD \> 25]{.c8}
3.  [Initiate inotropic support: ]{.c8}

```{=html}
<!-- -->
```
1.  [Dobutamine gtt for SCvO2 \< 60%, CI \< 2.2 and MAP \> 65.  Start at
    2mcg/kg/min. Up-titrate by 1-2mcg/kg/min every 30-60 minutes for
    goal parameters. Alternative strategies should be considered once
    dose exceeds 5mcg/kg/min.  Maximum dose is 10mcg/kg/min.]{.c8}

```{=html}
<!-- -->
```
4.  Ensure negative inotropes such as beta blockers, calcium channel
    blockers and antihypertensives are discontinued.

```{=html}
<!-- -->
```
12. [Candidacy for Mechanical Support]{.c17}

```{=html}
<!-- -->
```
1.  The benefit of Mechanical Support in COVID-19 is not yet clear. In
    one study of patients with severe COVID-19, five (83%) of six
    patients receiving ECMO died ([[Yang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016771057000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016771057000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016771057000){.c15}]{.c16}[).
    There is concern that the further decrease of lymphocytes from ECMO
    could contribute to higher mortality. However, this is a very small
    study and more information is needed.]{.c8}
2.  Patients who experience the following should prompt an immediate
    call to the cardiovascular medicine consult service for
    consideration of mechanical support:

```{=html}
<!-- -->
```
1.  [Dobutamine gtt at 5mcg/kg/min (or unable to tolerate dobutamine due
    to tachyarrhythmias) and SCVO2 \< 60% or CI \< 2.2]{.c8}
2.  Lactate \> 4 after medical therapy

```{=html}
<!-- -->
```
3.  [The criteria for ECMO and other mechanical cardiovascular support
    varies among centers and are difficult to develop under typical
    circumstances. The unclear trajectory of the COVID-19 pandemic makes
    these evaluations even more difficult. Please refer to the separate
    BWH ECMO and Cardiovascular Medicine guidelines which are in
    development. ]{.c8}

[]{.c8}

The following does not reflect the recommendation of the BWH ECMO and
Cardiovascular services. However, for the purposes of general education,
a [hypothetical]{.c57} set of[ inclusion criteria]{.c42}[ for ECMO or
MCS could cover: ]{.c8}

3.  [Younger age ]{.c8}
4.  [Expected life expectancy \>6 months pre-hospitalization]{.c8}
5.  [No evidence of solid or liquid malignancy]{.c8}
6.  [Able to tolerate anticoagulation]{.c8}
7.  [Platelets \>50,000]{.c8}
8.  [Absence of severe peripheral arterial disease]{.c8}
9.  [No evidence of irreversible neurological injury]{.c8}
10. [Able to perform ADLs at baseline prior to illness]{.c8}
11. Cannot have profound respiratory failure (defined as requiring prone
    ventilation at time of consult for MCS or having PaO2:FiO2 ratio
    \< 150) (for MCS other than ECMO)

[]{.c8}

5.  [ Cytokine Activation Syndrome]{.c11} {#h.7i62kagnynf0 style="display:inline"}
    -------------------------------------

```{=html}
<!-- -->
```
1.  [Incidence:]{.c17}

```{=html}
<!-- -->
```
1.  A subgroup of patients with severe COVID-19 may have cytokine storm
    syndrome and secondary HLH ([[Mehta et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32192578&sa=D&ust=1585016771061000){.c15}]{.c16}[[,
    Lancet,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32192578&sa=D&ust=1585016771061000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32192578&sa=D&ust=1585016771062000){.c15}]{.c16}).
    Patients who had cytokine storm developed rapid progression to ARDS,
    shock, and multiorgan failure ([[Chen et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&sa=D&ust=1585016771062000){.c15}]{.c16}[[,
    Lancet,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&sa=D&ust=1585016771062000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&sa=D&ust=1585016771063000){.c15}]{.c16}[)]{.c8}

```{=html}
<!-- -->
```
2.  [Pathophysiology: ]{.c17}

```{=html}
<!-- -->
```
1.  Neutrophil activation likely contributes to the pathogenesis of
    cytokine storm and ARDS ([[Wu et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771063000){.c15}]{.c16}[[,
    JAMA Intern
    Med,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771064000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771064000){.c15}]{.c16}).[ ]{.c64}[[Wu
    et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771064000){.c15}]{.c16}[ found
    that COVID-19 confirmed patients with ARDS have higher neutrophil
    counts, average 7.04 (95% CI: 3.98 to 10.12) vs. those without ARDS,
    average 3.06 (2.03 to 5.56) ]{.c8}
2.  Similar patterns of cytokine storm and ARDS have been seen with
    SARS, MERS ([[Kim et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27709848&sa=D&ust=1585016771065000){.c15}]{.c16}[[,
    J Korean Med
    Sci,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27709848&sa=D&ust=1585016771065000){.c15}
    ]{.c14}[[2016](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27709848&sa=D&ust=1585016771065000){.c15}]{.c16}[)]{.c8}
3.  Other studies have suggested that increased proinflammatory
    cytokines in the serum are associated with pulmonary injury in SARS,
    MERS, and COVID-19 ([[Wong et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15030519&sa=D&ust=1585016771066000){.c15}]{.c16}[[,
    Clin Exp
    Immunol,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15030519&sa=D&ust=1585016771066000){.c15}
    ]{.c14}[[2004](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15030519&sa=D&ust=1585016771066000){.c15}]{.c16}[)
    ]{.c8}

```{=html}
<!-- -->
```
3.  [Workup:]{.c17}

```{=html}
<!-- -->
```
1.  Suspect if clinical deterioration with shock and multiorgan failure
2.  CBC with diff, PT/INR, PTT, fibrinogen, d-dimer, ferritin, liver
    function test, triglycerides, c-reactive protein (CRP) ([[Ruan et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771067000){.c15}
    ]{.c16}[[Intensive Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771068000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771068000){.c15}]{.c16}[)]{.c8}

```{=html}
<!-- -->
```
1.  CRP seems to correlate with disease severity and prognosis of
    COVID-19 ([[Ruan et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771068000){.c15}
    ]{.c16}[[Intensive Care
    Med](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771069000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771069000){.c15}]{.c16};[ ]{.c22}[[Young
    et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125362&sa=D&ust=1585016771069000){.c15}]{.c16}[[,
    JAMA,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125362&sa=D&ust=1585016771070000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125362&sa=D&ust=1585016771070000){.c15}]{.c16})
2.  An HScore ([[MDcalc online
    calculator](https://www.google.com/url?q=http://www.mdcalc.com/hscore-reactive-hemophagocytic-syndrome&sa=D&ust=1585016771071000){.c15}]{.c16})
    may be helpful in estimating the probability of secondary HLH in
    these patients[ ]{.c64 .c65}

```{=html}
<!-- -->
```
4.  [Management: ]{.c17}

```{=html}
<!-- -->
```
1.  If high suspicion, discuss with ID about the use of IVIG, steroids,
    cytokine blockade, particularly IL-6 pathway and perhaps IL-1 (see
    [["Anti-IL6 Agents" section](#h.m6l0vgre9d0s){.c15}]{.c16} within
    [["COVID-19 Therapies and Clinical Trials"
    chapter](#h.kx686gedgtzg){.c15}]{.c16}[). While steroids have been
    implicated with worse lung injury and outcomes, they may be
    beneficial in the hyperinflammatory state.]{.c8}

[]{.c8}

Chapter 6: Thrombotic and Coagulation Manifestations {#h.5s70bzlr4ojz .c44}
====================================================

1.  [Thrombotic Disease]{.c11} {#h.9wzf9ick65rt style="display:inline"}
    --------------------------

```{=html}
<!-- -->
```
1.  [Incidence:]{.c17}

```{=html}
<!-- -->
```
1.  Unclear incidence, though case reports suggest there may be
    increased venous thromboembolism (VTE) in COVID-19 patients ([[Xie
    et
    al,](https://www.google.com/url?q=http://doi.org/10.1148/ryct.2020200067&sa=D&ust=1585016771073000){.c15}
    ]{.c16}[[Radiol: Cardiothoracic
    Imaging,](https://www.google.com/url?q=http://doi.org/10.1148/ryct.2020200067&sa=D&ust=1585016771073000){.c15}]{.c14}[[ 2020](https://www.google.com/url?q=http://doi.org/10.1148/ryct.2020200067&sa=D&ust=1585016771073000){.c15}]{.c16}[)]{.c8}

```{=html}
<!-- -->
```
2.  [Pathophysiology:]{.c17}

```{=html}
<!-- -->
```
1.  The mechanism for VTE are unknown and likely multifactorial:

```{=html}
<!-- -->
```
1.  [Systemic inflammatory response as seen in sepsis]{.c8}
2.  [Stasis/critical illness]{.c8}
3.  [Possibly direct endothelial damage from viral injury/ACE2
    binding]{.c8}

```{=html}
<!-- -->
```
2.  Colleagues from Wuhan have reported finding microthrombi in
    pulmonary vasculature on autopsy ([[Luo et
    al,](https://www.google.com/url?q=http://www.preprints.org/manuscript/202002.0407/v2&sa=D&ust=1585016771075000){.c15}
    ]{.c16}[[Preprints](https://www.google.com/url?q=http://www.preprints.org/manuscript/202002.0407/v2&sa=D&ust=1585016771075000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.preprints.org/manuscript/202002.0407/v2&sa=D&ust=1585016771075000){.c15}]{.c16}[[ 2020
    preprint](https://www.google.com/url?q=http://www.preprints.org/manuscript/202002.0407/v2&sa=D&ust=1585016771075000){.c15}]{.c16}[),
    which could contribute to local V/Q mismatch or hydrostatic changes
    causing edema. However these mechanisms remain entirely
    hypothetical.]{.c8}
3.  One theory: [SARS-CoV Spike protein can be cleaved by FXa and FIIa.
    Cleavage of the Spike protein activates it which promotes
    infectivity. By extension, it is hypothesized that anticoagulation
    might inhibit SARS-CoV-2 replication]{.c0}. There is a small case
    series suggesting dipyridamole may be useful, though anticoagulation
    and antiplatelet agents require further investigation prior to being
    used therapeutically ([[Liu et
    al,](https://www.google.com/url?q=http://doi.org/10.1101/2020.02.27.20027557&sa=D&ust=1585016771076000){.c15}
    ]{.c16}[[medRxiv,](https://www.google.com/url?q=http://doi.org/10.1101/2020.02.27.20027557&sa=D&ust=1585016771076000){.c15}]{.c14}[[ 2020
    preprint](https://www.google.com/url?q=http://doi.org/10.1101/2020.02.27.20027557&sa=D&ust=1585016771077000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
3.  [Management:]{.c17}

```{=html}
<!-- -->
```
1.  Initiate p[rophylactic anticoagulation therapy for all COVID-19
    patients unless otherwise contraindicated]{.c8}

```{=html}
<!-- -->
```
1.  [If CrCl \> 30: Lovenox 40 mg SC daily]{.c8}
2.  [If CrCl \< 30 or AKI: Heparin 5000 units SC TID]{.c8}
3.  [Hold if Platelets \<30,000 or bleeding, start TEDs and SCDs]{.c8}

```{=html}
<!-- -->
```
2.  If the patient is on direct oral anticoagulants (DOACs) or Warfarin
    for Afib or VTE, switch to full dose[ anticoagulation (LMWH or UFH,
    as indicated based on renal function or clinical scenario).]{.c8}
3.  [While therapeutic anticoagulation has been used empirically in some
    severe COVID-19 patients in Wuhan given the microthrombi in
    pulmonary vasculature (see "Pathophysiology" above), our
    interpretation of the data is that the risks outweigh the benefits
    at this time, unless documented DVT or PE.]{.c8}

```{=html}
<!-- -->
```
4.  [Prognosis:]{.c17}

```{=html}
<!-- -->
```
1.  Higher D-dimer and FDP levels track with multi-organ dysfunction
    syndrome and poorer prognosis ([[Wang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016771079000){.c15}
    ]{.c16}[[JAMA](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016771079000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016771079000){.c15}]{.c16};
    [[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771079000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771080000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771080000){.c15}]{.c16}[).]{.c8}

[]{.c8}

2.  [Disseminated Intravascular Coagulation (DIC)]{.c11} {#h.vpg0k312hzmd style="display:inline"}
    ----------------------------------------------------

```{=html}
<!-- -->
```
1.  [Incidence/pathophysiology:]{.c17}

```{=html}
<!-- -->
```
1.  Limited data: 16 of 183 hospitalized patients in Wuhan had DIC
    ([[Tang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771081000){.c15}
    ]{.c16}[[J Thromb
    Haemost,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771081000){.c15}]{.c14}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771082000){.c15}]{.c16}^[\[ab\]](#cmnt28){#cmnt_ref28}[\[ac\]](#cmnt29){#cmnt_ref29}^[).]{.c8}
2.  Laboratory changes in coagulation parameters and FDP track with
    multi-organ dysfunction ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771082000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771082000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771083000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
2.  [Time course:]{.c17}

```{=html}
<!-- -->
```
1.  Median time to onset of DIC was 4 days into hospital admission
    ([[Tang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771083000){.c15}
    ]{.c16}[[J Thromb
    Haemost,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771083000){.c15}]{.c14}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771084000){.c15}]{.c16}^[\[ad\]](#cmnt30){#cmnt_ref30}[\[ae\]](#cmnt31){#cmnt_ref31}^).

```{=html}
<!-- -->
```
3.  [Workup:]{.c17}

```{=html}
<!-- -->
```
1.  I[dentify and treat underlying condition]{.c8}
2.  ISTH DIC score ([[MDcalc online
    calculator](https://www.google.com/url?q=http://www.mdcalc.com/isth-criteria-disseminated-intravascular-coagulation-dic&sa=D&ust=1585016771085000){.c15}]{.c16})

```{=html}
<!-- -->
```
1.  [If score \< 5, no DIC; recalculate in 1-2 days]{.c8}

```{=html}
<!-- -->
```
4.  [Management:]{.c17}

```{=html}
<!-- -->
```
1.  [If bleeding, give blood products:]{.c8}

```{=html}
<!-- -->
```
1.  [For elevated PT/PTT and bleeding, use FFP or 4F-PCC (KCentra is
    less volume, but must discuss dose with HAT/pharmacy)]{.c8}

```{=html}
<!-- -->
```
2.  [If not bleeding, supportive care:]{.c8}

```{=html}
<!-- -->
```
1.  If fibrinogen \< 150: FFP, cryoprecipitate or fibrinogen concentrate
    (RiaSTAP)

```{=html}
<!-- -->
```
1.  [RiaSTAP is less volume, but dose must be discussed with
    HAT/pharmacy]{.c8}

```{=html}
<!-- -->
```
2.  [Transfuse platelets if \< 30K]{.c8}

```{=html}
<!-- -->
```
3.  Hold anticoagulation
    ^[\[af\]](#cmnt32){#cmnt_ref32}[\[ag\]](#cmnt33){#cmnt_ref33}^[for
    active bleeding. ]{.c8}

```{=html}
<!-- -->
```
1.  [Consider holding anticoagulation if patient requires blood products
    for supportive care, though clinician should weigh risks and
    benefits.]{.c8}

```{=html}
<!-- -->
```
4.  [Start anticoagulation only if:]{.c8}

```{=html}
<!-- -->
```
1.  Overt thromboembolism or organ failure due to clot ([i.e.]{.c22}[,
    purpura fulminans)]{.c8}
2.  There has been no mortality benefit of therapeutic anticoagulation
    in DIC ([[Levi et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29255070&sa=D&ust=1585016771087000){.c15}
    ]{.c16}[[Blood,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29255070&sa=D&ust=1585016771088000){.c15}]{.c14}[[ 2018](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29255070&sa=D&ust=1585016771088000){.c15}]{.c16})^[\[ah\]](#cmnt34){#cmnt_ref34}[\[ai\]](#cmnt35){#cmnt_ref35}^[.]{.c8}

```{=html}
<!-- -->
```
5.  [Prognosis:]{.c17}

```{=html}
<!-- -->
```
1.  DIC is associated with worse survival in COVID-19 patients. Out of
    183 COVID-19 patients in Wuhan, 71% of non-survivors had DIC (ISTH
    score ≥ 5; [[MDcalc online
    calculator](https://www.google.com/url?q=http://www.mdcalc.com/isth-criteria-disseminated-intravascular-coagulation-dic&sa=D&ust=1585016771089000){.c15}]{.c16})
    compared to 0.6% of survivors ([[Tang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771089000){.c15}
    ]{.c16}[[J Thromb
    Haemost,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771089000){.c15}]{.c14}[[ 2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771090000){.c15}]{.c16}^[\[aj\]](#cmnt36){#cmnt_ref36}[\[ak\]](#cmnt37){#cmnt_ref37}^[).]{.c8}

[]{.c29 .c45}

[Chapter 7: Renal Manifestations ]{.c23 .c49} {#h.9jn4ulxubc3h .c44}
=============================================

1.  [Acute Kidney Injury]{.c11} {#h.fj20lj7bpd6o style="display:inline"}
    ---------------------------

```{=html}
<!-- -->
```
1.  [Incidence:]{.c17}

```{=html}
<!-- -->
```
1.  Incidence of AKI in COVID-19 varies widely, but estimates range from
    2.1% to 29%.

```{=html}
<!-- -->
```
2.  [Pathophysiology:]{.c17}

```{=html}
<!-- -->
```
1.  Likely that the most common pathophysiology will be acute tubular
    necrosis (ATN) driven by shock ([[Xianghong et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145717&sa=D&ust=1585016771091000){.c15}]{.c16}[[,
    Natl Med J
    China,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145717&sa=D&ust=1585016771092000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145717&sa=D&ust=1585016771092000){.c15}]{.c16}[)
    and in some cases cytokine storm.]{.c8}

```{=html}
<!-- -->
```
1.  Areas for future research: Some have hypothesized that there could
    direct cellular injury by the virus via angiotensin converting
    enzyme II (ACE2). COVID-19 uses ACE2 for cell entry. ACE2 is
    expressed in proximal renal tubules more than glomeruli ([[Fan et
    al](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.12.20022418&sa=D&ust=1585016771092000){.c15}]{.c16}[[,
    medRxiv,](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.12.20022418&sa=D&ust=1585016771093000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.12.20022418&sa=D&ust=1585016771093000){.c15}]{.c16}[);
    but it remains likely that shock (and in some cases cytokine storm)
    are the main causes of ATN. ]{.c8}

[]{.c8}

3.  [Workup:]{.c33}

```{=html}
<!-- -->
```
1.  [Monitor Creatinine at least daily]{.c8}

```{=html}
<!-- -->
```
1.  Studies find variable onset of AKI, from 7 days ([[Cheng et
    al,](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771094000){.c15}
    ]{.c16}[[medRxiv](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771094000){.c15}]{.c14}[[,
    2020
    preprint](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771094000){.c15}]{.c16})
    to 15 days after illness onset ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771095000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771095000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771095000){.c15}]{.c16}).[ ]{.c64}Onset
    of AKI more rapid and severe in patients with underlying
    CKD[ ]{.c64}([[Cheng et
    al,](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771096000){.c15}
    ]{.c16}[[medRxiv](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771096000){.c15}]{.c14}[[,
    2020
    preprint](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771096000){.c15}]{.c16})[ ]{.c64}[ ]{.c8}

```{=html}
<!-- -->
```
2.  If evidence of rising BUN and/or creatinine, order
    urinalysis[ ]{.c17}

```{=html}
<!-- -->
```
1.  [Patients may present with proteinuria (44%), hematuria
    (26.9%)]{.c8}

```{=html}
<!-- -->
```
4.  [Management: ]{.c17}

```{=html}
<!-- -->
```
1.  [Consult ICU nephrology early at the first sign of renal injury for
    all COVID-19 confirmed patients ]{.c8}

```{=html}
<!-- -->
```
1.  Do not wait until need for RRT (renal replacement therapy)/dialysis
    for consultation.
2.  [At this time, all confirmed COVID-19 patients should be covered by
    ICU nephrology, not general nephrology]{.c8}

```{=html}
<!-- -->
```
1.  [ICU]{.c8}
2.  [RRT Triage]{.c8}
3.  Floor

```{=html}
<!-- -->
```
2.  [Managing AKI:]{.c8}

```{=html}
<!-- -->
```
1.  [Minimize nephrotoxic agents]{.c8}
2.  Give judicious fluids for suspected prerenal insults, but discuss
    with renal if any ambiguity (see [["Shock"
    chapter](#h.dpe5gr1hwjp){.c15}]{.c16} for conservative fluid
    recommendations)

```{=html}
<!-- -->
```
5.  [Renal Replacement Therapy (RRT):]{.c17}

```{=html}
<!-- -->
```
1.  Estimates for RRT range from 1 to 5%[ of hospitalized patients.
    Among critically ill patients, need for CRRT ranges from 5 to 23%
    ]{.c8}

```{=html}
<!-- -->
```
1.  Few studies have reported outcomes of RRT. One case series reported
    that out of 191 patients, 10 received CRRT, and all 10 died ([[Zhou
    et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771100000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771100000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771100000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
2.  Renal will be coordinating RRT continuation and initiation

```{=html}
<!-- -->
```
1.  Indications for dialysis in COVID-19 patients are the same as the
    indications for all patients.

```{=html}
<!-- -->
```
3.  [ICU nephrology will determine the need, timing, and modality of
    renal replacement on a case-by-case basis.]{.c8}

```{=html}
<!-- -->
```
6.  [Prognosis:]{.c33}

```{=html}
<!-- -->
```
1.  Increased serum creatine, BUN, AKI, proteinuria, or hematuria are
    each independent risk factors for in-hospital death ([[Cheng et
    al,](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771102000){.c15}
    ]{.c16}[[medRxiv](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771102000){.c15}]{.c14}[[,
    2020
    preprint](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771102000){.c15}]{.c16})[ ]{.c8}
2.  In two other studies, non-survivors had higher BUN and creatinine
    and higher rates of AKI ([[Wang et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016771103000){.c15}
    ]{.c16}[[JAMA](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016771103000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016771103000){.c15}]{.c16}[;
    ]{.c22}[[Yang et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016771103000){.c15}]{.c16}[[,
    Lancet Respir
    Med,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016771104000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016771104000){.c15}]{.c16}[[)](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&sa=D&ust=1585016771104000){.c15}]{.c16}[.]{.c8}
3.  Another study found that higher BUN and creatinine are associated
    with progression to ARDS, and higher BUN (though not creatinine) is
    associated with death (HR 1.06-1.20) ([[Wu et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771105000){.c15}]{.c16}[[,
    JAMA Intern
    Med,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771105000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771105000){.c15}]{.c16}).
4.  In comparison, AKI was found in 6.7% of SARS patients. AKI
    correlated with poor prognosis and 91.7% of patients with AKI
    died[ ]{.c33}(vs 8.8% without AKI, p \< 0.0001) ([[Chu et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&sa=D&ust=1585016771106000){.c15}]{.c16}[[,
    Kidney
    Int](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&sa=D&ust=1585016771106000){.c15}]{.c14}[[,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&sa=D&ust=1585016771107000){.c15}]{.c16}[[ ](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&sa=D&ust=1585016771107000){.c15}]{.c14}[[2005](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&sa=D&ust=1585016771107000){.c15}]{.c16}).

Chapter 8: Other Guidance {#h.l3i6lcz3jr27 .c39}
=========================

1.  [Liver Disease]{.c11} {#h.fg1hqkm6u1r8 style="display:inline"}
    ---------------------

```{=html}
<!-- -->
```
1.  [Incidence:]{.c17}

```{=html}
<!-- -->
```
1.  Up to 53% of patients had abnormal alanine aminotransferase (ALT)
    and aspartate aminotransferase (AST) ([[Zhang et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145190&sa=D&ust=1585016771108000){.c15}]{.c16}[[,
    Lancet Gastroenterol
    Hepatol,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145190&sa=D&ust=1585016771108000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145190&sa=D&ust=1585016771108000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
2.  [Pathophysiology:]{.c17}

```{=html}
<!-- -->
```
1.  [Possible mechanisms of liver injury include: ]{.c8}

```{=html}
<!-- -->
```
1.  [Direct viral infection of liver cells (2-10% of patients have
    diarrhea; COVID-19 found in stool samples)]{.c8}
2.  [Drug hepatotoxicity ]{.c8}
3.  [Cytokine storm]{.c8}
4.  [Shock]{.c8}

```{=html}
<!-- -->
```
3.  [Time course:]{.c17}

```{=html}
<!-- -->
```
1.  In general, liver injury in mild COVID-19 disease is transient and
    self-resolving. However,[ ]{.c22}[liver injury correlates with
    severity]{.c8}

```{=html}
<!-- -->
```
1.  ALT \> 40 is associated with higher odds of in-hospital death
    ([[Zhou et
    al,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771110000){.c15}
    ]{.c16}[[Lancet](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771110000){.c15}]{.c14}[[,
    2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&sa=D&ust=1585016771110000){.c15}]{.c16}[).]{.c8}
2.  AST is associated with progression to ARDS but not death; total
    bilirubin is associated with both progression to ARDS and death
    ([[Wu et
    al](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771110000){.c15}]{.c16}[[,
    JAMA Intern
    Med,](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771110000){.c15}
    ]{.c14}[[2020](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771111000){.c15}]{.c16}[).]{.c8}

```{=html}
<!-- -->
```
4.  [Monitoring: ]{.c17}

```{=html}
<!-- -->
```
1.  [Monitor LFTs every third day]{.c8}

```{=html}
<!-- -->
```
1.  [If on hepatotoxic medications, monitor more frequently in
    conjunction with pharmacy.]{.c8}
2.  If starting L[opinavir/]{.c83}R[itonavir and ]{.c83}C[hloroquine,
    monitor LFTs daily.]{.c8}

```{=html}
<!-- -->
```
2.  Workup for other etiologies of liver injury with RUQUS, doppler
    ultrasound, hepatitis serologies, etc., as clinically indicated.

```{=html}
<!-- -->
```
5.  [Management:]{.c17}

```{=html}
<!-- -->
```
1.  [Consult GI/Hepatology if concern for acute liver failure (severe
    liver injury with elevated bilirubin, encephalopathy, and
    INR \>1.5).]{.c8}
2.  [Run medication list for all possible offending agents and
    discontinue where possible.]{.c8}
3.  N-Acetyl-Cysteine is not recommended at this time due to significant
    volume load. [Chinese studies refer to giving "liver protective
    drugs" in case of severe liver injury but ]{.c83}[we recommend
    against this for now.]{.c8}
4.  There are no current [guidelines for treatment of COVID-19 patients
    with underlying cirrhosis, but societies such as AASLD are working
    on registries of these patients.]{.c83}

[]{.c8}

2.  Considerations for Oncology Patients   {#h.aayfijcxre19 style="display:inline"}
    --------------------------------------

```{=html}
<!-- -->
```
1.  [Data:]{.c17}

```{=html}
<!-- -->
```
1.  [As of March 16, 2020, there are no available published data
    specific to COVID-19 management in oncologic or immunosuppressed
    patients.]{.c8}

```{=html}
<!-- -->
```
2.  [Oncology Consultation/Coverage: ]{.c17}

```{=html}
<!-- -->
```
1.  [For established DFCI patients, oncology consultation and guidance
    is provided by each patient's primary oncologist (or coverage).
    ]{.c8}

```{=html}
<!-- -->
```
1.  [Contact primary oncologist via page, not the general pager.]{.c8}

```{=html}
<!-- -->
```
3.  [Prognosis: ]{.c17}

```{=html}
<!-- -->
```
1.  [Many patients have reasonable or even good prognosis with current
    therapies. Do not assume a prognosis, involve outpatient
    attending.]{.c8}

```{=html}
<!-- -->
```
4.  [Meds: ]{.c17}

```{=html}
<!-- -->
```
1.  [Check in Epic medications tab and in "Research: Active" tab.]{.c8}

```{=html}
<!-- -->
```
5.  [Workup: ]{.c17}

```{=html}
<!-- -->
```
1.  [Labs: ]{.c8}

```{=html}
<!-- -->
```
1.  [Weekly glucan/galactomannan in neutropenic/transplant
    patients.]{.c8}
2.  [Specific patient populations may require additional monitoring
    (such as CMV, EBV monitoring in transplant patients -- ask
    outpatient team).]{.c8}

```{=html}
<!-- -->
```
2.  [Exam: ]{.c8}

```{=html}
<!-- -->
```
1.  [Examine catheters (port, CVC, others) daily. ]{.c8}
2.  [Avoid rectal exams in neutropenic patients, but examine the
    perirectal area if symptoms or persistent fevers. ]{.c8}
3.  [Do not give per rectum therapies to neutropenic patients.]{.c8}

```{=html}
<!-- -->
```
6.  [Pain management: ]{.c17}

```{=html}
<!-- -->
```
1.  [Patients with cancer-related pain may have high opiate needs at
    baseline. Opiates should not be stopped but type may need to be
    adjusted in the setting of respiratory failure, renal injury, or
    liver injury.]{.c8}

```{=html}
<!-- -->
```
1.  [Pain / Palliative Care service can help guide dose titrations in
    these situations.]{.c8}

```{=html}
<!-- -->
```
7.  [Goals of Care: ]{.c17}

```{=html}
<!-- -->
```
1.  [Involve primary team whenever possible (recognizing that in
    critical/emergent situations may not be possible).]{.c8}

```{=html}
<!-- -->
```
8.  [Anticoagulation:]{.c17}

```{=html}
<!-- -->
```
1.  [Thrombosis prophylaxis should be initiated for all patients unless
    otherwise contraindicated, given that both COVID-19 infection and
    malignancy increase thrombotic risk, particularly with solid
    tumors.]{.c8}

```{=html}
<!-- -->
```
1.  See [["Thrombotic Disease"
    section](#h.9wzf9ick65rt){.c15}]{.c16} within [["Thrombotic and
    Coagulation Manifestations"
    chapter](#h.5s70bzlr4ojz){.c15}]{.c16}[ for guidelines on both
    prophylactic and therapeutic anticoagulation.]{.c8}
2.  [Remember to hold if platelet count \< 30K.]{.c8}

```{=html}
<!-- -->
```
9.  [Patients with Heme Malignancy and Stem Cell Transplant:]{.c17}

```{=html}
<!-- -->
```
1.  [Daily exam: Findings are more subtle or absent in neutropenic and
    immune suppressed patients. Examine catheters daily. Avoid rectal
    exam.]{.c8}

```{=html}
<!-- -->
```
10. [Febrile Neutropenia:]{.c17}

```{=html}
<!-- -->
```
1.  [Definition:]{.c8}

```{=html}
<!-- -->
```
1.  [ANC \< 500 cells/mm3 AND T ≥ 101F or T ≥ 100.5 for 1hr]{.c8}

```{=html}
<!-- -->
```
2.  [Workup: ]{.c8}

```{=html}
<!-- -->
```
1.  [Blood cultures from peripheral (ideally two sets), and each lumen
    of central line (label clearly); UA/sed with urine culture (UA may
    not be as informative with neutropenia); glucan and galactomannan
    (if not checked recently), sputum if able; CXR]{.c8}

```{=html}
<!-- -->
```
1.  [Continue DAILY blood cultures while febrile.]{.c8}
2.  [Monitor serum galactomannan and 1-3-beta glucan once weekly.]{.c8}
3.  [Any positive glucan or galactomannan prompts ID consult.]{.c8}

```{=html}
<!-- -->
```
3.  [Initial Empiric Antibiotics:]{.c8}

```{=html}
<!-- -->
```
1.  [GNRs: Ceftazidime OR Cefepime ]{.c8}

```{=html}
<!-- -->
```
1.  [Alternatives:  Piperacillin-tazobactam (2nd line) or meropenem (3rd
    line).]{.c8}

```{=html}
<!-- -->
```
2.  [GPCs: add Vancomycin if hemodynamically unstable, or if MRSA
    pneumonia or catheter-associated infection is suspected. Check
    dosing with pharmacy if able.]{.c8}

```{=html}
<!-- -->
```
4.  [Removal of lines:]{.c8}

```{=html}
<!-- -->
```
1.  [Catheter removal should be discussed if associated infection is
    suspected - involve primary oncologist and/or ID team to weigh risks
    and benefits, given that not all lines require removal.]{.c8}

```{=html}
<!-- -->
```
5.  [Persistent Neutropenic Fever:]{.c8}

```{=html}
<!-- -->
```
1.  [If fever persists x3 days despite antibiotics ]{.c8}

```{=html}
<!-- -->
```
1.  [Micafungin 100mg IV daily ]{.c8}
2.  [Consideration of further imaging even if patient appears stable
    (discuss with oncology / ID).]{.c8}

```{=html}
<!-- -->
```
6.  [Antiinfective course:]{.c8}

```{=html}
<!-- -->
```
1.  [Anti-Infectives should be continued until the patient has met all
    of these criteria: ]{.c8}

```{=html}
<!-- -->
```
1.  [clinically improved, and ]{.c8}
2.  [has been afebrile for 48h, and ]{.c8}
3.  [has been non-neutropenic for 48h.]{.c8}

```{=html}
<!-- -->
```
11. [Transfusions: ]{.c17}

```{=html}
<!-- -->
```
1.  Blood bank reviews orders and will release appropriate products
    ([i.e.]{.c22}[, irradiated, leukoreduced, etc).]{.c8}

```{=html}
<!-- -->
```
1.  [RBC transfusion if Hgb \< 7 or Hct \< 21.]{.c8}
2.  [Platelet transfusion if Platelets \< 10K. Higher transfusion goals
    if needed for procedures or if active bleeding:]{.c8}

```{=html}
<!-- -->
```
1.  Platelet count \> 20K if mild bleeding ([i.e.]{.c22}[, epistaxis,
    line oozing) or if patient has rigors.]{.c8}
2.  [Platelet count \> 50K if more serious bleeding; may be higher for
    CNS bleeding or neurosurgery required.]{.c8}

```{=html}
<!-- -->
```
3.  [Cryoprecipitate transfusion if fibrinogen \< 100.]{.c8}
4.  [FFP transfusion if procedure needed (INR of FFP = \~1.4).]{.c8}

```{=html}
<!-- -->
```
12. [Patients with Solid Tumors:]{.c17}

```{=html}
<!-- -->
```
1.  [Patients with solid tumors are at very high risk of thrombosis but
    at lower risk of infection than most heme malignancy patients.]{.c8}
2.  [Immune Checkpoint Inhibitors (ICIs) do not significantly
    immunosuppress patients when used alone.]{.c8}

```{=html}
<!-- -->
```
1.  [Most common are CTLA-4 inhibitor (ipilimumab) and PD-1/PD-L1
    inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab and
    avelumab).]{.c8}

```{=html}
<!-- -->
```
3.  [Immune toxicity: ]{.c8}

```{=html}
<!-- -->
```
1.  [If patient develops organ dysfunction, it may be due to immune
    toxicity- consult the service team of the involved organ system and
    inform primary oncologist.]{.c8}
2.  [Common immune toxicities include pneumonitis / respiratory failure
    (may be difficult to distinguish between COVID19 disease or may be
    aggravated by COVID19 infection), colitis, endocrine dysfunction
    (thyroid, pituitary / hypothalamic, adrenal), nephritis. Less common
    hepatitis, meningitis, dermatitis.]{.c8}

```{=html}
<!-- -->
```
1.  [Check TSH, ACTH, cortisol, T-spot, HIV, HBV, HCV serologies if
    concerned.]{.c8}

```{=html}
<!-- -->
```
3.  [Immune toxicities are usually treated with high dose steroids -
    risks and benefits must be weighed immediately with primary
    oncologist and ID consult teams if immune toxicity is suspected
    concurrent with COVID19 infection.]{.c8}
4.  BWH/DFCI iTox guidelines can be found
    [[here](https://www.google.com/url?q=http://dfcionline.org/clinical/clinicalresources/immunotherapy-toxicity/&sa=D&ust=1585016771121000){.c15}]{.c16}[ on
    BWH/DFCI intranet.]{.c8}

[]{.c8}

3.  [Goals of Care]{.c11} {#h.t1khoickfgoo style="display:inline"}
    ---------------------

```{=html}
<!-- -->
```
1.  [Assess understanding and sign Health Care Proxy form on
    admission:]{.c33}

```{=html}
<!-- -->
```
1.  [In conscious patients, review or sign Health Care Proxy form.]{.c8}
2.  Make sure families are aware that patients with significant comorbid
    illnesses or who have poor baseline functional or health status
    decompensate rapidly and have very high mortality due to COVID-19
    (see [["Non-ICU Management, Triage, Transfers"
    chapter](#h.d36vdx67mxka){.c15}]{.c16}).

```{=html}
<!-- -->
```
2.  [Goals of Care should be documented and focus on:]{.c17}

```{=html}
<!-- -->
```
1.  [A patient's desired quality of life]{.c8}
2.  [Tolerance for/desire for invasive measures]{.c8}
3.  [Understanding of disease process ]{.c8}

[]{.c59 .c45 .c75}

4.  [Management of Cardiac Arrest]{.c11} {#h.ipfys4gecnv0 style="display:inline"}
    ------------------------------------

```{=html}
<!-- -->
```
1.  [Early goals of care conversations are imperative.]{.c17}

```{=html}
<!-- -->
```
1.  The aim is to avoid unnecessary codes in patients without a
    reversible underlying condition.

```{=html}
<!-- -->
```
2.  [Health care workers should be protected in code situations: ]{.c17}

```{=html}
<!-- -->
```
1.  [PPE should be worn by all healthcare workers, even if donning
    prolongs time the patient spends in a low-flow state during cardiac
    arrest.]{.c8}
2.  [Codes should be run with an automated compression device where
    available and minimal personnel.]{.c8}

```{=html}
<!-- -->
```
3.  [Full code guidelines are forthcoming and will be included here when
    available.]{.c17}

[]{.c8}

5.  [The Role of Palliative Care]{.c11} {#h.6ogwg6sl9a40 style="display:inline"}
    -----------------------------------

```{=html}
<!-- -->
```
1.  This section in in progress^[\[al\]](#cmnt38){#cmnt_ref38}^

[]{.c8}

6.  [Ethical Considerations and Resource Allocation]{.c11} {#h.foc01qidskrl style="display:inline"}
    ------------------------------------------------------

```{=html}
<!-- -->
```
1.  This section is^[\[am\]](#cmnt39){#cmnt_ref39}^ in progress

[]{.c23 .c86}

------------------------------------------------------------------------

[]{.c23 .c86}

[]{.c23 .c86}

[            ]{.c86}

[Afterword]{.c59 .c42 .c33 .c66 .c77}

[We built the first iteration of these guidelines "from the bottom up"
in less than a week with the input of over 50 people. With the help of
our readers, we expect to correct and revise as we as a society learn
about COVID-19. ]{.c8}

[]{.c8}

[We hope that this pandemic brings with it a new era of collaborativity
and speed in Evidence Based Medicine. We welcome all help, and will be
restructuring this to be more navigable and collaborative in the coming
days.]{.c8}

[]{.c8}

Currently we are looking for ongoing section editors, please email
[<BWHCOVIDGuidelines@gmail.com>]{.c16}[ if you are interested.]{.c8}

[]{.c8}

[(signed)]{.c8}

[ ]{.c8}

[BWH intensivists, fellows, respiratory therapists and pharmacists]{.c8}

------------------------------------------------------------------------

[]{.c23 .c49} {#h.fu2z89vxpri3 .c44 .c79}
=============

REFERENCES   {#h.24n5wzicja05 .c44}
============

[]{.c23 .c10 .c0}

1.  [Afshari A, Bastholm bille A, Allingstrup M. Aerosolized
    prostacyclins for acute respiratory distress syndrome (ARDS). ]{.c10
    .c0}[Cochrane Database Syst Rev]{.c10 .c0 .c22}[. 2017;7:CD007733.
    DOI: ]{.c10
    .c0}[[10.1002/14651858.CD007733.pub3](https://www.google.com/url?q=http://dx.doi.org/10.1002/14651858.CD007733.pub3&sa=D&ust=1585016771129000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[28806480](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483148/&sa=D&ust=1585016771129000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}
2.  [Akerström S, Mousavi-jazi M, Klingström J, Leijon M, Lundkvist A,
    Mirazimi A. Nitric oxide inhibits the replication cycle of severe
    acute respiratory syndrome coronavirus. ]{.c10 .c0}[J Virol]{.c10
    .c0 .c22}[. 2005;79(3):1966-9. DOI: ]{.c10
    .c0}[[10.1128/JVI.79.3.1966-1969.2005](https://www.google.com/url?q=http://dx.doi.org/10.1128/JVI.79.3.1966-1969.2005&sa=D&ust=1585016771130000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[15650225](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&sa=D&ust=1585016771130000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
3.  [American College of Cardiology. Cardiologist's Insights From
    Treating COVID-19 Patients in China. Mar 12, 2020.  ]{.c10
    .c0}[[https://www.acc.org/latest-in-cardiology/articles/2020/03/12/17/02/cardiologists-insights-from-treating-covid-19-patients-in-china](https://www.google.com/url?q=https://www.acc.org/latest-in-cardiology/articles/2020/03/12/17/02/cardiologists-insights-from-treating-covid-19-patients-in-china&sa=D&ust=1585016771131000){.c15}]{.c16
    .c10 .c0}[ ]{.c10 .c0}
4.  [Arabi YM, Mandourah Y, Al-hameed F, et al. Corticosteroid Therapy
    for Critically Ill Patients with Middle East Respiratory Syndrome.
    ]{.c10 .c0}[Am J Respir Crit Care Med]{.c10 .c0 .c22}[.
    2018;197(6):757-767. DOI: ]{.c10
    .c0}[[10.1164/rccm.201706-1172OC](https://www.google.com/url?q=http://dx.doi.org/10.1164/rccm.201706-1172OC&sa=D&ust=1585016771132000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[29161116](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&sa=D&ust=1585016771132000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
5.  [Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA Statement Addresses
    Concerns Re: Using RAAS Antagonists in COVID-19. Mar 17, 2020.
    ]{.c10
    .c0}[[https://www.acc.org/sitecore/content/Sites/ACC/Home/Latest-in-Cardiology/Articles/2020/03/17/08/59/HFSA-ACC-AHA-Statement-Addresses-Concerns-Re-Using-RAAS-Antagonists-in-COVID-19](https://www.google.com/url?q=https://www.acc.org/sitecore/content/Sites/ACC/Home/Latest-in-Cardiology/Articles/2020/03/17/08/59/HFSA-ACC-AHA-Statement-Addresses-Concerns-Re-Using-RAAS-Antagonists-in-COVID-19&sa=D&ust=1585016771133000){.c15}]{.c16
    .c10 .c0}[ ]{.c23 .c10 .c0}
6.  [Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity:
    Mechanisms, manifestations and management. ]{.c10 .c0}[Blood
    Rev]{.c10 .c0 .c22}[. 2019;34:45-55. DOI: ]{.c10
    .c0}[[10.1016/j.blre.2018.11.002](https://www.google.com/url?q=http://dx.doi.org/10.1016/j.blre.2018.11.002&sa=D&ust=1585016771133000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[30528964](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&sa=D&ust=1585016771134000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}
7.  [Tschöpe C, Cooper LT, Torre-amione G, Van linthout S. Management of
    Myocarditis-Related Cardiomyopathy in Adults. ]{.c10 .c0}[Circ
    Res]{.c10 .c0 .c22}[. 2019;124(11):1568-1583.]{.c10 .c0}[ DOI:
    ]{.c10
    .c0}[[10.1161/CIRCRESAHA.118.313578](https://www.google.com/url?q=https://doi.org/10.1161/CIRCRESAHA.118.313578&sa=D&ust=1585016771135000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[31120823](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31120823&sa=D&ust=1585016771135000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}^[\[an\]](#cmnt40){#cmnt_ref40}^
8.  [Chen N, Zhou M, Dong X, et al. Epidemiological and clinical
    characteristics of 99 cases of 2019 novel coronavirus pneumonia in
    Wuhan, China: a descriptive study. ]{.c10 .c0}[Lancet]{.c10 .c0
    .c22}[. 2020;395(10223):507-513. DOI: ]{.c10
    .c0}[[10.1016/S0140-6736(20)30211-7](https://www.google.com/url?q=http://dx.doi.org/10.1016/S0140-6736(20)30211-7&sa=D&ust=1585016771136000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32007143](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&sa=D&ust=1585016771136000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
9.  [Cheng Y, Luo R, Wang K, et al. Kidney Impairment Is Associated with
    In-Hospital Death of COVID-19 Patients. ]{.c10 .c0}[medRxiv]{.c10
    .c0 .c22}[. 2020. DOI: ]{.c10
    .c0}[[10.1101/2020.02.18.20023242](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&sa=D&ust=1585016771137000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
10. [Chu KH, Tsang WK, Tang CS, et al. Acute renal impairment in
    coronavirus-associated severe acute respiratory syndrome. ]{.c10
    .c0}[Kidney Int]{.c10 .c0 .c22}[. 2005;67(2):698-705. DOI: ]{.c10
    .c0}[[10.1111/j.1523-1755.2005.67130.x](https://www.google.com/url?q=http://dx.doi.org/10.1111/j.1523-1755.2005.67130.x&sa=D&ust=1585016771137000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[15673319](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&sa=D&ust=1585016771138000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
11. [Day, M. COVID-19: ibuprofen should not be used for managing
    symptoms, say doctors and scientists. ]{.c10 .c0}[BMJ]{.c10 .c0
    .c22}[. 2020;368:m1086. DOI: ]{.c10
    .c0}[[10.1136/bmj.m1086](https://www.google.com/url?q=http://dx.doi.org/10.1136/bmj.m1086&sa=D&ust=1585016771138000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32184201](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32184201&sa=D&ust=1585016771139000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}
12. [Delaney JW, Pinto R, Long J, et al. The influence of corticosteroid
    treatment on the outcome of influenza A(H1N1pdm09)-related critical
    illness. ]{.c10 .c0}[Crit Care]{.c10 .c0 .c22}[. 2016;20:75. DOI:
    ]{.c10
    .c0}[[10.1186/s13054-016-1230-8](https://www.google.com/url?q=http://dx.doi.org/%252010.1186/s13054-016-1230-8&sa=D&ust=1585016771139000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[27036638](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27036638&sa=D&ust=1585016771140000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
13. [Famous KR, Delucchi K, Ware LB, et al. Acute Respiratory Distress
    Syndrome Subphenotypes Respond Differently to Randomized Fluid
    Management Strategy. ]{.c10 .c0}[Am J Respir Crit Care Med.]{.c10
    .c0 .c22}[ 2017;195(3):331-338. DOI: ]{.c10
    .c0}[[10.1164/rccm.201603-0645OC](https://www.google.com/url?q=http://dx.doi.org/10.1164/rccm.201603-0645OC&sa=D&ust=1585016771140000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[27513822](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27513822&sa=D&ust=1585016771141000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
14. [Fan C, Li K, Ding Y, Lu WL, Wang J. ACE2 Expression in Kidney and
    Testis May Cause Kidney and Testis Damage After 2019-NCoV Infection.
    ]{.c10 .c0}[medRxiv]{.c10 .c0 .c22}[. 2020. DOI: ]{.c10
    .c0}[[10.1101/2020.02.12.20022418](https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.12.20022418&sa=D&ust=1585016771141000){.c15}]{.c16
    .c10 .c0}[. ]{.c23 .c10 .c0}
15. [Fang, L, Karakiulakis G, Roth, M. Are patients with hypertension
    and diabetes mellitus at increased risk for COVID-19 infection?
    ]{.c10 .c0}[Lancet Respir Med]{.c10 .c0 .c22}[. 2020. DOI: ]{.c10
    .c0}[[10.1016/S2213-2600(20)30116-8](https://www.google.com/url?q=http://dx.doi.org/10.1016/S2213-2600(20)30116-8&sa=D&ust=1585016771141000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32171062](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&sa=D&ust=1585016771142000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}
16. [Fuller et al. The use of inhaled prostaglandins in patients with
    ARDS: a systematic review and meta-analysis. ]{.c10 .c0}[Chest]{.c10
    .c0 .c22}[. 2015; 147(6): 1510-1522. DOI: ]{.c10
    .c0}[[10.1378/chest.14-3161](https://www.google.com/url?q=https://dx.doi.org/10.1378/chest.14-3161&sa=D&ust=1585016771142000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
17. [Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet
    transfusion for nonbleeding patients in the intensive care unit:
    benefit or harm? ]{.c10 .c0}[Crit Care Med]{.c10 .c0 .c22}[.
    2006;34(5 Suppl):S170-3. DOI: ]{.c10
    .c0}[[10.1097/01.CCM.0000214288.88308.26](https://www.google.com/url?q=http://dx.doi.org/10.1097/01.CCM.0000214288.88308.26&sa=D&ust=1585016771142000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[25742022](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25742022&sa=D&ust=1585016771143000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}
18. [Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has
    shown apparent efficacy in treatment of COVID-19 associated
    pneumonia in clinical studies. ]{.c10 .c0}[Biosci Trends]{.c10 .c0
    .c22}[. 2020. DOI: ]{.c10
    .c0}[[10.5582/bst.2020.01047](https://www.google.com/url?q=http://dx.doi.org/10.5582/bst.2020.01047&sa=D&ust=1585016771143000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32074550](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32074550&sa=D&ust=1585016771143000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
19. [Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide
    for acute respiratory distress syndrome (ARDS) in children and
    adults. ]{.c10 .c0}[Cochrane Database Syst Rev]{.c10 .c0 .c22}[.
    2016;(6):CD002787. DOI: ]{.c10
    .c0}[[10.1002/14651858.CD002787.pub3](https://www.google.com/url?q=http://dx.doi.org/10.1002/14651858.CD002787.pub3&sa=D&ust=1585016771144000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[27347773](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&sa=D&ust=1585016771144000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
20. [Grissom CK, Hirshberg EL, Dickerson JB, et al. Fluid management
    with a simplified conservative protocol for the acute respiratory
    distress syndrome\*. ]{.c10 .c0}[Crit Care Med]{.c10 .c0 .c22}[.
    2015;43(2):288-95. DOI: ]{.c10
    .c0}[[10.1097/CCM.0000000000000715](https://www.google.com/url?q=http://dx.doi.org/10.1097/CCM.0000000000000715&sa=D&ust=1585016771144000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[25599463](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&sa=D&ust=1585016771145000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
21. [Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of
    Coronavirus Disease 2019 in China. ]{.c10 .c0}[N Engl J Med]{.c10
    .c0 .c22}[. 2020. DOI: ]{.c10
    .c0}[[10.1056/NEJMoa2002032](https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJMoa2002032&sa=D&ust=1585016771145000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32109013](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&sa=D&ust=1585016771146000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
22. [Guérin C, Reignier J, Richard JC, et al. Prone positioning in
    severe acute respiratory distress syndrome. ]{.c10 .c0}[N Engl J
    Med]{.c10 .c0 .c22}[. 2013;368(23):2159-68. DOI: ]{.c10
    .c0}[[10.1056/NEJMoa1214103](https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJMoa1214103&sa=D&ust=1585016771146000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c0
    .c10}[[23688302](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&sa=D&ust=1585016771147000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
23. [Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized,
    controlled clinical trial of transfusion requirements in critical
    care. Transfusion Requirements in Critical Care Investigators,
    Canadian Critical Care Trials Group. ]{.c10 .c0}[N Engl J Med]{.c10
    .c0 .c22}[. 1999;340(6):409-17. DOI: ]{.c10
    .c0}[[10.1056/NEJM199902113400601](https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJM199902113400601&sa=D&ust=1585016771147000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[9971864](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&sa=D&ust=1585016771148000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}
24. [Holst LB, Haase N, Wetterslev J, et al. Lower versus higher
    hemoglobin threshold for transfusion in septic shock.]{.c10 .c0}[ N
    Engl J Med]{.c10 .c0 .c22}[. 2014;371(15):1381-91. DOI: ]{.c10
    .c0}[[10.1056/NEJMoa1406617](https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJMoa1406617&sa=D&ust=1585016771148000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[25270275](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25270275&sa=D&ust=1585016771149000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
25. [Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved
    with glucocorticoid and human immunoglobulin. ]{.c10 .c0}[Eur Heart
    J]{.c10 .c0 .c22}[. 2020. DOI: ]{.c10
    .c0}[[10.1093/eurheartj/ehaa190](https://www.google.com/url?q=http://dx.doi.org/10.1093/eurheartj/ehaa190&sa=D&ust=1585016771149000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32176300](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&sa=D&ust=1585016771150000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
26. [Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during
    high-flow nasal cannula therapy CPAP different masks. ]{.c10
    .c0}[Eur Respir J]{.c10 .c0 .c22}[. 2019;53(4). DOI: ]{.c10
    .c0}[[10.1183/13993003.02339-2018](https://www.google.com/url?q=http://dx.doi.org/10.1183/13993003.02339-2018&sa=D&ust=1585016771150000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[30705129](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30705129&sa=D&ust=1585016771151000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
27. [Kallet RH, Matthay MA. Hyperoxic acute lung injury. ]{.c10
    .c0}[Respir Care]{.c10 .c0 .c22}[. 2013;58(1):123-41. DOI: ]{.c10
    .c0}[[10.4187/respcare.01963](https://www.google.com/url?q=http://dx.doi.org/10.4187/respcare.01963&sa=D&ust=1585016771151000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[23271823](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23271823&sa=D&ust=1585016771152000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
28. [Kim ES, Choe PG, Park WB, et al. Clinical Progression and Cytokine
    Profiles of Middle East Respiratory Syndrome Coronavirus Infection.
    ]{.c10 .c0}[J Korean Med Sci]{.c10 .c0 .c22}[.
    2016;31(11):1717-1725. DOI: ]{.c10
    .c0}[[10.3346/jkms.2016.31.11.1717](https://www.google.com/url?q=http://dx.doi.org/10.3346/jkms.2016.31.11.1717&sa=D&ust=1585016771152000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[27709848](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27709848&sa=D&ust=1585016771153000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
29. [Lee N, Allen chan KC, Hui DS, et al. Effects of early
    corticosteroid treatment on plasma SARS-associated Coronavirus RNA
    concentrations in adult patients. ]{.c10 .c0}[J Clin Virol]{.c10 .c0
    .c22}[. 2004;31(4):304-9. DOI: ]{.c10
    .c0}[[10.1016/j.jcv.2004.07.006](https://www.google.com/url?q=http://dx.doi.org/10.1016/j.jcv.2004.07.006&sa=D&ust=1585016771153000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[15494274](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&sa=D&ust=1585016771154000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
30. [Levi M, Scully M. How I treat disseminated intravascular
    coagulation. ]{.c10 .c0}[Blood]{.c10 .c0 .c22}[.
    2018;131(8):845-854. DOI: ]{.c10
    .c0}[[10.1182/blood-2017-10-804096](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/29255070&sa=D&ust=1585016771154000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[29255070](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29255070&sa=D&ust=1585016771155000){.c15}]{.c16
    .c10}[.]{.c10}
31. [Lippi G and Plebani M. Procalcitonin in patients with severe
    coronavirus disease 2019: A meta-analysis. ]{.c10 .c0}[Clin Chim
    Acta]{.c10 .c0 .c22}[. 2020;505:190-191. DOI: ]{.c10
    .c0}[[10.1016/j.cca.2020.03.004](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32145275&sa=D&ust=1585016771155000){.c15}]{.c16
    .c10}[. PMID:
    ]{.c10}[[32145275](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&sa=D&ust=1585016771155000){.c15}]{.c16
    .c10}[.]{.c10}
32. [Liu X, Li Z, Liu S, Chen Z, Zhao Z, Huang Y, Zhang Q, Wang J, Shi
    Y, Xu Y, Sun J, Xian H, Fang R, Fan Bai F, Changxing Ou, Bei Xiong,
    Andrew M Lew, Jun Cui, Hui Huang, Jincun Zhao, Xuechuan Hong,  H-BL.
    Therapeutic effects of dipyridamole on COVID-19 patients with
    coagulation dysfunction. ]{.c10 .c0}[medRxiv]{.c10 .c0 .c22}[. 2020.
    ]{.c10 .c0}[DOI: ]{.c10 .c0
    .c87}[[10.1101/2020.02.27.20027557](https://www.google.com/url?q=https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1&sa=D&ust=1585016771156000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}
33. [Luo, W., Yu, H., Gou, J., et al. Clinical Pathology of Critical
    Patient with Novel Coronavirus Pneumonia (COVID-19). ]{.c10
    .c0}[Preprints]{.c10 .c0 .c22}[. 2020. ]{.c10
    .c0}[[2020020407](https://www.google.com/url?q=https://www.preprints.org/manuscript/202002.0407/v1&sa=D&ust=1585016771157000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}
34. [MacIntyre CR, Chughtai AA, Barnes M et al (2018) The role of
    pneumonia and secondary bacterial infection in fatal and serious
    outcomes of pandemic influenza a(H1N1)pdm09.]{.c10 .c0}[ ]{.c10}[BMC
    Infect Dis]{.c10 .c22}[.]{.c10}[ 2018 Dec 7;18(1):637. DOI:
    ]{.c10}[[10.1186/s12879-018-3548-0](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/30526505&sa=D&ust=1585016771158000){.c15}]{.c16
    .c10}[. PMID:
    ]{.c10}[[30526505](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30526505&sa=D&ust=1585016771158000){.c15}]{.c16
    .c10}[.]{.c10}
35. [Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ.
    COVID-19: consider cytokine storm syndromes and immunosuppression.
    ]{.c10 .c0}[Lancet]{.c10 .c0 .c22}[. 2020;0(0). DOI:]{.c10
    .c0}[[10.1016/S0140-6736(20)30628-0](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32192578&sa=D&ust=1585016771159000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32192578](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32192578&sa=D&ust=1585016771159000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
36. [Nates JL]{.c10}[, ]{.c10}[Nunnally M]{.c10}[, ]{.c10}[Kleinpell
    R]{.c10}[, ]{.c10}[Blosser S]{.c10}[, ]{.c10}[Goldner J]{.c10}[,
    ]{.c10}[Birriel B]{.c10}[, ]{.c10}[Fowler CS]{.c10}[, ]{.c10}[Byrum
    D]{.c10}[, ]{.c10}[Miles WS]{.c10}[, ]{.c10}[Bailey H]{.c10}[,
    ]{.c10}[Sprung CL]{.c10}[. ICU Admission, Discharge, and Triage
    Guidelines: A Framework to Enhance Clinical Operations, Development
    of Institutional Policies, and Further Research. ]{.c10}[Crit Care
    Med.]{.c10 .c22}[ 2016 Aug;44(8):1553-602. DOI:
    ]{.c10}[[10.1097/CCM.0000000000001856](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/27428118&sa=D&ust=1585016771161000){.c15}]{.c16
    .c10}[. PMID:
    ]{.c10}[[27428118](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27428118&sa=D&ust=1585016771161000){.c15}]{.c16
    .c10}[.]{.c10}
37. [Penn Medicine Treatment Guidelines for SARS-CoV-2 Infection. Mar
    14 2020. Accessed Mar 18 2020. ]{.c10
    .c0}[[http://www.uphs.upenn.edu/antibiotics/COVID19.html](https://www.google.com/url?q=http://www.uphs.upenn.edu/antibiotics/COVID19.html&sa=D&ust=1585016771162000){.c15}]{.c16
    .c10 .c0}[.]{.c10 .c0}
38. [Ruan et al. Clinical predictors of mortality due to COVID-19 based
    on an analysis of data of 150 patients from Wuhan, China. ]{.c10
    .c0}[Intensive Care Med]{.c10 .c0 .c22}[. 2020 Mar 3. DOI: ]{.c10
    .c0}[[10.1007/s00134-020-05991-x](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771163000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32125452](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&sa=D&ust=1585016771163000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
39. [Rubin DB, Danish HH, Ali AB, et al. Neurological toxicities
    associated with chimeric antigen receptor T-cell therapy. ]{.c10
    .c0}[Brain]{.c10 .c0 .c22}[. 2019;142(5):1334-1348. DOI: ]{.c10
    .c0}[[10.1093/brain/awz053](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/30891590&sa=D&ust=1585016771164000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[30891590](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&sa=D&ust=1585016771164000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
40. [Shahpori R, Stelfox HT, Doig CJ, Boiteau PJ, Zygun DA. Sequential
    Organ Failure Assessment in H1N1 pandemic planning. ]{.c10 .c0}[Crit
    Care Med]{.c10 .c0 .c22}[. 2011 Apr;39(4):827-32. DOI: ]{.c10
    .c0}[[10.1097/CCM.0b013e318206d548](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/21263327&sa=D&ust=1585016771165000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[21263327](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/21263327&sa=D&ust=1585016771165000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
41. [Silversides JA, Major E, Ferguson AJ, et al. Conservative fluid
    management or deresuscitation for patients with sepsis or acute
    respiratory distress syndrome following the resuscitation phase of
    critical illness: a systematic review and meta-analysis. ]{.c10
    .c0}[Intensive Care Med]{.c10 .c0 .c22}[. 2017;43(2):155-170. DOI:
    ]{.c10
    .c0}[[10.1007/s00134-016-4573-3](https://www.google.com/url?q=http://dx.doi.org/10.1007/s00134-016-4573-3&sa=D&ust=1585016771166000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[27734109](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27734109&sa=D&ust=1585016771166000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
42. [Stockman LJ, Bellamy R, Garner P. SARS: systematic review of
    treatment effects. ]{.c10 .c0}[PLoS Med.]{.c10 .c0
    .c22}[ 2006;3:e343. DOI: ]{.c10
    .c0}[[10.1371/journal.pmed.0030343](https://www.google.com/url?q=http://doi.org/10.1371/journal.pmed.0030343&sa=D&ust=1585016771167000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[16968120](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16968120&sa=D&ust=1585016771167000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
43. [Stevenson LW, Perloff JK. The limited reliability of physical signs
    for estimating hemodynamics in chronic heart failure. ]{.c10
    .c0}[JAMA]{.c10 .c0 .c22}[. 1989;261(6):884-8. DOI: ]{.c10
    .c0}[[10.1001/jama.1989.03420060100040](https://www.google.com/url?q=http://dx.doi.org/10.1001/jama.1989.03420060100040&sa=D&ust=1585016771168000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[2913385](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&sa=D&ust=1585016771168000){.c15}]{.c16
    .c10 .c0}[. ]{.c10 .c0}
44. [Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are
    associated with poor prognosis in patients with novel coronavirus
    pneumonia. ]{.c10 .c0}[J Thromb Haemost]{.c10 .c0 .c22}[. 2020 Feb.
    DOI: ]{.c10
    .c0}[[10.1111/jth.14768](https://www.google.com/url?q=http://doi.org/10.1111/jth.14768&sa=D&ust=1585016771169000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32073213](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&sa=D&ust=1585016771169000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
45. [Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol
    generating procedures and risk of transmission of acute respiratory
    infections to healthcare workers: A systematic review. ]{.c10
    .c0}[PLoS One.]{.c10 .c0 .c22}[ 2012;7(4). DOI: ]{.c10
    .c0}[[10.1371/journal.pone.0035797](https://www.google.com/url?q=http://doi.org/10.1371/journal.pone.0035797&sa=D&ust=1585016771170000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[22563403](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22563403&sa=D&ust=1585016771170000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
46. [Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138
    Hospitalized Patients With 2019 Novel Coronavirus--Infected
    Pneumonia in Wuhan, China. ]{.c10 .c0}[JAMA]{.c10 .c0 .c22}[. 2020
    Feb. DOI: ]{.c10
    .c0}[[10.1001/jama.2020.1585](https://www.google.com/url?q=http://doi.org/10.1001/jama.2020.1585&sa=D&ust=1585016771171000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32031570](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&sa=D&ust=1585016771171000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
47. [Lee N, Allen Chan KC, Hui DS, et al. Effects of early
    corticosteroid treatment on plasma SARS-associated Coronavirus RNA
    concentrations in adult patients. ]{.c10 .c0}[J Clin Virol]{.c10 .c0
    .c22}[. 2004;31(4):304-9. DOI: ]{.c10
    .c0}[[10.1016/j.jcv.2004.07.006](https://www.google.com/url?q=http://dx.doi.org/10.1016/j.jcv.2004.07.006&sa=D&ust=1585016771172000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[15494274](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&sa=D&ust=1585016771172000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
48. [Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and
    chemokines in severe acute respiratory syndrome. Clin Exp Immunol.
    2004;136(1):95-103. DOI: ]{.c10
    .c0}[[10.1111/j.1365-2249.2004.02415.x](https://www.google.com/url?q=http://dx.doi.org/10.1111/j.1365-2249.2004.02415.x&sa=D&ust=1585016771173000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[15030519](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15030519&sa=D&ust=1585016771173000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
49. [World Health Organization. Clinical management of severe acute
    respiratory infection when novel coronavirus (nCoV) infection is
    suspected. WHO. 2020;(January):12. ]{.c10
    .c0}^[\[ao\]](#cmnt41){#cmnt_ref41}^
50. [Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute
    Respiratory Distress Syndrome and Death in Patients With Coronavirus
    Disease 2019 Pneumonia in Wuhan, China. ]{.c10 .c0}[JAMA Intern
    Med]{.c10 .c0 .c22}[. 2020 Mar. DOI: ]{.c10
    .c0}[[10.1001/jamainternmed.2020.0994](https://www.google.com/url?q=http://doi.org/10.1001/jamainternmed.2020.0994&sa=D&ust=1585016771174000){.c15}]{.c16
    .c10 .c0}[. PMID: ]{.c10
    .c0}[[32167524](https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&sa=D&ust=1585016771174000){.c15}]{.c16
    .c10 .c0}[.]{.c23 .c10 .c0}
51. [Xianghong Y, Renhua S, Dechang C. Diagnosis and treatment of
    COVID-19: acute kidney injury cannot be ignored. Natl Med J China.
    2020;100(00):E017-E017.
    doi:10.3760/cma.j.cn112137-20200229-00520]{.c23 .c10 .c0}
52. [Xie Y, Wang X, Yang P, Zhang S. COVID-19 Complicated by Acute
    Pulmonary Embolism. Radiol Cardiothorac Imaging. 2020;2(2).]{.c23
    .c10 .c0}
53. [Yang et al. COVID-19 control in China during mass population
    movements at New Year.]{.c10 .c0}[ Lancet, Feb 2020;
    ]{.c10}[[https://doi.org/10.1016/S0140-6736(20)30421-9](https://www.google.com/url?q=https://doi.org/10.1016/S0140-6736(20)30421-9&sa=D&ust=1585016771175000){.c15}]{.c10}
54. [Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of
    critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a
    single-centered, retrospective, observational study. Lancet Respir
    Med. 2020;0(0). doi:10.1016/S2213-2600(20)30079-5]{.c23 .c10 .c0}
55. [Yao et al. In Vitro Antiviral Activity and Projection of Optimized
    Dosing Design of Hydroxychloroquine for the Treatment of Severe
    Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect
    Dis, March 2020]{.c23 .c10 .c0}
56. [Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and
    Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
    JAMA, March 2020; doi:10.1001/jama.2020.3204]{.c23 .c10 .c0}
57. [Zeng, et al. First Case of COVID-19 Infection with Fulminant
    Myocarditis Complication: Case Report and Insights. Preprints 2020;
    doi: 10.20944/preprints202003.0180.v1]{.c10 .c0 .c23}
58. [Zeng, J., Huang, J. & Pan, L. How to balance acute myocardial
    infarction and COVID-19: the protocols from Sichuan Provincial
    People's Hospital. Intensive Care Med, 2020;
    https://doi.org/10.1007/s00134-020-05993-9]{.c23 .c10 .c0}
59. [Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and
    challenges. Lancet Gastroenterol Hepatol, March 2020;
    doi:10.1016/S2468-1253(20)30057-1]{.c23 .c10 .c0}
60. [Zheng, Y et al. COVID-19 and the cardiovascular system. Nat Rev
    Cardiol, 2020; doi.org/10.1038/s41569-020-0360-5]{.c23 .c10 .c0}
61. [Zhonghua et al. \[Expert consensus on chloroquine phosphate for the
    treatment of novel coronavirus pneumonia\]. CMAPH, Feb
    2020;43(0):E019. doi: 10.3760/cma.j.issn.1001-0939.2020.0019.]{.c23
    .c10 .c0}
62. [Zhonghua Xin Xue Guan Bing Za Zhi.  Analysis of myocardial injury
    in patients with COVID-19 and association between concomitant
    cardiovascular diseases and severity of COVID-19\]. March
    2020;48(0):E008. doi: 10.3760/cma.j.cn112148-20200225-00123.  ]{.c23
    .c10 .c0}
63. [Zhou F, et al. Lancet 2020;
    DOI:https://doi.org/10.1016/S0140-6736(20)30566-3. Hamming I, et al.
    J Pathol 2004; 203(2): 631-7.]{.c23 .c10 .c0}
64. [Zhou F, Yu T, Du R, et al. Clinical course and risk factors for
    mortality of adult inpatients with COVID-19 in Wuhan, China: a
    retrospective cohort study. Lancet. March 2020.
    doi:10.1016/S0140-6736(20)30566-3]{.c23 .c10 .c0}
65. [Zhou  P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated
    with a new coronavirus of probable bat origin. Nature.
    2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7]{.c23 .c10
    .c0}
66. [Zuo M-Z, Huang Y-G, Ma W-H, et al. Expert Recommendations for
    Tracheal Intubation in Critically ill Patients with Novel
    Coronavirus Disease 2019. Chin Med Sci J. February 2020.]{.c10
    .c0}[ ]{.c10
    .c0}[[doi:10.24920/003724](https://www.google.com/url?q=https://doi.org/10.24920/003724&sa=D&ust=1585016771178000){.c15}]{.c16
    .c10 .c0}

[]{.c85 .c96 .c66 .c80 .c97}

------------------------------------------------------------------------

[]{.c23 .c49} {#h.t36cynad724o .c44 .c79}
=============

[ADDENDUM: COVID ICU Bundle Checklist  ]{.c23 .c49} {#h.9um4ryva0zlb .c44}
===================================================

Rationale: Use of a daily checklist ensures that routine quality
measures are in place for each patient.  Review Bundle Checklist at the
end of each patient's presentation, every day.  [Each section should be
performed unless there is a contraindication or barrier to
implementation]{.c42}[. If a contraindication is present, discuss how
barriers may be overcome. ]{.c8}

[]{.c8}

[Ventilator]{.c33}[ ]{.c8}

[🗆 Spontaneous Awakening Trial (SAT)]{.c8}

[= turn off sedation ]{.c8}

[🗆 Spontaneous Breathing Trial (SBT)]{.c8}

[= Place patient on Pressure Support 5/5]{.c8}

[- Perform SAT & SBT concurrently if able]{.c8}

[- Contraindications to SAT/SBT include FiO2 \> 50%, PEEP \> 8, O2 sat
\< 90%, pH \< 7.30, SBP \< 90 or MAP \< 60, paralysis, intracranial
pressure \>15, concern for significant bleeding]{.c8}

[🗆 If ARDS: goal Vt 4-6 cc/kg of ideal body weight (calculated by
height), plateau pressure \< 30]{.c8}

[]{.c8}

[🗆 Head of bed at \>30 degrees ]{.c8}

[🗆 Oral care is ordered ]{.c8}

[]{.c17}

[Sedation / Delirium]{.c17}

[🗆 Ask: Is patient delirious (CAM+)? ]{.c8}

[🗆 Review med list for any deliriogenic medications and
discontinue/change where possible]{.c8}

[🗆 Define RASS goal]{.c8}

[🗆 Record QTc daily, consider changing medications if QTc \> 500 ]{.c8}

[]{.c17}

[Restraints]{.c17}

[🗆 Ask: Are restraints needed? ]{.c8}

[🗆 Sign necessary restraint orders]{.c8}

[🗆 Discuss barriers to removing restraint orders ]{.c8}

[]{.c17}

[Mobility]{.c33}[ ]{.c8}

[🗆 Consult PT for early mobility]{.c8}

[- Contraindications include: deep sedation, paralysis]{.c8}

[]{.c8}

[Pressure Ulcers]{.c17}

[🗆 Ask: Are pressure ulcers present? Is a wound care consult needed?
]{.c8}

[🗆 Discuss whether any changes are needed to ulcer management plan]{.c8}

[]{.c17}

[DVT prophylaxis]{.c17}

[🗆 Review patient's current DVT prophylaxis orders and adjust if needed
]{.c8}

[- Contraindications to LMWH DVT ppx include AKI (switch to UFH TID),
clinically significant bleeding (hold pharmacologic), platelet count \<
30K (hold pharmacologic)]{.c8}

[- Add sequential compression boots if holding pharmacologic
prophylaxis]{.c8}

[]{.c17}

[GI / Nutrition ]{.c17}

[🗆 Famotidine 20mg IV BID in intubated patients; Pantoprazole 20-40mg IV
daily if history of GERD or GI bleed]{.c8}

[🗆 Review nutrition, consult nutrition if not already done.  While
awaiting nutrition input, start enteral nutrition: ]{.c8}

[- In most patients, Osmolite 1.5 \@10mL/hr, advance by 20mL Q6h to goal
50mL/hr]{.c8}

[- If renal failure and high K or phos: Nepro @ 10mL/hr, advance by 10mL
Q6h to goal 40mL/hr]{.c8}

[- MVI with minerals daily ]{.c8}

[- thiamine 100mg daily x3 days]{.c8}

[- folate 1mg daily x 3 days]{.c8}

[🗆 Ask: Is bowel regimen adequate? Make changes if necessary. ]{.c8}

[🗆 Review glucose range over past 48h and insulin regimen, adjust
regimen if needed. ]{.c8}

[- Goal glucose range is 70-180]{.c8}

[]{.c75 .c66 .c80 .c85}

[Tubes / Lines / Drains]{.c17}

[🗆 List all tubes / lines / drains and discuss if any can be removed or
should be changed]{.c8}

[]{.c17}

[Patient / Family Communication ]{.c17}

[🗆 Discuss if patient has healthcare making capacity - if not, activate
healthcare proxy ]{.c8}

[🗆 Update families by phone ]{.c8}

[- Suggest RN update at least daily ]{.c8}

[- MD update Q3 days, with any significant clinical change, or per
family request]{.c8}

[]{.c17}

[Disposition]{.c33}

[🗆 Discuss anticipated dispo, barriers to dispo]{.c8}

[]{.c17}

[Code Status]{.c17}

[🗆 Review current code status, discuss if goals of care are realistic
with prognosis - if not, discuss with patient / family]{.c8}

[]{.c8}

[Abbreviations: ]{.c8}

[SAT = Spontaneous Awakening Trial ]{.c8}

[SBT = Spontaneous Breathing Trial ]{.c8}

[CAM = Confusion Assessment Method]{.c8}

[RASS = Richmond Agitation and Sedation Scale]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

[]{.c8}

<div>

[]{.c8}

</div>

::: {.c25}
[\[a\]](#cmnt_ref1){#cmnt1}[Having trouble finding this exact quote in
the resource cited]{.c8}
:::

::: {.c25}
[\[b\]](#cmnt_ref2){#cmnt2}[add ref to bibliography J Crit Care. 2012
Oct;27(5):434-9.]{.c8}
:::

::: {.c25}
[\[c\]](#cmnt_ref3){#cmnt3}[Am J Respir Crit Care Med.
2012;185:1307--1315.]{.c8}
:::

::: {.c25}
[\[d\]](#cmnt_ref4){#cmnt4}[insert ref into bibliograph N Engl J Med.
2020 Mar 12;382(11):999-1008.]{.c8}
:::

::: {.c25}
[\[e\]](#cmnt_ref5){#cmnt5}[Link ECMO guidelines when available]{.c8}
:::

::: {.c25}
[\[f\]](#cmnt_ref6){#cmnt6}[Also may want to link
http://handbook.partners.org/content/pdf/BWHCovid19Treatment.pdf in the
document just not sure where the best place would be]{.c8}
:::

::: {.c25}
[\[g\]](#cmnt_ref7){#cmnt7}[need becky and kevin to decide]{.c8}
:::

::: {.c25}
[\[h\]](#cmnt_ref8){#cmnt8}[my comment to Becky was \"No strong
objections to the use of Dornase in COVID. I had just mentioned in the
document that the data for dornase for management of secretions in
non-CF patients is very poor. The other factors I was considering were
drug cost (\$450 a dose) as well as drug availability, neither of which
would be a consideration in a trial setting. ]{.c8}

[]{.c8}

[I know there have been some reports of its benefit in COVID, but
obviously that is limited in number so not sure if would make first line
therapy. ]{.c8}

[]{.c8}

[But if the PETAL group is interested in doing a study on dornase, I am
definitely in support of that\"]{.c8}
:::

::: {.c25}
[\[i\]](#cmnt_ref9){#cmnt9}[Do we have a link for this?]{.c8}
:::

::: {.c25}
[\[j\]](#cmnt_ref10){#cmnt10}[May need to be added to References
section]{.c8}
:::

::: {.c25}
[\[k\]](#cmnt_ref11){#cmnt11}[There are no trials currently onging (that
I am aware of not sure if PETAL network is) involving Toci at BWH. Would
change to \"to be used in conjunction with infectious disease
consultation in severe COVID-19 disease and suspicision of CRS\"]{.c8}
:::

::: {.c25}
[\[l\]](#cmnt_ref12){#cmnt12}[Can someone confirm that this is the right
reference here? (Changed from \"Savarino et al, J AIDS, 1996\" which I
was unable to find)]{.c8}
:::

::: {.c25}
[\[m\]](#cmnt_ref13){#cmnt13}[(also probably needs to be added to
References section)]{.c8}
:::

::: {.c25}
[\[n\]](#cmnt_ref14){#cmnt14}[Can someone confirm that this is the right
reference here? (Changed from \"Savarino et al, J AIDS, 1996\" which I
was unable to find)]{.c8}
:::

::: {.c25}
[\[o\]](#cmnt_ref15){#cmnt15}[(also probably needs to be added to
References section)]{.c8}
:::

::: {.c25}
[\[p\]](#cmnt_ref16){#cmnt16}[per the treatment guidelines this also may
be used in patients not requiring supplemental oxygen but have a risk
factor for progression to severe disease . Would consider adding \"or in
those not on supplemental oxygen but at risk for progression to severe
disease\"]{.c8}
:::

::: {.c25}
[\[q\]](#cmnt_ref17){#cmnt17}[Chloroquine on longterm manufacturer
backorder]{.c8}
:::

::: {.c25}
[\[r\]](#cmnt_ref18){#cmnt18}[all new]{.c8}
:::

::: {.c25}
[\[s\]](#cmnt_ref19){#cmnt19}[lots of changes here]{.c8}
:::

::: {.c25}
[\[t\]](#cmnt_ref20){#cmnt20}[Would like to include a clip of the
timecourse here\... trop rise starts late? or thats when the problems
manifest?]{.c8}
:::

::: {.c25}
[\[u\]](#cmnt_ref21){#cmnt21}[Paper doesn\'t mention specifically if
that\'s when the problems start, but it does say that in 23/50 (46%) non
survivors had trop rises \>28 and whereas only 1/95 (1%) survivors had
such a trop rise.]{.c8}
:::

::: {.c25}
[\[v\]](#cmnt_ref22){#cmnt22}[Hi guys, glad to join!]{.c8}
:::

::: {.c25}
[\[w\]](#cmnt_ref23){#cmnt23}[If you look at the Zhou paper from the
Lancet there is a beautiful figure showing the timeline of events. It\'s
Figure 2 - and if we have space might be nice to include.]{.c8}
:::

::: {.c25}
[\[x\]](#cmnt_ref24){#cmnt24}[Here are the data by virus, but thought
this was less important: Incidence ratios within 7 days of detection by
virus: influenza B: 10.11(95% CI, 4.37-23.38); influenza A 5.17 (95% CI,
3.02 to 8.84), RSV 3.51 (95% CI, 1.11 to 11.12), and other viruses 2.77
(95% CI, 1.23 to 6.24).]{.c8}
:::

::: {.c25}
[\[y\]](#cmnt_ref25){#cmnt25}[Not sure this is what you meant but in
case you want to keep it, here is the citation.]{.c8}

[]{.c8}

[Kwong J, Schwartz K, Campitelli M, et al. Acute Myocardial Infarction
after Laboratory-Confirmed Influenza Infection. N Engl J Med
2018;378:345-53. DOI: 10.1056/NEJMoa1702090]{.c8}
:::

::: {.c25}
[\[z\]](#cmnt_ref26){#cmnt26}[New addition with citation]{.c8}
:::

::: {.c25}
[\[aa\]](#cmnt_ref27){#cmnt27}[Also did a little reformatting]{.c8}
:::

::: {.c25}
[\[ab\]](#cmnt_ref28){#cmnt28}[Matt: can clarify threshold to hold AC?
should know this but i dont]{.c8}
:::

::: {.c25}
[\[ac\]](#cmnt_ref29){#cmnt29}[No well-defined threshold from what I
understand.  Usually we hold for active bleeding or if requiring
substantial blood products - kind of a gray area/clinical decision.  At
least that is my usual ICU practice.  you?]{.c8}
:::

::: {.c25}
[\[ad\]](#cmnt_ref30){#cmnt30}[Matt: can clarify threshold to hold AC?
should know this but i dont]{.c8}
:::

::: {.c25}
[\[ae\]](#cmnt_ref31){#cmnt31}[No well-defined threshold from what I
understand.  Usually we hold for active bleeding or if requiring
substantial blood products - kind of a gray area/clinical decision.  At
least that is my usual ICU practice.  you?]{.c8}
:::

::: {.c25}
[\[af\]](#cmnt_ref32){#cmnt32}[Matt: can clarify threshold to hold AC?
should know this but i dont]{.c8}
:::

::: {.c25}
[\[ag\]](#cmnt_ref33){#cmnt33}[No well-defined threshold from what I
understand.  Usually we hold for active bleeding or if requiring
substantial blood products - kind of a gray area/clinical decision.  At
least that is my usual ICU practice.  you?]{.c8}
:::

::: {.c25}
[\[ah\]](#cmnt_ref34){#cmnt34}[Matt: can clarify threshold to hold AC?
should know this but i dont]{.c8}
:::

::: {.c25}
[\[ai\]](#cmnt_ref35){#cmnt35}[No well-defined threshold from what I
understand.  Usually we hold for active bleeding or if requiring
substantial blood products - kind of a gray area/clinical decision.  At
least that is my usual ICU practice.  you?]{.c8}
:::

::: {.c25}
[\[aj\]](#cmnt_ref36){#cmnt36}[Matt: can clarify threshold to hold AC?
should know this but i dont]{.c8}
:::

::: {.c25}
[\[ak\]](#cmnt_ref37){#cmnt37}[No well-defined threshold from what I
understand.  Usually we hold for active bleeding or if requiring
substantial blood products - kind of a gray area/clinical decision.  At
least that is my usual ICU practice.  you?]{.c8}
:::

::: {.c25}
[\[al\]](#cmnt_ref38){#cmnt38}[Mike is doing this section]{.c8}
:::

::: {.c25}
[\[am\]](#cmnt_ref39){#cmnt39}[Will is adding generic language here, not
BWH specific]{.c8}
:::

::: {.c25}
[\[an\]](#cmnt_ref40){#cmnt40}[Out of alphabetical order]{.c8}
:::

::: {.c25}
[\[ao\]](#cmnt_ref41){#cmnt41}[Update to march one]{.c8}
:::
